Identification of Fucose-α(1-2)-Galactose Binding Proteins in the Mammalian Brain by Wibowo, Arif
Identification of Fucose-α(1-2)-Galactose 
Binding Proteins in the Mammalian 
Brain 
 
Thesis by 
Arif Wibowo 
 
In Partial Fulfillment of the Requirements for the 
degree of 
Doctor of Philosophy 
 
 
 
 
 
 
 
CALIFORNIA INSTITUTE OF TECHNOLOGY 
Pasadena, California 
2013 
(Defended 30 May 2013)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2013 
Arif Wibowo 
All Rights Reserved
 
 
 
 
 
 
 
 
Knowledge Speaks but Wisdom Listens ~ Jimi Hendrix 
 
 
 
 
 
 
 
 
 
 
 
ACKNOWLEDGEMENTS 
First and foremost, I want to thank God, whose many blessings have made me who 
I am today. My Caltech experience, both scientific and personal, has been bittersweet. I 
would not be where I am today if not for my family, friends and coworkers at Caltech. 
Sincerely, I would like to thank everyone who has been part of my life for the past 7 years. 
Specifically, I would like to thank my advisor, Linda Hsieh-Wilson, for the 
opportunity to do great science. She taught me many things but most importantly to always 
strive for excellence. When I leave Caltech, I am a better scientist because of you. To my 
committee members: Peter Dervan, Jack Beauchamp and Bob Grubbs, I can’t thank you 
enough for all your guidance and kind support. You have inspired many scientists 
throughout your career and I feel privileged to have this experience first-hand.   I would 
also like to thank David Tirrell for his advice and generous support and for his valuable 
input on the dendritic protein synthesis work. To my undergraduate advisor, Richmond 
Sarpong, thank you for giving me a chance to start in research.  
My colleagues in the Hsieh-Wilson lab, both past and present, have been truly 
invaluable. In particular, I am greatly indebted to Manish Rawat, Song Gil Lee and Wen Yi 
for being an excellent teacher and even better friend. I would also like to thank Cristal 
Gama and Jessica Rexach for teaching me how to work with neurons.  I have to give 
special mention to my classmates, Chithra Krishnamurthy and Young In Oh, for being 
available, especially during a moment of personal tragedy. In addition, I would like to 
thank Abby Pulsipher, Matt Griffin and Elizabeth Jensen for reading my thesis and 
 
correcting my mistakes. To the rest of the Hsieh-Wilson lab, I am honored to work with a 
group of talented scientists like all of you.  
I am lucky to have had many excellent sources of support in the Caltech 
community. I would like to thank Anne Penney, Agnes Tong, Joe Drew, Rick Gerhart, 
Chris Smith, Michael Werner, Susan Mucha, Laura Flower Kim, and Natalie Gilmore for 
making my life as a graduate student so much easier. For the Caltech staff: Scott Ross, 
David VanderVelde, Mona Shahgoli, Naseem Torian, Scott Wang and Jennifer Costanza, 
thank you for helping me do great science. I would also like to thank Michael Bethune, 
Jiang Xia, Yan Xia, John Matson, Ishu Saraogi and Lea Goentoro for your valuable advice 
on my career path.  
To my friends from Caltech and outside of the campus, your friendship has kept me 
where I am today. I can’t name all of you but I want to thank you for your prayers and 
encouragements, especially when my heart was heavy. For the friends that have put some 
normalcy into to my life outside of science, thank you. To my Berkeley, Singapore and 
Indo friends both at Caltech and elsewhere, I am grateful to have developed such a lasting 
friendship with all of you.  Finally, I want to thank my family for their unconditional love. 
Levina, I hope I can inspire you. Mom, thank you for being my rock. Dad, I know you’re 
smiling down from heaven.   
 
 
 
 
ABSTRACT 
Fucose-α(1-2)-galactose (Fucα(1-2)Gal) carbohydrates have been implicated in 
cognitive functions. However, the underlying molecular mechanisms that govern these 
processes are not well understood. While significant progress has been made towards 
identifying glycoconjugates bearing this carbohydrate epitope, a major challenge remains 
the discovery of interactions mediated by these sugars.  Here, we employ the use of 
multivalent glycopolymers to enable the proteomic identification of weak affinity, low 
abundant Fucα(1-2)Gal-binding proteins (i.e., lectins) from the brain.  End-biotinylated 
glycopolymers containing photoactivatable crosslinkers were used to capture and enrich 
potential Fucα(1-2)Gal-specific lectins from rat brain lysates.  Candidate lectins were 
tested for their ability to bind Fucα(1-2)Gal, and the functional significance of the 
interaction was investigated for one such candidate, SV2a, using a knock-out mouse 
system.  Our results suggest an important role for this glycan-lectin interaction in 
facilitating synaptic changes necessary for neuronal communication. This study highlights 
the use of glycopolymer mimetics to discover novel lectins and identify functional 
interactions between fucosyl carbohydrates and lectins in the brain. 
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C h a p t e r  1  
CARBOHYDRATE-MEDIATED INTERACTIONS IN ANIMALS 
1.1. Introduction 
Complex cellular processes are regulated by networks of interacting biomolecules 
both inside and outside of cells.  These interactions contribute to the structure and function 
of a living cell and are mediated by various cellular components, such as proteins, DNA, 
RNA and small molecules.1,2 An important component of this network is characterized by 
the interactions between carbohydrates and their corresponding binding partner(s). The 
various combinations of the naturally occurring monosaccharides, joined through numerous 
possible linkages and branch points, have the potential to generate complex sets of 
oligosaccharide structures. These oligosaccharides are covalently bound to lipids and 
proteins, forming glycolipids and glycoproteins, respectively. With such structural 
diversity, these sugars carry enormous potential for encoding molecular information 
significant for modulating complex processes in living organisms.  
Glycoconjugates (e.g., glycoproteins, GPI-anchored glycans and glycolipids) are 
abundant in every organism from bacteria, fungi, virus and plants to mammals. 
Approximately more than 50% of all proteins are modified with glycans.3 Even though 
carbohydrate architectures are structurally diverse, they are exposed to the same 
glycosylation machinery. As such, carbohydrate biosynthesis must be tightly regulated by 
the concerted actions of cellular enzymes and substrates. Gene transcription has a major 
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impact on glycan formation, as reflected by the cell type-specific and developmentally 
modulated expression of many glycosyltransferases and glycosidases. Furthermore, 
subcellular localization of these enzymes and their nucleotide sugar donor substrates could 
facilitate the formation of different saccharide linkages in the endoplasmic reticulum (ER) 
and Golgi. Changes in the glycome in response to environmental and genetic stimuli are 
potentially associated with the acquisition of altered cellular phenotypes. Vertebrates, 
especially mammals, have evolved a highly complex glycan repertoire that is structurally 
distinct from that of invertebrates, lower eukaryotes and prokaryotes. As a result, the 
variation in glycomes among vertebrates may serve as the molecular basis for mediating 
different cellular functions. 
Glycans serve important biological roles in protein maturation and turnover, cell 
adhesion and trafficking and receptor binding and activation.4–7 In addition, aberrant 
glycosylation can lead to various diseases. The congenital disorders of glycosylation 
(CDGs) affect children by causing severe morphogenic and metabolic defects due to a 
general failure in glycan formation.8,9 Alterations in glycosylation profiles are a common 
feature of tumor cells and may affect any types of cell glycoconjugates such as 
glycoproteins, glycolipids or glycosaminoglycans.10  In fact, overexpression of the sialyl, 
fucosyl and Tn antigens have been observed in malignant tissues throughout the body, 
including the brain, colon, breast and prostate.11–16 Carbohydrate-mediated interactions in 
the nervous system also play important roles during development, regeneration and 
synaptic plasticity.17,18 Therefore, glycan-mediated interactions are involved in a number of 
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cellular functions, including protein folding and trafficking, cell-cell communication, 
receptor activation and signal transduction. 
1.2. The Nature of Glycan-Protein Interactions 
Glycosylation produces different types of glycoconjugates that are typically 
attached to cellular proteins and lipids. Glycoproteins, glycosaminoglycans and MUCINS 
exhibit glycans that are covalently attached to protein backbones in various linkages. There 
are two broad groups of glycoproteins, N-glycans and O-glycans, which differ in the nature 
of their linkage to the protein backbone. N-glycans are attached to asparagine residues of 
proteins, specifically a subset residing in the Asn-X-Ser/Thr motif, whereas O-glycans are 
attached to a subset of serine and threonine residues.19,20 Glycosaminoglycans are also 
linked to serine and threonine residues, but they are made up of structurally linear 
oligosaccharide polymers that can often be highly sulfated.21 Glycolipids are characterized 
by a membrane-embedded ceramide moiety that anchors the extracellular glycan 
component of the glycolipid to the cell. Neutral and sialylated glycosphingolipids (GSLs) 
exist as the major glycolipid constituents in mammals. Neutral GSLs are derived from the 
core glycosylceramides precursor and are implicated in cellular homeostasis and tissue 
development, while the sialylated forms, often termed gangliosides, are relatively enriched 
in the brain and participate in cellular adhesion and signaling.22,23 Extensive carbohydrate 
presentations from these glycoconjugates indicate that glycans are involved in modulating 
many cellular functions. As such, glycan receptor(s) identification is critical for 
understanding the molecular mechanism of carbohydrate-mediated signaling events. 
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Structural information encoded by glycans is recognized by specific glycan binding 
proteins (GBPs). A class of these proteins, lectins, binds mono- and oligosaccharides 
reversibly and with high specificity, are devoid of catalytic activity and are not products of 
the immune response.  Lectins, like their glycoconjugate counterparts exist in most 
organisms, ranging from viruses and bacteria to plants and animals.24 The interactions 
between glycans and lectins typically occur with weak affinity (Ka = 103–106 M-1)25 but 
with significant avidity, given that most lectins can simultaneously bind multiple glycan 
moieties. In nature, the typically weak binding interactions between GBPs and individual 
glycans are compensated by their multivalent displays on glycoprotein scaffolds.26,27 In 
many instances, the glycan structure alone is not sufficient enough to generate a recognition 
event below a certain epitope density threshold.  As a result, the multivalent binding 
activities of carbohydrate-lectin interactions are extremely important because they lead to 
the augmentation of glycoprotein organization (clustering).28 In turn, glycoprotein 
clustering contributes to the regulatory mechanism by which cell-surface glycan epitope 
density is maintained for downstream signaling events.29  
The multivalency of glycoproteins is also exhibited in GBPs, as they frequently 
possess more than one glycan-binding site (subsite multivalency). The involvement of 
secondary binding interactions in regions of the receptor other than the primary binding site 
have been shown to provide substantial affinity enhancements.30 In addition, lectins can 
oligomerize to form multiple receptor binding sites for increased binding interactions. 
Furthermore, the chelating effects between multivalent ligands and multiple receptors 
decrease the binding off-rate because the translational entropy expenditure is made with the 
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first receptor-ligand contact.31 Nevertheless, the apparent affinity of a multivalent 
interaction often is less than might be expected, presumably due to the conformational 
entropy restrictions incurred by multipoint binding. As a consequence, there are a number 
of different modes through which GBPs and glycoproteins can engage each other 
Lectins undergo few changes in conformation upon binding to sugar.32 
Carbohydrate binding sites are typically broad and shallow, characterized by several 
general principles. First, the epimeric -OH that distinguishes particular sugars is involved in 
hydrogen bonding to the lectin, providing a direct read-out towards glycan affinity. Next, 
specificity is established by the steric exclusion of disfavored ligands, rather than the mere 
loss of contact within the binding sites. The combination of hydrogen bonding of the -OH 
groups and the van der Waals packing of the hydrophobic face of each sugar ring impose 
geometric constraints on the oligosaccharides, evoking the desired energetic conformation 
that leads to a substantial binding enhancement for multivalent ligands. Higher selectivity 
is further achieved through an extended binding pocket which recognizes the protein 
domain contribution of the glycoconjugate, in addition to its glycan structure.33–35 Finally, 
the selectivity and enhanced affinity between the glycan and lectin pair can be achieved by 
bridging water molecules and/or divalent cations.  In particular, Ca2+ and Mn2+ have been 
shown to stabilize the lectin binding site by coordinating the interactions between specific 
amino acids and carbohydrate ligands.32 
 
6 
 
 
1.3. Mammalian Lectins and Their Functions 
Fig 1.1. Schematic examples of major types of animal lectins. Reproduced with 
permission from Essentials of Glycobiology, 2nd Edition, Chapter 26. 
Mammalian lectins have been identified and classified by their carbohydrate 
recognition domain (CRD) motif, such as those that define the C-, S-, P-, and  I-type lectins 
(Fig 1.1).36 C-type lectins (CTLs) are the most abundant of all animal lectins, and the CTL 
superfamily is grouped into three families: selectins, collectins and endocytic lectins.37,38 A 
majority of CTLs are large, asymmetric, possess one or more CRD and exist as Ca2+-
dependent proteins found in secreted or membrane-bound forms.37,39 The collectin family 
of CTLs mediates pathogen neutralization through soluble collagenous lectins, such as 
mannose-binding proteins (MBPs), pulmonary surfactant SP-A and SP-D and conglutinin. 
The selectin family consisting of the E-, L- and P-selectins, is directly involved in adaptive 
immune response by mediating transient interactions between leukocytes and the 
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endothelium. These selectins have a single epidermal growth (EGF)-like domain, an 
extracellular CRD, a cytoplasmic tail, a transmembrane domain and two to nine short 
consensus repeat units that may participate in cellular adhesion.40,41 The physiological 
ligands for the selectins contain fucosylated core trisaccharides designated as Lewisx (Lex) 
and Lewisa (Lea) and their corresponding sialylated counterparts (sLex and sLea).37,40 
Finally, the other families of CTLs include the macrophage mannose receptor, DC-SIGN 
and the hepatic asialoglycoprotein receptor (ASGR). These receptors have all been 
implicated in pathogen recognition, leading to the cellular uptake and subsequent 
processing of its endocytic contents.42,43 
In contrast, the S-type lectins (galectins) are generally small, non-glycosylated, 
soluble and exist as Ca2+ independent proteins that are found both inside and outside of  
cells.37,44 To date, 15 galectins have been identified in mammals, most with wide tissue 
distribution, and many bind N-acetyllactosamine (Galβ1-nGlcNAc-R) through β-gal 
residue recognition.39 Most galectins are either bivalent or multivalent with regard to their 
carbohydrate-binding activities, which allows them to recognize multiple binding partners 
for activating distinct signaling pathways. Galectins display an intriguing combination of 
intra- and extracellular activities and are implicated in the regulation of immunity and 
inflammation,45 progression in cancer 46 and in specific developmental processes.47  
The I-type lectins are a class of carbohydrate-recognizing proteins that belong to the 
immunoglobulin (Ig) superfamily. A major component of the I-type lectin family is the 
Siglec, a type 1 transmembrane protein that bind to sialic acid epitopes with low affinity 
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(Kd = 0.1 – 3 mM)  through its N-terminal V-set Ig domain.48 Ten Siglecs have been 
identified in mammals, most with unique expression patterns in different cell types, 
implicating roles in highly specialized and specific cellular processes.49 In fact, most 
Siglecs present an immunoreceptor tyrosine-based motif from their intracellular domain, 
suggesting roles in both cell-cell interactions and cellular signaling events.50 Other 
members of the I-type lectins have also been reported to recognize different glycan 
epitopes and include a family of adhesion molecules, such as the L1-cell adhesion molecule 
(L1-CAM), neural cell adhesion molecule (NCAM) and intercellular adhesion molecule 1 
(ICAM-1).49 Efforts are currently underway to identify the endogenous ligand(s) for the I-
type lectin family and their functions in cellular activity.    
The P-type lectins serve an essential role in the generation of functional lysosomes 
within the cells of higher eukaryotes. The recruitment of soluble acid hydrolases to newly 
synthesized lysosomes is initiated by the formation of mannose 6-phosphate (M6P) 
residues, which become a targeting signal for the P-type lectin receptors.51 Following M6P 
recognition, the hydrolase-receptor complex is transported to pre-lysosomal compartments, 
where the low-pH environment induces release of the enzymes from the receptors. This 
trafficking process is mediated by two P-type lectin receptor families located in the trans-
Golgi network (TGN): the cation-dependent mannose 6-phosphate receptor (CD-MPR) and 
the insulin-like growth factor II/cation-independent mannose 6-phosphate receptor (IGF-
II/CI-MPR). Both receptors contain a single transmembrane-spanning segment, a C-
terminal cytoplasmic region and an N-terminal ligand-binding region.52 In contrast to the 
CD-MPR, the multifunctional IGF-II/CI-MPR binds to several distinct nonglycosylated 
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ligands, including IGF-II, in addition to mannose 6-phosphorylated proteins.53–55 As a 
result, CI-MPR is also implicated in other cellular processes, including apoptosis, viral 
entry and proteolytic activation of enzyme and growth factor precursors. 
 
 
 
 
 
 
 
Fig 1.2. Glycan-receptor interaction encompasses a number of 
cellular functions including protein folding, trafficking, adhesion and 
signal transduction. Adapted with permission from (56). 
The biological activities of mammalian lectins are due to their carbohydrate-
binding properties. The success of deciphering carbohydrate-encoded information is based 
on lectin selectivity towards the different glycan epitopes and the corresponding interaction 
between specific glycan-receptor pairs. By binding to lectins and sterically modulating 
molecular interactions, mammalian glycans participate in multiple cellular activities, such 
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as protein folding, cell recognition and adhesion, trafficking, receptor activation, signal 
transduction and endocytosis (Fig 1.2).56 Conversely, these functional roles are dependent 
on the nature of the interactions, specifically, the formation or disruption of intra- and 
intermolecular binding involving both homotypic and heterotypic substrates. In addition, 
the biological relevance of glycan-mediated interactions is determined by the 
spatiotemporal control of the lectin-glycoconjugate pair. Thus, although the glycan 
structure is expressed on many glycoproteins, the subcellular localization of the lectin and 
its glycoconjugate exclude other glycoproteins from being physiologically relevant.  
Mammalian lectin involvement in cell-cell adhesion is best characterized by the 
selectins and their glycan ligands, which include a key fucose linkage on the sLex 
oligosaccharide. This cell adhesion system is highly regulated on the cell-surface 
endothelium and on most leukocytes, thereby contributing to leukocyte trafficking during 
an immune-system response and inflammation.57 Glycan recognition by mammalian lectin 
is also critical in pathogenic infection. A key example of this phenomenon involves DC-
SIGN, a C-type lectin expressed by dendritic cells (DCs), which functions as a receptor for 
several viruses, including the Ebola virus, cytomegalovirus (CMV), hepatitis C virus, 
human immunodeficiency virus (HIV) and dengue virus.58 In particular, DC-SIGN 
recognizes many different viral envelope glycoproteins expressing relatively large numbers 
of N-linked carbohydrates. One such example involves the DC-SIGN capture of HIV-1 at 
low titers through its increased affinity interaction due to high mannose expression on its 
envelope glycoprotein (gp120).59 Interestingly, DC-SIGN does not facilitate HIV-1 
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processing by DCs but protects the virus from intracellular degradation, a process which is 
not completely understood.60 
The plasma membrane is organized into various subdomains of clustered 
macromolecules. These clusters are organized by specialized scaffolding proteins including 
caveolins, which stabilize lipid rafts, and galectins, which crosslink multiple glycoproteins 
to form lattice microdomains. The crosslinking of these cell-surface glycoconjugates 
facilitates protein-protein interactions within various subdomains, triggering a cascade of 
transmembrane signaling events.46,61 Indeed, galectins are implicated in different steps of 
tumorigenic processes, including tumour cell transformation, cell-cycle regulation and 
apoptosis.62 For example, galectin-1 and galectin-3 are involved in tumorigenesis through 
their interactions with oncogenic Ras, which promotes Ras-mediated signal transduction 
involving the phosphatidylinositol-3-kinase (PI3K) and extracellular signal-regulated 
kinase (ERK) 1/2 pathways.63,64 Similarly, the activation of several C-type lectin receptors 
(CLRs) family leads to a cascade of signaling events mediated by the action of protein 
kinases and phosphatases at their cytoplasmic domains.65  Dectin-1, a member of the CLR 
family, is activated when it recognize the β-1,3-glucan epitope during fungal infection, 
resulting in the phosphorylation of its cytoplasmic domain and subsequent NF-κB pathway 
activation.66 While mammalian lectin function is generally ascribed to cellular recognition, 
its involvement in cellular signaling is undoubtedly becoming more evident. 
Studies have found that mammalian glycans produced in the Golgi modulate the 
endocytosis of cell-surface glycoproteins, which in turn, regulate receptor expression and 
12 
 
 
thereby, influencing cell signaling. The poly N-acetyllactosamine, for example, retards 
EGF and TGF-β receptor endocytosis, thus altering receptor activation and signaling 
among epithelial carcinoma cells.67 The hepatic ASGR, an endocytic recycling receptor 
belonging to the CTL family, is responsible for the molecular trafficking and removal of 
desialylated glycoprotein from circulation.68 Furthermore, intracellular animal lectins have 
played important roles in glycoprotein sorting along the secretory pathway. Calnexin and 
calreticulin operate as chaperones to ensure the proper folding and oligomerization of many 
glycoproteins in the ER. The mannose lectin ERGIC-53 behaves as a cargo receptor, 
mediating the transport of glycoproteins from the ER to the Golgi, while the homologous 
lectin VIP36 controls the glycosylation events within the Golgi.69   
Research on the function of mammalian glycosylation demonstrates that glycans 
and their associated lectins are involved in host-pathogen interactions, cellular homeostasis 
and transmembrane signaling. With such diverse functions, it is increasingly evident that 
carbohydrate-lectin interactions play critical roles in biology and in medicine. As a result, 
identifying functional glycan-receptor interactions is key to understanding how 
glycobiology governs and affects cellular physiology and disease. Therefore, technological 
advances in glycan-based methodologies should be capitalized for the identification of 
bioactive carbohydrate ligands and their corresponding lectins. We will discuss our efforts 
towards identifying functional glycan-receptor interactions in the next chapter. In 
particular, we will focus on the role of Fucose-α(1-2)-Galactose  in mediating neuronal 
communication in the brain. 
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C h a p t e r  2  
THE ROLE OF FUCOSE α(1-2) GALACTOSE CARBOHYDRATES IN 
NEURONAL COMMUNICATION 
2. 1. Cellular Fucosylation 
Fucosylation is one of the most prevalent modifications involving oligosaccharides 
on glycoproteins or glycolipids. Fucosylation represents the attachment of fucose residue to 
the terminal or core glycan structures of N-glycans, O-glycans and glycolipids. Fucose is 
distinct from other naturally occurring sugars because it is a deoxyhexose sugar that exists 
exclusively in the L-configuration. In mammals, fucose-containing glycans serve important 
roles as blood group antigen determinants, in selectin-mediated leukocyte-endothelial 
adhesion and in host–microbe interactions.1–5 Increased levels of fucosylation and the 
expression of the corresponding fucosyl transferases have been reported in a number of 
pathological conditions, including inflammation and cancer.6–13 Therefore, the upregulation 
of tumor-associated fucosyl carbohydrates can serve as biomarkers for detection of cancer 
malignancy and metastatic potential. Importantly, the correlations between carbohydrate 
expression and disease progression can be utilized for therapeutic purposes.  
In contrast to the modification of terminal oligosaccharides, fucose may also be 
directly linked to the hydroxyl groups of serine and threonine residues. Indeed, O-
fucosylation of the mammalian Notch receptor is implicated in many developmental 
processes and cellular differentiation.14,15 The binding of specific ligands to the 
extracellular domain of the Notch receptor leads to the proteolytic cleavage of its 
intracellular domain, which results in the transcriptional activation of several 
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developmental genes. Interestingly, Notch signaling and its ligand binding are regulated 
by O-fucosylation.16 Indeed, disruption of O-fucose glycan synthesis causes severe Notch 
signaling defects in drosophila and mammals, resulting in acute developmental 
disorders.17–20  
To date, thirteen fucosyltransferase genes have been identified in the human 
genome. Given the structural diversity of fucosylated glycans, it is not surprising that more 
than a dozen different glycosyltransferases are involved in the formation of fucose 
linkages, most of which exist in the terminal Golgi compartments.21 In particular, a family 
of human α(1,2)-fucosyltransferases, FUT1 and FUT2, is responsible for transferring 
fucose onto the galactose of type 1 (Galβ3GlcNAc) or type 2 (Galβ4GlcNAc) disaccharide 
precursors to form the H blood group antigen (Fucα(1-2)Gal glycans).22–24 A gene 
homologous to FUT1 and FUT2, termed Sec1, contains translational frameshifts and stop 
codons that interrupt potential open reading frames and thus appears to be a pseudogene.25 
The H antigen is further modified by the ABO locus-encoded glycosyltransferase to form 
the A and B blood group antigens, while the unmodified H antigen is expressed on the cell 
surface of type O individuals (Fig 2.1).26 FUT1 and FUT2 knock-out (KO) mice appear 
viable and healthy, but their α(1,2)fucosyl expression is downregulated in the epididymal 
cell surface and uterine, epithelium, respectively.27  In addition, FUT1 and FUT2 -deficient 
mice have been shown to differentially regulate Fucα(1-2)Gal expression in the olfactory 
bulb and gastrointestinal tract.28,29  Therefore, FUT1 and FUT2 genes may act individually 
in specific tissues, retain a redundant function, or have compensatory mechanisms when 
the other gene is knocked out.  
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Figure 2.1. Biosynthesis of complex Fucα(1-2)Gal glycans from the 
H antigen precursors. 
2. 2. Fucosylation in Neuronal Development 
Pivotal roles for glycans in regulating the nervous system during development, 
regeneration and synaptic plasticity, have recently emerged. Glycan function in cellular 
adhesion and recognition is critical for the maintenance of the specific molecular 
architecture responsible for neural cell interactions.30 For instance, glycosylation influences 
various neuronal processes, such as neurite outgrowth and morphology, and may contribute 
to the molecular events that underlie learning and memory.31,32 Glycosylation is also an 
efficient modulator of cell signaling and has been implicated in memory consolidation 
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pathways.33–36 Specifically, glycans can mediate growth factor interactions with their 
associated receptors to control cell proliferation, regulate axon guidance and facilitate 
intercellular signaling.37–40 Genetic ablation of glycosylation enzymes often leads to 
developmental defects and can influence various organismal behaviors, such as stress and 
cognition.41–44 Thus, the complexity of glycan functions help to orchestrate proper neuronal 
development during embryogenesis, as well as influence behaviors in the adult organism.  
Multiple studies have suggested a role for fucosylation in learning and memory. 
First, fucose has been reported to play a significant role in neural development.45–47 
Fucosylated glycoproteins are highly enriched at neuronal synapses,48,49 where they are 
expressed as complex N-linked oligosaccharides.50 Furthermore, the incorporation of 
fucose into glycoconjugates in the brain is significantly enhanced by task-dependent 
learning in both chicks and rats.51-54 In particular, [3H]-fucose is highly incorporated into 
synaptic glycoconjugates in animals that are trained in a brightness discrimination task to 
avoid entering a dark chamber.53 Moreover, fucosyltransferases activity is upregulated 
during synaptogenesis and upon passive-avoidance training in animals.55,56 Finally, 
exogenous application of L-fucose or 2-Fucosyllactose (Fig 2.2) enhance long-term 
potentiation (LTP), an electrophysiological model for learning and memory, both in vivo 
and in hippocampal slices.57,58 In contrast, fucose incorporation into hippocampal 
glycoproteins is found to be significantly reduced in trained rats when treated with 2-
deoxy-D-galactose (2-dGal; Fig 2.2).59, 60 Overall, these studies suggest that  Fucα(1-2)Gal 
glycans (Fig 2.2) are implicated in a variety of complex and critical neuronal 
communication processes. 
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Fig 2.2. Chemical structures of L-fucose, 2-deoxy-D-galactose (2d-Gal), Fucose-(1-2)-
Galactose (Fuc(1-2)Gal) and 2-Fucosyllactose (Fuc(1-2)Gal(1-4)Glc).  
The significance of Fuc(1-2)Gal is supported by behavioral and 
electrophysiological studies using the unnatural 2-dGal sugar analogue. Specifically, 2-
dGal, which competes with native galactose for incorporation into glycan chains, inhibits 
the formation of the specific (1-2) fucose linkage because it lacks a hydroxyl group at the 
C-2 position (Fig 2.3). As a result, administration of 2-dGal treatment on animals during 
passive-avoidance training, has resulted in reversible amnesia and reduced protein 
fucosylation, presumably due to inhibition of the (1-2) linkage formation.61–63 Similarly, 
2-dGal treatment suppresses LTP maintenance in the hippocampus both in vitro and in 
vivo.64 In contrast, other small molecule sugars, such as galactose or glucose, had no effect 
on memory formation, suggesting a unique function for Fucα(1−2)Gal disaccharides. 
Furthermore, application of a monoclonal antibody specific for Fucα(1−2)Gal65 
significantly impaired memory formation in animals most likely by blocking the interaction 
with the Fucα(1−2)Gal epitope.66   
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Fig 2.3. Incorporation of 2-dGal inhibits the formation of Fuc(1-2)Gal linkages.  
Despite these intriguing behavioral and electrophysiological results, the roles of 
Fucα(1−2)Gal carbohydrates on synaptic remodeling and neuronal morphologies have  
been largely uncharacterized. An understanding of their precise functions has been 
hampered by a lack of information regarding Fucα(1−2)Gal glycoproteins. Presently, 
synapsin I, a presynaptic phosphoprotein involved in neurotransmitter release and 
synaptogenesis,67 is the only well-characterized Fucα(1−2)Gal glycoprotein identified in 
the mammalian brain.68 Fucosylation is shown to regulate the stability and turnover of 
synapsin I, protecting it from proteolytic degradation by the calcium-activated protease 
calpain. Inhibition of protein fucosylation with 2-dGal reduces synapsin expression and 
delays synapse formation in hippocampal cultures.68 Efforts to identify additional 
Fucα(1−2)Gal glycoproteins are currently underway to elucidate their functional roles in 
neuronal communications and memory consolidation. However, these studies are only 
partially effective because no Fuc(1-2)Gal lectins have been identified from the 
mammalian nervous system. 
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2. 3. Fucose-α(1-2)-Galactose and Lectin Association in the Brain 
Recent works from our lab has provided the first demonstration that Fucα(1−2)Gal 
and its associated lectins induces hippocampal neuron outgrowth.69 The presence of 
endogenous neuronal lectins specific to Fucα(1−2)Gal carbohydrates are confirmed on 
several fronts. First, lectin receptors are labeled using chemical probes bearing the 
Fucα(1−2)Gal recognition element. The interactions between Fucα(1−2)Gal glycans and 
these ‘unidentified’ lectins promote neurite outgrowth and are only specific to 
Fucα(1−2)Gal carbohydrates (Fig 2.4). As carbohydrates have weak binding affinities for 
lectins, their interactions are multivalent in nature. Indeed, the stimulatory effect of 
Fucα(1−2)Gal polymers on hippocampal neurons is dependent on the concentration and 
valency of the disaccharide epitope. In particular, the growth-promoting activity of the 
Fucα(1−2)Gal glycan increases with each polymer concentration, while the potency of the 
compounds is dramatically enhanced with increasing carbohydrate density (Fig 2.5) . In 
contrast, a monovalent ligand showed only modest activity even though it was capable of 
binding to neurons. These results suggest that the multivalent presentation of a glycan 
epitope on a polymeric scaffold (PAA) promotes the interaction of Fucα(1−2)Gal with 
lectin receptors and facilitates their assembly into higher-order structures. The clustering of 
these lectin receptors presumably initiates receptor complex activation, which elicit 
downstream signaling events, leading to neuronal growth.    
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Fig 2.4. Neurite outgrowth activity is specific to Fucα(1-2)Gal PAA treatment (130 µM). 
PAA: polyacrylamide; GlcNAc: Acetylglucosamine; Gal: Galactose; Fuc: Fucose; 
FucGlcNAc: Fucoseα(1-3)GlcNAc. Reprinted with permission from (69). 
 
 
 
 
 
 
Fig 2.5. The multivalent interaction between Fucα(1−2)Gal and its associated lectin. 
Neurite outgrowth activity increases with increasing Fucα(1−2)Gal concentration and 
polymer valency. Reprinted with permission from (69). 
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Fig 2.6. Inhibition of Fucα(1−2)Gal linkages with 2-dGal leads 
to stunted neurite outgrowth in hippocampal neurons. D-Gal is 
able to rescue the effects of 2-dGal. 3-dGal has no effect on 
neurite outgrowth. Scale bar = 45 µM. Images courtesy of 
Cristal Gama. 
The effects of 2-dGal on neuronal growth and morphology were also investigated in 
hippocampal neurons. Treatment of neurons with 2-dGal leads to a significant retraction of 
dendrites and the collapse of synapses, whereas 3-dGal had no effect on neurite outgrowth. 
Interestingly, the effect of 2-dGal is partially reversed by the subsequent addition of D-Gal, 
which stimulates the regeneration of neuronal processes (Fig 2.6). The partial rescue of D-
Gal can be attributed to the decreased plasticity of older neurons. These results indicate that 
the growth-promoting activity of fucosyl glycans is mediated only by the specific α(1-2)-
linked fucose epitope. Therefore, disruption of fucosylated glycan synthesis, in particular, 
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Fucα(1−2)Gal glycoconjugates, alters neuronal morphology and modifies functional 
neuronal connections.  
Collectively, these results highlight the importance of Fucα(1−2)Gal 
glycoconjugates and their associated lectins in synaptic remodeling and neuronal 
communication. These studies show that Fucα(1−2)Gal carbohydrates stimulate neurite 
outgrowth, while 2-dGal treatment perturbs its biosynthesis and abolishes its growth-
promoting activity. Furthermore, this stimulatory effect is facilitated by the interactions 
with lectin receptors that are specific to Fucα(1−2)Gal disaccharides and are multivalent in 
nature. Understanding the molecular mechanisms by which Fucα(1-2)Gal sugars contribute 
to such processes has been challenging, at least in part, by the fact that no Fucα(1-2)Gal 
lectins have been identified from the mammalian nervous system. Therefore, we seek to 
identify these lectins and elucidate the specific mechanisms and pathways leading to 
neuronal growth.  
Despite their importance, efforts to identify novel mammalian lectins that interact 
with specific glycan ligands of interest have been challenging. Many of the well-
characterized lectins are derived from plants and were discovered through the slow process 
of isolating and purifying individual proteins.70 Furthermore, lectin-like properties can only 
be inferred from their agglutinating activities and structural homology towards other 
existing lectins.71  In fact, database searches for mammalian lectins that have structural 
homology towards known Fucα(1−2)Gal lectin of plants origin, Ulex europaeus agglutinin 
I (UEAI), have yet to provide  great results. Moreover, the weak binding affinities for their 
carbohydrate ligands complicate efforts to capture and identify endogenous lectins. Indeed, 
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the development of general, systems-level approaches to identify glycan-binding proteins 
is important for understanding the biological roles of specific glycan structures. This thesis 
describes the development of chemical probes for the proteomic identification of novel 
mammalian lectins. We will focus on the synthesis of multivalent probes and their use in 
lectin enrichment. Captured lectins are identified with mass-spectrometry (MS)-based 
analyses and validated for their Fucα(1−2)Gal binding in vitro. Finally, the functional 
relevance of these binding events was examined by studying lectin activity in 
Fucα(1−2)Gal-deficient (FUT1 or FUT2 KO) mice. 
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C h a p t e r  3  
SYNTHESIS OF PHOTOACTIVATABLE GLYCOPOLYMERS  
3.1. Synthetic Probes for Lectin Isolation 
The low-affinity interactions between lectins and their glycan ligands generally 
require multivalency to accomplish their intended biological effect. Accordingly, many 
methods to assess lectin-glycan interactions depend upon multiple displays of one or both 
binding partners. Indeed, many glycomimetic designs are multivalent, in which the relevant 
groups are presented on a scaffold that is preorganized for binding.1,2 Multivalent 
carbohydrate derivatives can exploit unique modes of recognition not available to their 
monovalent counterparts. Indeed, many lectins contain more than one saccharide-binding 
site or can oligomerize to form larger structures with multiple binding sites. Therefore, 
multivalent ligands that can interact with these clustered binding sites have an advantage 
over their monovalent counterparts. The designs of many synthetic ligands or glycan-based 
inhibitors have focused on multimeric structures.3–6 Highly valent glycodendrimers and 
glycopolymers have been demonstrated as tools to study lectin biology and have been used 
to inhibit the binding of toxins7 and viruses,8,9 selectin-mediated inflammation10 and 
leukocyte trafficking.11,12  
 Chemical synthesis provides architecturally diverse multivalent ligands, including 
low-molecular-weight displays (glycoclusters), dendrimers, polymers, liposomes, and 
neoglycoproteins.13,14  Unlike naturally occurring multivalent glycan ligands, the valency of 
a synthetic ligand can be controlled by varying length or size of the scaffold. The flexibility 
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offered by chemical synthesis is illustrated by the different biological application of 
multivalent ligand architecture. For example, discrete polymers of defined lengths and 
spacing have been shown to elicit signaling events in neurons and the immune system.15,16  
In addition, many features of the scaffold such as shape, rigidity, ligand density and 
orientation can have significant effects on biological activity. Given these diverse variables, 
synthetic scaffold is an attractive tool for studying receptor-ligand interactions. Therefore, 
we will apply synthetic glycopolymers as glycoprotein mimetics to isolate novel lectins in 
the brain. These glycopolymers exploit multivalency by amplifying weak lectin-
carbohydrate interactions and enabling affinity enrichment of the Fucα(1-2)Gal lectins.  
Early attempts by our laboratory to use monovalent Fucα(1-2)Gal ligands  
conjugated to an agarose support or to photoactivatable cross-linking groups resulted in the 
detection of putative neuronal Fucα(1-2)Gal lectins but were unsuccessful at isolating them 
in sufficient quantities for mass spectrometry (MS) analysis. In these experiments, 
monovalent-biotinylated probes containing photoactivatable trifluoromethyl 
phenyldiazirine were incubated with neuronal cells and cross-linked by UV irradiation (350 
nm). Captured proteins were isolated by streptavidin affinity purification and resolved by 
SDS-PAGE for subsequent proteomic analysis. Efforts using multivalent biotinylated 
glycopolymers to isolate lectins from neuronal lysates were also tested. Cellular lysates 
from the hippocampi of rat pups were incubated with biotinylated polymers containing 
Fucα(1-2)Gal epitope to probe for endogenous lectins. These lectins were isolated by 
streptavidin affinity purification while a parallel competitive experiment using L-fucose 
was performed to identify any non-specific binding.  Lectins from both experiments were 
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eluted from the affinity column and resolved by SDS-PAGE. Comparisons between 
these experiments showed no significant differences in their lectin enrichment profiles, 
presumably due to the high background signal (Fig 3.1). Distinct protein bands 
corresponding to putative lectin candidates were extracted from the gel and analyzed by 
MS. However, the low amount of protein capture rendered the analyses inconclusive. 
Therefore, better enrichment methods are required for isolating weak binding Fucα(1-2)Gal 
lectins in the presence of high, non-specific binding interactions. 
.  
 
 
 
 
 
 
Fig 3.1. Lectin capture from rat pup lysates using Fucα(1-2)Gal affinity column. Lane 1: 
Eluent from the Fucα(1-2)Gal affinity column. Lane 2: Eluent from the L-fucose 
competition column to eliminate false positives. Proteins at ~ 65, 80, 140, and 300 kDa 
(bands indicated by arrows) were selectively captured by the Fucα(1-2)Gal affinity column 
(Lane 1).  The UEAI lectin was also specifically captured (arrowhead, Lane 1). Image 
courtesy of Cristal Gama. 
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3.2. Design and Synthesis of Photoactivatable Glycovalent Probes 
We sought to exploit synthetic glycopolymers containing multiple key elements 
(Fig 3.2). First, we used multivalent Fucα(1-2)Gal units to augment weak carbohydrate-
lectin interactions and facilitate affinity enrichment of the lectins.  Second, we incorporated 
a photoreactive phenylazide group to enable covalent crosslinking of the glycopolymer to 
associated proteins. Lastly, we labeled the glycopolymers with a terminal biotin 
functionality to allow for facile purification and identification of the lectins (Fig 3.3).  
Although synthetic glycopolymers have been used extensively to study glycan-protein 
interactions,16–18 to our knowledge,  they have not been exploited for systems-level, 
proteomics-based profiling of lectins.  
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Fig 3.2. Multivalent Biotinylated Fucα(1-2)Gal Glycopolymer. Biotin handle for affinity 
purification. Fucα(1-2)Gal disaccharide for lectin binding. Phenyl azide photoactivatable 
crosslinker for protein capture.  
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Fig 3.3. Lectin  isolation with multivalent probes. Glycopolymers containing a biotin handle, 
multiple Fucα(1-2)Gal ligands and phenyl azide crosslinker units were used to covalently 
label potential lectins in  mammalian brain. Captured proteins were isolated and identified by 
LC-MS/MS. 
With these considerations in mind, we explored a cyanoxyl (OCN)-mediated 
radical polymerization strategy for glycopolymer synthesis due in part to its broad 
functional group tolerance and water compatibility. To incorporate a biotin handle in the 
glycopolymers, we adopted a straightforward approach using a biotin-derivatized initiator 
system that has been developed by Chaikoff and coworkers.19 We envisioned that the use 
of a simple biotin-arylamine initiator ensured complete installation of the biotin handle in 
our glycopolymers. A phenylazide group was chosen as the photoactivatable crosslinking 
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agent due to its successful application to proteins at membrane interfaces.20 In addition, 
OCN-mediated polymerizations exhibit qualities of a controlled/living process due to the 
persistent, stabilized cyanoxyl radicals.21,22  Using this process, we were able to readily 
synthesize well-characterized, biotin end-functionalized glycopolymers with varying ratios 
of Fucα(1-2)Gal to phenylazide moieties in order to optimize glycan-lectin interactions. 
We also synthesized a control polymer with each starting disaccharide monomer unit 
replaced by two equivalents of N-(3-hydroxypropyl)acrylamide. By analyzing lectin 
enrichment with the control polymer, we identify lectins that specifically interact with 
Fucα(1-2) carbohydrates and eliminate proteins that were captured non-specifically. 
Traditional synthesis of oligosaccharides is often a tedious task, owing to time-
consuming work-up and purification steps. A main characteristic of many glycan syntheses 
is their orthogonal protecting group manipulations. Indeed, traditional Fucα(1-2)Gal 
synthesis required more than ten steps to afford the disaccharide in a mixture of α/β 
isomers.23 This preparation of Fucα(1-2)Gal monomer was reported to proceed via Lewis 
acid-catalyzed reaction with an activated fucosyl imidate donor. Given this synthetic 
challenge, we sought to develop a new route that is shorter, modular and scalable. We 
envisioned using a single protecting group to minimize the need for selective protection 
and deprotection of the sugar hydroxyl groups. Indeed, Fucα(1-2)Gal monomer was 
exclusively prepared in eight steps, from L-fucose, using several multi-step, one-pot 
reactions with minimal protecting group manipulations (Scheme 3.1)  
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Scheme 3.1. Synthesis of Fuc(1-2)Gal glycomonomer 2 
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Fucα(1-2)Gal monomer 2 was prepared on a large-scale from L-fucose 
monosaccharide 5. Solvent-free per-O-acetylation of 5 with stoichiometric acetic anhydride 
and catalytic iodine proceeded to give the pyranose products as anomeric mixtures. 
Peracetylation of L-fucose was followed by the subsequent anomeric substitution using 
TMSI, which was generated in situ from iodine and hexamethyldisilane,24 to give the 
corresponding fucosyl iodides. Further treatment with dimethyl disulfide yielded 
thiofucoside 6 in 65% yield over a one-pot, three steps reaction.25 Thioglycoside 6 was 
deacetylated under Zemplén conditions, neutralized and concentrated before being re-
introduced into a solution of p-methoxybenzyl chloride under basic condition.  The 
subsequent introduction of a single p-methoxybenzyl (PMB) protecting group afforded 
fucosyl donor 7 in 71% overall yield. Direct reaction of the 1,6 anhydro-3,4 O-
Isopropylidene-β-D-galactopyranose acceptor with  an anomeric mixture of donor 7 in the 
presence of iodonium di(sym-collidine) perchlorate (IDCP), gave the α-linked disaccharide 
8 exclusively26 in 55% yield. Glycosylation of 7 was mediated presumably by an 
oxocarbenium intermediate that was susceptible to nucleophilic attack from either the axial 
or equatorial position. Consequently, installation of the PMB protecting group precluded 
acetyl coordination at the anomeric position, which would have favored the undesired β-
linked disaccharides formation (Scheme 3.2).  Without a participating group, the observed 
stereochemistry of 8 could be attributed to the kinetic preference of the α-linkages due to 
the anomeric effects. (Scheme 3.3)  
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Scheme 3.2. Directing Stereoselectivity by Protecting Group Manipulation   
 
Scheme 3.3. Anomeric Effect on Glycan Linkage 
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Disaccharide 8 was treated with ceric ammonium nitrate (CAN) for the 
simultaneous removal of the p-methoxybenzyl and isopropylidene groups, and the 
intermediate was then acetylated in the same pot to give 9 in 68% yield. The 1,6-anhydro 
ring of disaccharide 9 was subsequently hydrolyzed for thiophenylation using 
(phenylthio)trimethylsilane and zinc iodide. Following hydrolysis, the reaction mixture was 
deprotected without further purification using tetrabutylammonium fluoride (TBAF), and 
the resulting free hydroxyl group was acetylated to form thioglycoside 10.27 Next, the latent 
amino propyl spacer was installed to facilitate expedient presentation of the disaccharide 
away from the polymer backbone. Initial coupling of 3-azidopropanol with thioglycoside 
donor 10 in the presence of thiophilic promoter NIS/AgOTf in CH2Cl2 yielded an anomeric 
α/β mixture. However, the use of MeCN promoted formation of the β-linked glycoside 11 
as the major product in 64% yield. By coordinating to the anomeric carbon in the axial 
position, the nitrilium ion could presumably be displaced by the attack of an incoming 
azidopropanol from the equatorial position.28  Catalytic hydrogenation of 11 over Pd/C led 
to the amine intermediate, which was directly transformed without further purification into 
12 using acryloyl chloride. Finally, facile deacetylation of the N-acryloyl glycoside 12 
under Zemplén conditions afforded glycomonomer 2 in 90% yield.   
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Phenylazide monomer 4 was readily synthesized from the commercially 
available compounds, 3-azidopropylamine and N-azido-nitrobenzoyloxysuccinimide 
(ANB-NOS) (Scheme 3.4).  First, 3-azidopropylamine was end-functionalized with 
acryloyl chloride to give azidopropylacrylamide 13 in 83% yield. Staudinger reaction of 13 
with resin-bound diphenylphosphine reduced the azide selectively. This reaction was then 
followed by the coupling of the amine intermediate to ANB-NOS to afford capture 
monomer 4. Biotin-derivatized arylamine initiator 1 was conveniently prepared in a single 
step by reacting 2-(4-aminophenyl)ethylamine with N-biotin succinimide (Scheme 3.5).29 
Scheme 3.4. Synthesis of Phenylazide cross-linker monomer 4  
 
Scheme 3.5. Synthesis of Biotin-Arylamine Initiator 1 
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Scheme 3.6. Synthesis of Biotin-Chain-Terminated Glycopolymer 
 
With the monomers in hand, we first generated glycopolymers I containing 
monomer 2 while using an acrylamide comonomer as the polymer backbone to test for 
ligand density. A spacer arm between the biotin and polymer backbone was used for further 
optimization of polymer-streptavidin interaction during affinity purification. Treatment of 1 
with HBF4 and NaNO2 in degassed H2O/THF (1:1) gave the arenediazonium cation, which 
upon reaction with NaOCN at 60 oC generated the biotinyl aryl radical and the cyanoxyl 
(▪OCN) free radical in situ. This initiator system triggered acrylamide and glycomonomer 2 
addition to form a growing polymer chain that was terminated by the addition of OCN 
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radical species (Scheme 3.6). Next, we synthesized glycopolymers II containing 2 and 4 
in a 3:1 monomer ratio to afford polymers with optimal density and solubility (Scheme 
3.7). By varying the glycan to phenylazide content of the polymer, we sought to maximize 
multivalent glycan-lectin interactions while still maintaining the polymer’s covalent 
capture functionality. Similarly, we generated control polymers III containing 3 and 4 in a 
6:1 monomer ratio where each starting disaccharide monomer unit replaced by two 
equivalents of N-(3-hydroxypropyl)-acrylamide 3 (Scheme 3.7). Characterization of the 
glycopolymers by 1H-NMR and size- exclusion chromatography multi-angle laser light 
scattering (SEC-MALLS) revealed narrow polydispersity index (PDI) values (~ 1.2) with 
number average molecular weight (Mn) of 24 – 26 kDa, which corresponds to up to 30 
disaccharide units per polymer (Table 1). Importantly, the ligand-to-crosslinker ratio in the 
glycopolymer was readily tunable as shown by the close agreement to the initial monomer 
ratio in the polymerization reaction (Table 3.1). 
Table 3.1. Biotin End-Functionalized Glycopolymer 
Pol Monomer [C]o/[L]oa xb yb zb Mnc PDIc 
I 2 - 19 - - 26300 1.17 
II 2 and 4 1/3 30 9 - 23900 1.22 
III 3 and 4 1/6 - 7 43 23000 1.17 
a) Initial ratio of crosslinker (4) to ligand (2 or 3). b) Crosslinker and ligand content in the 
resulting polymer (Scheme 3.7) are estimated by 1H NMR. c) Number average molecular weight 
(Mn) in (g/mol) and polydispersity index (PDI) were determined by SEC-RI/MALLS. 
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Scheme 3.7. Synthesis of Biotin End-Functionalized Photoactivatable Glycopolymer 
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Information on the structure and spatial distribution of many soluble lectins and 
membrane-bound receptors were largely unknown.  With the synthesis of these multivalent 
glycopolymer probes, we sought to capture Fucα(1-2)Gal lectins by covalent cross-linking. 
Based on our earlier attempts, lectins enrichment requires extensive washing to remove the 
many non-specific interactions. Thus, the UV-light cross-linking ensured the capture of 
weak glycan-receptor interactions that might otherwise be disrupted during affinity 
purification.  In addition to the design of the glycopolymers, the linear scaffold endowed 
greater flexibility for lectin binding, unlike other rigid glycovalent structures (e.g., 
dendrimers). The linear scaffolds facilitate optimal glycan-lectins interactions because they 
can accommodate many types of binding sites and are therefore suitable for lectin isolation. 
Given the complexity of the lectin profile of the brain, we would first evaluate the capture 
of a known Fucα(1-2)Gal, UEA I, in vitro using our multivalent capture probe.  These 
efforts and their subsequent applications in neuronal lysates are discussed in the next 
chapter.  
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3.3.1.   Methods and Materials  
Unless otherwise stated, reactions were performed in flame-dried glassware under 
an argon atmosphere, using dry solvents. Solvents were dried by passage through an 
activated alumina column under argon. All other commercially obtained reagents were 
used as received unless otherwise noted. Thin-layer chromatography (TLC) was performed 
using E. Merck silica gel 60 F254 precoated plates (0.25 mm). Visualization of the 
developed chromatogram was performed by UV, p-anisaldehyde and ninhydrin stain as 
necessary. ICN silica gel (particle size 0.032 - 0.063 mm) was used for flash 
chromatography. Gel filtration chromatography (Sephadex LH-20, and G-25 ultrafine) was 
used in order to achieve purification of the final products. 1H NMR was recorded on Varian 
Inova 500 (500 MHz) and Varian Inova 600 (600 MHz) spectrometers and are reported in 
parts per million (δ) relative to CDCl3 (7.26 ppm), CD3OD (4.87 ppm) and D2O (4.80 
ppm). Data for 1H are reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, 
d = doublet, t = triplet, q = quartet, m = multiplet), coupling constant in Hz, and integration. 
13C NMR was recorded on Varian Inova 500 (125 MHz) spectrometers and are reported in 
terms of chemical shift. High-resolution mass spectra were obtained from the Caltech Mass 
Spectral Facility.  
GPC was carried out in 100 mM NaNO3 and 200 ppm NaN3 in water on an OHpak 
SB – 804 HQ column (Shodex), which was connected in series with a miniDAWN TREOS 
MALLS detector and Optilab rEX differential refractometer (both from Wyatt 
Technology). The dn/dc values were obtained for each injection assuming 100% mass 
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elution from the column using dextran (40K) as a calibration standard to confirm 
complete mass recovery. 
 
3.3.2.   Synthetic Procedure 
 
 
 
Methyl 2,3,4-tri-O-acetyl-1-thio-L-fucopyranoside (6). Compound 6 was 
prepared following a procedure by Mukhopadhyay et al.30 To a suspension of L-fucose 5 
(5.00 g, 30.46 mmol) in acetic anhydride (11.8 ml, 124.3 mmol) was added solid iodine 
(0.542 g, 2.13 mmol) and the mixture was allowed to stir at room temperature. After 
acetylation was completed as monitored by TLC (2:1 Hex:EtOAc), CH2Cl2 (30.0 ml) was 
added into the reaction mixture followed by addition of solid iodine (4.648 g, 18.28 mmol) 
and Hexamethyldisilane (3.95 ml, 18.28 mmol). The mixture was allowed to stir for 2 
hours at room temperature to allow full conversion to fucosyl iodide as monitored by TLC 
(19:1 CH2Cl2:Acetone). After complete conversion to fucosyl iodide, dimethyl sulfide 
(1.62 ml, 18.28 mmol) was added to the mixture and allowed to stir overnight. TLC 
showed complete conversion of the iodide to a slightly lower spot before the reaction 
mixture was diluted with CH2Cl2 and washed successively with 10% aq Na2S2O3, saturated 
aq NaHCO3 and water. The organic extract was dried (Na2SO4) and concentrated in vacuo 
before the crude product was purified by column chromatography (2:1 Hex:EtOAc) to 
afford white solid 6 (6.38 g, 65.4%).  
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1H NMR (CDCl3):  [α]: δ 5.56 (d, J = 5.6 Hz, 1H), 5.29 (dd, J = 10.4, 4.4 Hz, 2H), 5.23 
(dd, J = 10.7, 3.3 Hz, 1H), 4.45 (q, J = 6.5 Hz, 1H), 2.17 (s, 3H), 2.07 (s, 3H), 2.05 (s, 3H), 
1.99 (s, 3H), 1.17 (d, J = 6.5 Hz, 3H).  [β]: δ 5.30 (d, J = 1.0 Hz, 1H), 5.25 (t, J = 9.9 Hz, 
1H), 5.05 (dd, J = 10.0, 3.4 Hz, 1H), 4.36 (d, J = 9.8 Hz, 1H), 3.85 (dd, J = 12.8, 6.4 Hz, 
1H), 2.20 (s, 3H), 2.18 (s, 3H), 2.08 (s, 3H), 1.99 (s, 3H), 1.22 (d, J = 6.4 Hz, 3H). ESI-MS 
m/z calculated for C13H20O7S [M+Na]+  343.1;  Found : 343.1 
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Methyl 2,3,4-Tri-O-(p-methoxybenzyl)-1-thio-L-fucopyranoside (7). Compound 
7 is prepared following a procedure by Izumi et al.26 To a solution of 6 (6.38 g, 19.92 
mmol) in MeOH (39.8 ml) was added 0.5M NaOMe (20.0 ml, 9.96 mmol), and the mixture 
was left to stir for 1.5 hours at room temperature. After deacetylation was completed as 
monitored by TLC, the reaction mixture was neutralized to pH ~ 7 by the addition of 
Dowex 50W-X4-200 (H+) and the resin was filtered off. The filtrate was concentrated in 
vacuo and dried under high vacuum before it was re-dissolved in DMF (79.0 ml). NaH 
(4.16 g, 173.26 mmol) was added at 0oC to the solution and the mixture was stirred for 30 
minutes before PMBCl (13.8 ml, 99.60 mmol) was added. The reaction mixture was 
allowed to stir overnight at room temperature. Methanol was added to the solution before 
the reaction mixture was diluted with EtOAc and washed extensively with aq NaCl. The 
organic extract was dried (Na2SO4) and concentrated in vacuo before the crude product was 
purified by column chromatography (3:1 Hex:EtOAc) to afford white solid 7 (9.70 g, 
70.9%).  
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1H NMR (500 MHz, CDCl3) [α]: δ 7.35 – 7.23 (m, 6H), 6.90 – 6.81 (m, 6H), 5.30 (d, J = 
5.5 Hz, 1H), 4.89 (d, J = 11.3 Hz, 1H), 4.76 (d, J = 11.4 Hz, 1H), 4.68 (d, J = 11.6 Hz, 1H), 
4.65 – 4.56 (m, 2H), 4.24 (dd, J = 9.9, 5.5 Hz, 1H), 4.14 – 4.05 (m, 1H), 3.81 (d, J = 2.4 
Hz, 3H), 3.81 – 3.79 (m, 6H), 3.75 (dd, J = 9.9, 2.7 Hz, 1H), 2.00 (s, 3H), 1.08 (d, J = 6.4 
Hz, 3H). [β]:  δ 7.36 – 7.26 (m, 6H), 6.90 – 6.83 (m, 6H), 4.90 (d, J = 11.5 Hz, 1H), 4.77 
(dd, J = 22.1, 9.8 Hz, 2H), 4.68 (q, J = 11.4 Hz, 2H), 4.62 (d, J = 11.6 Hz, 1H), 4.26 (d, J = 
9.6 Hz, 1H), 3.82 (s, 3H), 3.80 (s, 3H), 3.80 (s, 3H), 3.77 (d, J = 9.4 Hz, 1H), 3.55 (d, J = 
2.8 Hz, 1H), 3.53 (d, J = 2.8 Hz, 1H), 3.47 – 3.42 (m, 1H), 2.19 (d, J = 1.1 Hz, 3H), 1.15 
(d, J = 6.4 Hz, 3H). ESI-MS m/z calculated for C31H38NaO7S [M+Na]+ 557.2; Found = 
577.2 
O
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1,6 Anhydro-3,4-O-Isopropylidine 2-O-(Methyl 2,3,4-Tri-O-p-methoxybenzyl-
L-fucopyranosyl)-β-D-galactopyranoside (8). A mixture of 1,6 anhydro-3,4 O-
Isopropylidene-β-D-galactopyranose (5.00 g, 24.73 mmol, Toronto Research Chemical) 
and IDCP (10.02 g, 21.17 mmol)31 in (CH2Cl2)2 - Et2O (1:5) (110.0 ml) with 4Å molecular 
sieves was stirred for 1 hr at 0oC under Ar atmosphere. To the mixture was added a 
solution of 7 (9.70 g, 14.12 mmol, 40 ml) and the reaction mixture was stirred for 2.5 hrs 
while it warmed up to room temperature. After complete consumption of donor 7 as 
monitored by TLC (3:2 Hex:EtOAc), reaction mixture was diluted with chloroform, and 
washed with 2 M aq Na2S2O3. The organic extract was dried (Na2SO4) and concentrated in 
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vacuo before the crude product was purified by column chromatography (3:2 
Hex:EtOAc) to afford yellowish-white solid 3 (5.39 g, 53.9 %). 
1H NMR (500 MHz, CDCl3) δ 7.47 – 7.14 (m, 6H), 6.89 (d, J = 8.6 Hz, 3H), 6.83 (dd, J = 
8.7, 2.4 Hz, 3H), 5.41 (s, 1H), 4.87 (dd, J = 12.4, 7.6 Hz, 2H), 4.76 (dd, J = 11.3, 3.2 Hz, 
2H), 4.65 (d, J = 11.1 Hz, 1H), 4.56 (dd, J = 11.4, 1.9 Hz, 2H), 4.45 (dt, J = 13.1, 6.0 Hz, 
2H), 4.22 (d, J = 7.2 Hz, 1H), 4.08 (d, J = 7.5 Hz, 1H), 4.01 – 3.92 (m, 2H), 3.87 (dd, J = 
10.2, 2.9 Hz, 1H), 3.82 (s, 3H), 3.80 (s, 3H), 3.79 (s, 3H), 3.68 (s, 1H), 3.64 (d, J = 1.8 Hz, 
1H), 3.55 (dd, J = 7.3, 5.4 Hz, 1H), 1.53 (s, 3H), 1.32 (s, 3H), 1.06 (d, J = 6.5 Hz, 3H). ESI-
MS m/z calculated for C39H48NaO12 [M+Na]+  731.3;  Found = 731.3 
 
 
 
 
 
3,4-Di-O-acetyl-1,6-anhydro-2-O- (Methyl 2,3,4-Tri-O-acetyl-α-L-
fucopyranosyl)-β-D-galactopyranoside (9).  A solution of disaccharide 8 (5.39 g, 7.61 
mmol) and Ceric Ammonium Nitrate (CAN) in MeCN/H2O (9:1) was stirred at rt for 2.5 h. 
After complete deprotection of p-methoxy benzyl and isopropylidene group as monitored 
by TLC, pyridine, acetic anhydride and catalytic amount of DMAP were added to the 
reaction mixture at 0oC before the reaction mixture was allowed to stir at rt. After the 
reaction was completed as monitored by TLC, the mixture was diluted with chloroform and 
washed successively with aq CuSO4, H2O and aq NaHCO3. The organic extract was dried 
O
OAcAcO
O
O
O
AcOOA
c
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(MgSO4) and concentrated in vacuo before the crude product was purified by column 
chromatography (3:2 Hex:EtOAc) to afford white solid 8 (2.69 g, 68.2%).  
1H NMR (500 MHz, CDCl3) δ 5.43 (s, 1H), 5.35 – 5.30 (m, 2H), 5.24 (d, J = 3.8 Hz, 1H), 
5.19 (t, J = 4.7 Hz, 1H), 5.13 (dd, J = 10.8, 3.6 Hz, 1H), 5.08 (d, J = 5.4 Hz, 1H), 4.47 (t, J 
= 4.4 Hz, 1H), 4.34 – 4.26 (m, 2H), 3.72 (dd, J = 7.2, 5.1 Hz, 1H), 3.61 (s, 1H), 2.16 (s, 
3H), 2.14 (s, 3H), 2.09 (s, 3H), 2.05 (s, 3H), 1.99 (s, 3H), 1.13 (d, J = 6.6 Hz, 3H). 13C 
NMR (125 MHz, CDCl3) δ 170.87, 170.76, 170.23, 169.92, 169.34, 100.52, 97.23, 72.22, 
71.01, 68.23, 68.09, 67.62, 65.31, 65.27, 64.58, 62.44, 21.02, 20.89, 20.84, 20.83, 20.77, 
16.07. HRMS m/z Calculated for C22H31O14 [M+H]+ 519.1714. Found : 519.1731. 
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Phenyl 3,4,6-Tri-O-acetyl-2-O-(Methyl 2,3,4-Tri-O-acetyl-α-L-fucopyranosyl)-
1-thio-D-galactopyranoside (10). A mixture of 9 (510 mg, 0.98 mmol), (phenylthio)-
trimethylsilane (0.77 ml, 3.94 mmol) and zinc iodide (1.29 g, 3.94 mmol) in CH2Cl2 (1.0 
ml) was stirred overnight at rt.32 After complete consumption of the starting material as 
monitored by TLC, the mixture was diluted with EtOAc and washed successfully with aq 
NaHCO3, H2O and aq NaCl. The organic extract was dried with Na2SO4 and concentrated 
in vacuo before it was re-dissolved in dry THF (2.80 ml) and 1M tetrabutylammonium 
fluoride in THF (1.97 ml) was added into the solution. After one hour, solvent was 
removed in vacuo and the residue was re-dissolved in EtOAc, washed with H2O, aq 
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NaHCO3, and aq NaCl, dried over with Na2SO4 and concentrated to afford thioglycoside. 
To a solution of thioglycoside in dry pyridine (9.55 ml, 118.08 mmol) was added catalytic 
amount of DMAP and acetic anhydride (6.05 ml, 63.96 mmol) before the mixture was 
allowed to stir at rt. After complete protection of free hydroxyl group, the reaction mixture 
was diluted with EtOAc, washed successively with aq CuSO4, aq NaHCO3, H2O and aq 
NaCl. The organic extract was dried with Na2SO4 and concentrated in vacuo before the 
crude product was purified by column chromatography (3:2 Hex:EtOAc) to afford white 
solid 9 (363 mg, 55%). 
1H NMR (500 MHz, CDCl3) δ 7.48 (d, J = 7.3 Hz, 2H), 7.36 – 7.27 (m, 3H), 5.69 (d, J = 
5.7 Hz, 1H), 5.45 (d, J = 3.1 Hz, 1H), 5.34 (d, J = 3.2 Hz, 1H), 5.30 (d, J = 3.7 Hz, 2H), 
5.21 (dd, J = 10.6, 3.4 Hz, 1H), 5.03 (dd, J = 10.7, 3.9 Hz, 1H), 4.73 (t, J = 6.5 Hz, 1H), 
4.36 (q, J = 6.5 Hz, 1H), 4.29 (dd, J = 10.6, 5.7 Hz, 1H), 4.07 (t, J = 6.4 Hz, 2H), 2.15 (s, 
3H), 2.14 (s, 3H), 2.04 (s, 3H), 1.99 (s, 6H), 1.96 (s, 3H), 1.00 (d, J = 6.5 Hz, 3H). 13C 
NMR (125 MHz, CDCl3) δ 170.69, 170.65, 170.56, 170.27, 170.03, 169.97, 133.22, 
131.70 (2C), 129.32 (2C), 127.78, 98.21, 87.81, 73.15, 70.99, 70.09, 68.16 (2C), 67.89, 
67.35, 65.87, 61.83, 20.92, 20.88, 20.84 (2C), 20.81, 20.80, 16.03. HRMS m/z Calculated 
for C30H38O15S [M]+ 670.1931. Found : 670.1941. 
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3-azidopropyl 3,4,6-Tri-O-acetyl-2-O-(Methyl 2,3,4-Tri-O-acetyl-α-L-
fucopyranosyl)-D-galactopyranoside (11). The following is modified procedure from 
Kanie et al.33 Compound 10 (363 mg, 0.54 mmol) and 3-azidopropanol (75 ul, 0.81 mmol) 
was azeotroped with toluene, dissolved in acetonitrile with 4Å molecular sieves and cooled 
to -20oC. To the mixture, N-Iodosuccinimide (192 mg, 0.81 mmol) was added and it was 
allowed to stir for 15 minutes. Next, silver triflate (209 mg, 0.81 mmol) was added and the 
mixture was allowed to warm up to room temperature and stirred for 1 h. After the reaction 
was completed as monitored by TLC, the reaction mixture was diluted with EtOAc and 
washed successively with sat aq Na2SO3, aq NaHCO3, and aq NaCl. The organic extract was 
dried with MgSO4 and concentrated in vacuo before the crude product was purified by 
column chromatography (3:2 Hex:EtOAc) to afford pale-yellow solid 10 (228 mg, 64%, 
α:β = 1:3). 
1H NMR (500 MHz, CDCl3) [β]: δ 5.39 (d, J = 3.9 Hz, 1H), 5.35 – 5.25 (m, 3H), 5.05 – 
4.98 (m, 2H), 4.54 – 4.44 (m, 2H), 4.18 (dd, J = 11.2, 6.5 Hz, 1H), 4.10 (dd, J = 11.3, 6.9 
Hz, 1H), 4.01 – 3.85 (m, 3H), 3.68 (dt, J = 9.9, 6.3 Hz, 1H), 3.43 (t, J = 6.6 Hz, 2H), 2.16 
(s, 3H), 2.13 (s, 3H), 2.05 (s, 3H), 2.01 (s, 3H), 1.99 (d, J = 3.4 Hz, 6H), 1.93 – 1.86 (m, 
2H), 1.13 (d, J = 6.5 Hz, 3H).13C NMR (125 MHz, CDCl3) δ 170.78, 170.73, 170.54, 
170.41 (2C), 170.20, 101.75, 95.85, 73.83, 71.91, 71.25, 70.63, 68.33, 67.73, 67.31, 67.02, 
64.77, 61.38, 48.28, 29.44, 20.88, 20.84 (3C), 20.80, 20.77, 15.90. HRMS m/z Calculated 
for C27H39O16Na [M+Na]+ 684.2228. Found : 684.2228. 
O
AcO OAc
AcO
O
O
AcO
OAc
OAc
O N3
 53 
 
O
AcO OAc
AcO
O
O
AcO OA
c
OAc
O
H
N
O
 
3-N-Acryoyl-aminopropyl-3,4,6-Tri-O-acetyl-2-O-(Methyl 2,3,4-Tri-O-acetyl-
α-L-fucopyra-nosyl)-D-galactopyranoside (12). A suspension of 11 (204 mg, 0.31 mmol) 
and Pd/C (20% by wt) in dry EtOAc (3.1 ml) was charged with H2 gas for 3.5 h in the 
presence of catalytic amount of triethyl amine. After reduction of azido group was 
completed, reaction mixture was diluted with EtOAc and was filtered off packed celite. The 
filtrate was concentrated in vacuo and the crude material was dissolved in dioxane (3.0 ml) 
before the addition of aq NaHCO3 (32.8 mg in 2.9 ml H2O, 0.39 mmol). The mixture was 
cooled to 0oC, stirred for 15 mins before acryolyl chloride (37.2 μl, 0.45 mmol) was added 
dropwise and allowed to warm up overnight while minimizing exposure to light. Once 
reaction was completed, the mixture was diluted with EtOAc and washed with H2O. The 
organic layer was concentrated in vacuo and the crude product was purified by column 
chromatography (1:9 MeOH:CH2Cl2) to afford 11 as colorless oil (119 mg, 57%). 
1H NMR (500 MHz, CDCl3) δ 6.30 (dd, J = 17.0, 1.4 Hz, 1H), 6.14 (dd, J = 17.0, 10.3 Hz, 
1H), 5.64 (dd, J = 10.3, 1.4 Hz, 1H), 5.40 (d, J = 3.8 Hz, 1H), 5.32 – 5.27 (m, 3H), 5.04 – 
4.97 (m, 2H), 4.54 (q, J = 6.6 Hz, 1H), 4.47 (d, J = 7.8 Hz, 1H), 4.18 (dd, J = 11.3, 6.7 Hz, 
1H), 4.11 (dd, J = 12.4, 6.9 Hz, 1H), 3.97 – 3.86 (m, 3H), 3.76 – 3.69 (m, 1H), 3.44 (q, J = 
6.6 Hz, 2H), 2.16 (s, 3H), 2.14 (s, 3H), 2.05 (d, J = 2.1 Hz, 3H), 2.01 (s, 3H), 2.00 (s, 3H), 
1.99 (s, 3H), 1.89 (td, J = 13.1, 6.6 Hz, 2H), 1.13 (d, J = 6.5 Hz, 3H). 13C NMR (125 MHz, 
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CDCl3) δ 170.71, 170.70, 170.53, 170.47, 170.32, 170.30, 165.86, 131.02, 126.35, 
101.74, 95.67, 73.72, 71.62, 71.15, 70.77, 68.24, 67.98, 67.83, 67.40, 64.79, 61.44, 37.03, 
29.69, 20.88, 20.81, 20.78 (2C), 20.73 (2C), 15.83. HRMS m/z Calculated for C30H44NO17 
[M+H]+ 690.2609. Found : 690.2629. 
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3-N-Acryoyl-aminopropyl-2-O-(α-L-fucopyranosyl)-D-galactopyranoside (2). 
To a solution of 12 (119 mg, 0.17 mmol) in MeOH (1.1 ml) was added 0.5M NaOMe (0.10 
ml, 0.052 mmol), and the mixture was left to stir at rt for 1 h. After deacetylation was 
completed as monitored by TLC, the reaction mixture was neutralized to pH ~ 7 by the 
addition of Dowex 50W-X4-200 (H+) and the resin was filtered off. The filtrate is 
concentrated in vacuo and purified with gel filtration chromatography (Sephadex LH-20) to 
obtain glycomonomer 2 (68 mg, 89.7%). 
1H NMR (500 MHz, D2O) δ 6.25 (dd, J = 17.1, 10.2 Hz, 1H), 6.17 (dd, J = 17.1, 1.3 Hz, 
1H), 5.74 (dd, J = 10.2, 1.3 Hz, 1H), 5.23 (d, J = 3.9 Hz, 1H), 4.48 (d, J = 7.9 Hz, 1H), 4.29 
(q, J = 6.5 Hz, 1H), 3.95 (dt, J = 10.2, 6.8 Hz, 1H), 3.89 (d, J = 3.3 Hz, 1H), 3.84 (dt, J = 
9.5, 2.7 Hz, 2H), 3.81 – 3.71 (m, 5H), 3.67 (dd, J = 7.7, 4.5 Hz, 1H), 3.58 (dd, J = 9.5, 7.9 
Hz, 1H), 3.35 (dd, J = 11.3, 6.7 Hz, 2H), 1.91 – 1.84 (m, 2H), 1.19 (d, J = 6.6 Hz, 3H). 13C 
NMR (125 MHz, D2O) δ 168.68, 130.08, 127.30, 101.68, 99.67, 77.09, 75.14, 73.83, 
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72.01, 69.64, 69.09, 68.48, 67.87, 66.98, 61.12, 36.57, 28.70, 15.51. HRMS m/z 
Calculated for C18H31NO11Na [M+Na]+ 460.1795. Found : 460.1781. 
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3-N-Acryloyl- aminopropyl azide (13). A solution of 3-azidopropylamine (873 
mg, 8.721 mmol) in dioxane (20 ml) was added with aq NHCO3 (953 mg in 12 ml H2O, 
11.34 mmol) and was stirred and cooled to 0oC. After 15 mins, acryolyl chloride (1.08 ml, 
13.08 mmol) was added dropwise to the reaction mixture and allowed to warm up to room 
temperature while minimizing exposure to light. After 2 h, the mixture was diluted with 
EtOAc, washed with H2O, and the organic layer was concentrated in vacuo. Crude product 
was purified with column chromatography (1:1 Hex:EtOAc) to afford colorless oil 13 (1.12 
g, 83%). 
1H NMR (500 MHz, CDCl3) δ 6.29 (dd, J = 17.0, 1.3 Hz, 1H), 6.08 (dd, J = 17.0, 10.3 Hz, 
1H), 5.66 (dd, J = 10.3, 1.3 Hz, 1H), 3.44 (dd, J = 13.0, 6.5 Hz, 2H), 3.40 (t, J = 6.6 Hz, 
2H), 1.88 – 1.80 (m, 2H). 13C NMR (125 MHz, CDCl3) δ 165.84, 130.77, 126.80, 49.52, 
37.36, 28.87. HRMS m/z Calculated for C6H10N4O [M]+ 154.0855. Found : 154.0842. 
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3-N-Acrlyloyl-aminopropyl-2-Nitro-phenylazide (4). The following is modified 
procedure from Lindsley et al.34 and Hemming et al.35 Triphenylphosphine polystyrene 
resin (Novabiochem) was first equilibrated by washing successively with THF, CH2Cl2 and 
MeOH. After drying in vacuo, A suspension of the resin (3.40 g, 3.40 mmol) and 13 (526 
mg, 3.39 mmol) in THF (21 ml) was gently shaken at 37oC for 24 h. The mixture was 
filtered off and the residual beads were washed successively with THF, CH2Cl2 and 
MeOH. After drying in vacuo, the resin was resuspended in THF/H2O (10:1) (15 ml), and 
gently shaken at 37oC for 48 h before the reaction mixture was filtered off. The filtrate was 
collected, and the resins were washed off with CH2Cl2 and MeOH. The filtrate and the 
washes were combined and concentrated in vacuo to afford the amine intermediate (185 
mg, 42.6 %). To a solution of the amine in dry DMF (7.5 ml) was added Et3N (0.110 ml, 
0.786) and ANB-NOS (Pierce) (200 mg, 0.655 mmol). The reaction was allowed to stir 
overnight in dark and concentrated in vacuo before the crude product was purified by 
column chromatography (10:1 EtOAc: MeOH) to afford crosslinker 6 ( 69 mg, 33%). 
1H NMR (500 MHz, CDCl3) δ 8.13 (d, J = 8.7 Hz, 1H), 7.15-7.11 (m, 2H), 6.23 (dd, J = 
17.0, 1.3 Hz, 1H), 6.10 (dd, J = 16.9, 10.2 Hz, 1H), 5.66 (dd, J = 10.2, 1.3 Hz, 1H), 3.54 – 
3.45 (m, 4H), 1.89 – 1.81 (m, 2H). 13C NMR (125 MHz, CDCl3) δ 166.93, 166.33, 146.52, 
142.34, 135.78, 130.58, 127.16, 127.07, 120.13, 119.13, 36.51, 36.25, 29.41. HRMS m/z 
Calculated for C13H15N6O4 [M+H]+ 319.1155. Found : 319.1154. 
 
 57 
NHNH
O
S
H
N
O
NH2  
2-(4-Aminophenyl) Ethyl-Biotinylamide (1). Compund 1 was synthesized 
according following previous work by Tseng et al.29 To a solution of 4, 2-aminoethyl 
aniline (47 μl, 0.35 mmol) in DMF (1.0 ml), was added triethyl amine (51 μl, 0.37 mmol) 
and stirred for 30 min. Next, NHS-biotin dissolved in DMF (100 mg in 2.5 ml, 0.29 mmol) 
was transferred into the reaction mixture and stirred overnight. After all NHS-biotin was 
reacted, as monitored by TLC, reaction mixture was concentrated in vacuo before the crude 
product was purified by column chromatography (CHCl3:MeOH = 8:1) to obtain pale 
yellow solid 12 (88.2 mg, 84%). 
1H NMR (500 MHz, CD3OD) δ 6.97 (d, J = 8.2 Hz, 2H), 6.68 (d, J = 8.2 Hz, 2H), 4.50 (dd, 
J = 7.8, 4.9 Hz, 1H), 4.30 (dd, J = 7.8, 4.5 Hz, 1H), 3.35 (ddd, J = 10.2, 7.6, 4.6 Hz, 2H), 
3.23 – 3.16 (m, 1H), 2.94 (dd, J = 12.7, 5.0 Hz, 1H), 2.74 – 2.64 (m, 3H), 2.17 (t, J = 7.3 
Hz, 2H), 1.75 – 1.53 (m, 4H), 1.44 – 1.35 (m, 2H). 13C NMR (126 MHz, CD3OD) δ 
175.95, 166.13, 146.81, 130.41 (2C), 130.09, 116.89 (2C), 63.37, 61.64, 56.97, 42.17, 
41.04, 36.81, 35.71, 29.68, 29.48, 26.93. ESI-MS m/z Calculated for C18H27N4O2S [M+H]+ 
363.2. Found : 363.2 
 
Copolymerization reaction with a biotin-derivatized initiator. Copolymerization 
reaction was set up according to procedure modified from Hou et al.36 In a typical 
polymerization experiment, 4-aminobenzyl-biotinylamide 1 (16.6 mg, 45.9 µmol) was 
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dissolved in degassed H2O/THF (1:1) (0.8 ml) and reacted with HBF4 (8.7 μl, 50 wt % 
aqueous solution, 68.8 µmol) at 0oC under an Ar atmosphere. The diazonium salt was 
generated by the addition of NaNO2 (3.92 mg, 55.1 µmol) into the reaction mixture. After 
30 min, a degassed mixture of glycomonomer 2 (75.25 mg, 172.1 µmol), crosslinker 
monomer 4 (18.26 mg, 57.4 µmol), acrylamide (48.9 mg, 688 µmol), and NaOCN (15.15 
mg, 224 µmol) in H2O/THF (1:1) (1.2 ml) were introduced to the diazonium salt and the 
reaction mixture was heated to 60 oC for 16 h. Copolymers formed are dialyzed (3000 MW 
Cutoff) at 4oC against H2O for 48 h and purified by gel filtration chromatography (G-25). 
The resulting polymer was lyophilized to afford biotin-polymer as fluffy powder.  
Conversion of the glycosyl monomer was calculated by comparing the integrals of the 
methyl peaks of fucose (1.24 ppm, 3H) and those of the phenyl group of the biotin handle 
(7.18 ppm, 4H). Conversion of the crosslinker was calculated by comparing the integrals of 
the phenyl azide proton peaks (8.27 ppm, 3H) and those of the phenyl group of the biotin 
handle.  
 
FucGal polymer (I). Polymer I was prepared using the above procedure without 
the crosslinker monomer to yield an orange fluffy powder (41.8%). Mn (SEC) = 26300.  
PDI (SEC) = 1.17. 1H NMR (500 MHz, D2O) δ 7.18 (d, J = 15.5 Hz, 5H), 5.24 (s, 11H), 
5.11 – 5.01 (m, 5H), 4.55 – 4.26 (m, 32H), 4.13 – 3.51 (m, 186H), 3.48 – 3.12 (m, 38H), 
2.43 – 2.04 (m, 229H), 1.91 – 1.44 (m, 500H), 1.30 – 1.15 (m, 58H). 
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FucGal crosslinker polymer (II). Polymer II was prepared using the above 
procedure to yield a light yellow fluffy powder (19.5% yield). Mn (SEC) = 23900. PDI 
(SEC) = 1.22. 1H NMR (500 MHz, D2O) δ 8.27 – 7.95 (m, 28H), 7.18 (d, J = 16.3 Hz, 6H), 
5.24 (s, 25H), 5.12 – 4.99 (m, 18H), 4.55 – 4.25 (m, 58H), 4.12 – 3.49 (m, 374H), 3.42 – 
3.12 (m, 80H), 2.44 – 2.00 (m, 159H), 1.89 – 1.46 (m, 338H), 1.24 – 1.14 (m, 91H). 
 
Control crosslinker polymer (III). Polymer III was prepared using the above 
procedure, substituting 2 with 3, to yield a white fluffy powder (20.8% yield). Mn (SEC) = 
23000.  PDI (SEC) = 1.17. 1H NMR (500 MHz, D2O) δ 8.29 – 7.90 (m, 20H), 7.18 (d, J = 
16.1 Hz, 5H), 3.63 (s, 85H), 3.24 (s, 98H), 2.46 – 1.94 (m, 213H), 1.70 (d, J = 54.2 Hz, 
477H). 
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C h a p t e r  4  
PROTEOMIC IDENTIFICATION OF FUCα(1-2)GAL LECTINS 
4.1. Lectin Discovery by Mass Spectrometry 
Mass-spectrometry (MS)-based strategies have been highly successful in 
identifying and profiling proteins in complex mixtures. Key insights into composition, 
regulation and function of molecular complexes and pathways have been characterized 
using MS-based technologies. Indeed, new MS-based method for rapid analysis of protein 
structures and function, are responsible for generating large data sets, which ultimately are 
translated into novel discoveries.  These large-scale approaches to protein science are 
collectively termed proteomics. 
The goal of proteomics is to investigate the protein spectrum and its biological 
functions, and consequently to extract meaningful information for disease prognosis and 
drug targeting.1 Large-scale proteomic analysis is supported by the advances in MS 
technology, computer and software sciences and the enormous amount of genomic 
information, which is now available for many organisms. A proteomic analysis comprises 
two steps: (i) separation of protein mixtures and (ii) identification of the separated proteins 
by various analytical methods, mainly by mass spectrometry.2–6 MS has become the 
dominant technique for several reasons, mainly because of its unparalleled ability to 
acquire high-content quantitative information about complex biological samples from 
many different tissue samples including the brain.7–9 Furthermore, MS can be used for de 
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novo sequencing to determine structural information (in particular post-translational 
modifications) as well as to quantify relative and absolute amounts of proteins through 
isotopic or chemical labeling methods.10–12 
The challenge of studying glycosylation in cellular environment is attributed to the 
heterogeneity of the glycans, the complex biosynthesis of the epitopes, the multivalent 
nature of glycan recognition and the subtle phenotypes of glycan manipulation that often 
require multicellular environments to manifest.13 The development of large-scale 
systematic MS methods is critical for advancing the frontiers of functional glycomics and 
for understanding the biological roles of specific glycan structures.14 Identification of 
glycoproteins typically requires the combination of affinity purification using lectin 
enrichment or chemical tagging and MS-based analysis of the glycan structures. On the 
other hand, general, systems-level approaches for the proteome-wide identification of 
glycan-binding proteins have been lacking. As a result, we seek to address these challenges 
by employing our multivalent crosslinking probes for the discovery of novel mammalian 
lectins. 
4.2. Lectin Capture with Biotinylated Multivalent Probes  
To show the application of our capture probes, we first targeted the known Fucα(1-
2)Gal plant lectin Ulex europaeus agglutinin I (UEAI), which binds α−L-Fucose-OMe 
with weak affinity (Ka= 6.4 x 103 M-1).15 UEAI was also found to agglutinate human red 
cells due to its strong affinity for the H-type 2 determinant (Fucα(1-2)Galβ(1-
4)GlcNAc).16,17 The UEAI-H-type 2 glycan complex consisted of a single UEAI dimer, 
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two Ca2+ and Mn2+ ions (one Ca2+ and Mn2+ per subunit) and a single H-type 2-OMe 
glycan epitope.18  The increased hydrogen bonding of Gal and GlcNAc epitopes towards 
the respective R102 and R222 residues of UEAI binding site, resulted in affinity 
enhancement  (Ka= 1.8 x 106 M-1) and stabilization of the UEAI-H-type2 carbohydrate 
complex.17–19 Consequently, these studies confirmed the multivalent interactions between 
UEAI and Fucα(1-2)Gal carbohydrates. As a result, we sought to demonstrate that the 
glycopolymer capture probes would be suitable for lectin enrichment. In addition, we will 
further evaluate the UV crosslink enrichment to assess the potential for lectin isolation and 
identification from more complex samples. 
 Fluorescein-conjugated UEAI was incubated with polymer II for 3 h at 37oC, 
exposed to 365 nm light, and the crosslinked proteins were isolated by affinity purification 
using immobilized streptavidin resin conjugate. Captured UEAI was eluted, resolved with 
SDS-PAGE and quantified by in-gel fluorescence imaging. As a control, we used polymer 
III to determine the specificity of UEAI enrichment to the carbohydrate ligand. Only 
glycopolymer II was capable of capturing UEAI, indicating the selective binding to 
Fucα(1-2)Gal glycan (Fig 4.1). Moreover, incorporation of the photoactivatable 
crosslinking group in the polymer led to a twofold increase in UEAI capture.  These results 
validate the polymer design and show that synthetic glycopolymers can be used for 
efficient affinity capture of lectins with weak carbohydrate-binding affinity.  
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Fig 4.1. UEAI Capture with Glycopolymer probes. UEAI 
isolation is specific to Fucα(1-2)Gal (lane 2 vs 1) and UV 
irradiation increases captured protein enrichment (lane 4 vs 2). 
4.3. Identification of Fucα(1-2)Gal Lectins in the Brain 
We next investigated the use of polymer II to target Fucα(1-2)Gal lectins from 
neurons. To ensure that the multivalent probes were non-toxic to neuronal cells, we 
examined the effects of polymer treatment on neuronal morphology. Hippocampal neurons 
were isolated from E18 rats, cultured for 24 h in vitro and treated with polymer II for 20 h. 
Following fixation and staining with tubulin antibody, neurons were imaged with 
fluorescence microscopy and analyzed for neurite outgrowth. Treatment of hippocampal 
neurons with the glycopolymer probes elicited no visible sign of cellular toxicity after 20 h 
incubation (Fig 4.2). Furthermore, neurons exposed to the Fucα(1-2)Gal glycopolymer 
exhibited a 22% increase in neurite outgrowth relative to the untreated control (Fig 4.3), 
indicating that the multivalent probes were suitable for our biological study even at high 
concentration treatment (60 µM). 
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Fig 4.2. Synthetic Fucα(1-2)Gal Multivalent Probes are non-toxic to 
hippocampal neurons a) untreated neurons b) treatment with 60 µM Pol II.  
 
 
 
 
Fig 4.3. Fucα(1-2)Gal stimulates neuronal growth. Neurite Outgrowth was 
quantified from 70-80 neurons in three separate experiments. p values are 
relative to the untreated control neurons (p < 0.01). 
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Having tested these polymers on neuronal cells, we next investigated the use of 
polymer II to identify Fucα(1-2)Gal lectins from the brain . While recent works by Cisar et 
al.20 and Li et al.21 highlight the elegant applications of SILAC-based quantitative 
proteomic technologies to identify weak-binding interactions, such approaches cannot be 
applied to post-mitotic neuronal cells. As a result, we performed a series of proteomic 
experiments on different brain lysate fractions to identify protein subsets that bind to 
Fucα(1-2)Gal carbohydrates. Using these strategies, we sought to characterize lectin 
distribution across different cellular compartments and isolate lectin candidates from the 
membrane interface.  By profiling lectin distribution across various lysate fractions, we 
sought to develop functional understanding of the Fucα(1-2)Gal interactions in different 
cellular localization.  
Subcellular fractions from rat brain were incubated with polymer II or III for 3 h at 
37oC, exposed to 365 nm light, and the crosslinked proteins were isolated by streptavidin 
affinity chromatography. Captured proteins were eluted, resolved with SDS-PAGE, 
proteolytically digested and subjected to LC-MS/MS analysis (Fig 4.4).  Lectin enrichment 
profiles were analyzed by silver staining to screen for distinct protein bands that were 
captured by Fucα(1-2)Gal polymer II but were absent from control polymer III. We 
observed limited specificity towards Fucα(1-2)Gal binding in whole lysates as well as the 
cytosolic, nuclear and cytoskeletal fractions (Fig 4.5). In contrast, we discovered enhanced 
protein capture specificity from both synapse-enriched (synaptosome) and neuronal 
membrane fractions, indicating that Fucα(1-2)Gal interactions could be concentrated 
around the synaptic region (Fig 4.6).  
 68 
 
Fig 4.4. Strategies for Fucα(1-2)Gal lectin enrichment from neuronal protein lysates 
using multivalent capture probe. 
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Fig 4.5. Representative gel profiling captured lectins from the 
whole lysates, cytoskeleton, cytosol and membrane fractions. 
 
 
 
 
 
 
Fig 4.6. Representative gel profiling captured lectins from the 
synaptosome and membrane fractions (n=3 each). 
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Synaptic vesicle glycoprotein 2a (SV2a) ATP synthase alpha subunit (Atp5a1)
Alpha coat protein (Copa) Glutamate receptor 2 (Gria2)
Chaperone protein (Hspcb) ADP/ATP carrier protein (Slc25a4)
Microtubule associated protein (Map2)
TATA binding protein (Cand1) Kinesin motor protein (Kif5c)
RNA helicase (Ddx1) Dynein motor protein  
Doublecortin-like kinase 1 (DCLK1)
Dihydropyrimidinase-related protein (Crmp1)
Protein kinase C epsilon (PKCε)
GTPase associated Protein (Centg3)
Lon mitochondrial protease (Prss15)
Ubiquitin hydrolases (Uspx9)
Cellular Adhesion (5%)
Mitochondrial dehydrogenase (Odo1)
Cadherin-associated protein (Ctnna2)
Catenin delta-1 (Ctnnd1)
Cellular Metabolism (20%) Cellular Signaling (16%)
Fatty acid synthase (Fasn)
Trafficking Protein (18%)
Protein Synthesis (14%)
Cytoskeletal Protein (20%)
Ion and Solute Transporters (7%)
In total, we identified 44 candidate Fucα(1-2)Gal lectins and/or receptors from 
six total experiments (three each using synaptosome or neural membrane fractions)  with 
highly stringent identification criteria. Lectin candidates were selected when: 1) the 
proteins contained at least 3 unique peptides and are absent in the negative control, 2) the 
proteins are identified at least twice out of the three sample runs and 3) the total number of 
unique peptides for each protein is ≥ 6. Bioinformatics analyses were performed on 
candidate lectins using NCBI-Pubmed and EMBL-EBI database search, and each protein 
was inspected in 3 categories: spectral abundance, protein structures and molecular 
function.  Interestingly, the candidate lectins fall into a broad range of functional classes, 
including those involved in cellular signaling, protein trafficking, protein scaffolding and 
cellular metabolism (Fig 4.7). In addition, sequence coverage and unique peptide 
assignments that were specific to the protein candidate were listed in Table 4.1.  
 
Fig 4.7. Functional classifications of Fucα(1-2)Gal lectins in the brain. 
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Ascension Unique Coverage MW 
Number Peptideb (%)b (Da)
Cellular Adhesion
Ctnna2 IPI00364916.2 8 13.6 100000 Cellular differentation
Ctnnd1 IPI00359491.3 6 10 105000 Cellular recognition
Cellular Signalling
Dclk1 (Ania 4) IPI00778626.1 13 23.8 84000 Neuronal migration
Centg3 IPI00358128.3 6 9 102000 Signal transduction
Crmp1 (DRP-1; Ulip3; Dpysl1) IPI00561065.2 9 16 74000 Axonal guidance
Crimp4 (Dpysl3; TUC-4b) IPI00203250.1  7 13.6 74000 Neurite outgrowth
Gαo IPI00231505.5 7 22.3 40000 Signal transduction
Gnaq IPI00230868.4 6 20.1 42000 Signal transduction
Pkcε IPI00551781.4 10 17.8 83000 Phosphorylation
Cytoskeletal Associated Protein
Ckap5 IPI00764313.1 9 5.9 197000 Microtubule elongation
Cyln2 (Clip2) IPI00195929.1 10 12.3 111000 Microtubule associated transport
Dync1h1 (dyhc1, map1c) IPI00327630.1 54 13.5 532000 Dynein motor protein
Kif5b  IPI00364904.2 10 15.1 110000 Kinesin motor protein
Kif5c IPI00193402.4 16 21.2 109000 Kinesin motor protein
Macf1 (LOC362587) IPI00359003.4 6 1 831000 Actin regulation
Map4 (LOC367171 ) IPI00393975.2 8 10.4 110000 Microtubule assembly
Mtap2 (Map2) IPI00206171.1  10 7.1 202000 Cytoskelatal organization
Tbcd (LOC363309) IPI00765967.1 6 5.6 134000 Microtubule regulation
Cellular Metabolism
Aco2 IPI00421539.3 8 13.1 85000 Mitochondrial metabolism
Cad IPI00365582.3  6 3.1 243000 Enzymatic biosynthesis
Fasn IPI00200661.1 21 11.1 273000 Lipid biosynthesis
Hk1 IPI00202543.1 10 13 102000 Mitochondrial metabolism
Immt IPI00364895.4 7 12.4 82000 Mitochondrial  homeostasis
Odo1 (LOC360975) IPI00215093.1 13 17.9 116000 Mitochondrial metabolism
Phgdh IPI00475835.3 7 16.9 56000 Enzymatic biosynthesis
Prss15 IPI00205076.1 10 12.9 106000 Mitochondrial proteases
Uspx9 IPI00204923.4 11 5.4 291000 Ubiquitin Hydrolases
Protein Synthesis
Aars IPI00363563.3 8 11.5 107000 Translation
Cand1 IPI00205466.1 8 7.1 136000 Transcription
Ddx1 IPI00555314.1 8 12.8 82000 Transcription
Lrpprc Leucine rich protein 157 IPI00360075.2 12 10.7 157000 Transcription
Nars IPI00565217.3 7 15.2 64000 Translation
Tufm IPI00371236.3 7 19.7 50000 Translation
Transporters
Atp5a1 IPI00396910.1 10 24.6 60000 ADP/ATP biosynthesis
Gria2 IPI00780113.1 6 7.5 103000 Glutamate Receptor
Slc25a4 IPI00231927.11 8 29.9 33000 ADP/ATP Translocase
Trafficking Protein
Dctn1 IPI00196703.1 8 7.2 142000 Retrograde vesicle transport
Dmx-like 2 (LOC315676) IPI00369671.3 7 3.1 344000 Synaptic vesicle scaffolding
Hspcb IPI00471584.7 13 18.9 83000 Chaperone for protein folding
Hspd1 (CH60) IPI00339148.2 12 33 61000 Chaperone for mitochondrial protein
Sv2a IPI00208115.4 6 10.8 83000 Neurotransmitter release
Syn2 IPI00210036.1 6 17.1 63000 Neurotransmitter release
Vac14 IPI00230981.1 7 11.6 88000 Endosome regulation
Vps35 (Mem3) IPI00363493.2 6 9.6 92000 Retrograde protein transport
Protein Function
Table 4.1. Fucα(1-2)Gal lectins from rat synaptosome and membrane fractions.a 
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a) Proteins from Sprague Dawley Rat were captured using the Biotinylated Glycopolymer probe. Proteins are 
tabulated by function, accession  id, number of unique sequence peptides and unique peptide coverage 
b) The number of full tryptic unique peptides and their coverage were identified from a reversed database 
searching strategy. See Materials and Methods for procedures and analysis criteria. 
 
In summary, we reported the first successful capture of Fucα(1-2)Gal binding 
proteins using synthetic multivalent probes. We identified novel lectin candidates from the 
brain and discovered that Fucα(1-2)Gal binding proteins were highly enriched in the 
membrane and synaptic region. The functional diversity represented by this set of proteins 
implicates novel and important roles for Fucα(1-2)Gal glycans.  Projecting forward, we 
seek to validate binding interactions between Fucα(1-2)Gal carbohydrates and these lectin 
candidates.  Importantly, we are interested in understanding functional significance of these 
binding events. We hope to perform specific functional assays to confirm and elucidate 
Fucα(1-2)Gal role in mediating neuronal communication.  Efforts towards validating lectin 
interaction with Fucα(1-2)Gal will be discussed in the next chapter. 
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4.4. Experimental Methods 
Animals, Tissue Isolation and Synaptosome Preparation. Sprague Dawley rats, 
C57BL/6 wild type, FUT1-/- and FUT2-/- mice were maintained in accordance with proper 
Institute of Animal Care and Use Committee (IACUC) procedures. Adult mice (3-4 months 
of age) and postnatal day 3 (P3) pups were anesthetized with CO2 and dissected to remove 
the cortex and hippocampus. Synaptosomes (P2’) were prepared from P3 rat pups by using 
a sucrose density gradient as previously described22 and were dissolved in lectin binding 
buffer [100 mM Tris (pH 7.5), 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 0.5% NP-40, 
and 0.2% sodium deoxycholate supplemented with EDTA-free Complete protease 
inhibitors (Roche)]. To prepare neuronal lysate fractions, cortices from P3 rat pups were 
extracted and fractionated using the Qproteome Cell Compartment Kit (Qiagen) to give a 
final protein concentration of 5 mg/ml. 
Immunocytochemistry of Hippocampal Neuronal Cultures. After 48 h in 
culture, the hippocampal neurons on coverslips were rinsed one time with PBS, fixed in 4% 
paraformaldehyde for 20 min at rt, washed thrice with PBS, permeabilized in 0.3% Triton 
X-100 for 5 min at rt, and washed twice with PBST (PBS + 0.05% Tween 20). Non-
specific binding was blocked by incubating with 5% goat serum for 1 h at 4oC and then 
rinsing twice with PBST. Cells were then incubated with anti-tubulin antibodies (rabbit 
polyclonal, 1:500; Sigma) in 5% goat serum  overnight at 4 °C. Excess antibody was rinsed 
away 5 times with PBST. Secondary antibody, anti-rabbit IgG AlexaFluor 488 (1:500; 
Molecular Probes), was added for 1 h at 37 °C in 5% goat serum. Excess secondary 
antibody was washed off 5 times with PBST. The coverslips were mounted onto glass 
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slides using Vectashield mounting medium (Vector Labs) and sealed with clear nail 
polish. Cells were imaged on a Nikon Eclipse TE2000-S inverted microscope. The images 
were captured with MetaMorph 6.1 software using a 40x plan fluor oil objective. 
Morphometric Analysis. All experiments were performed in triplicate and 70-80 
randomly selected cells were analyzed for each experiment. To ensure accurate 
measurements, only neurites longer than ~ 10 μm and not in contact with other cells were 
quantified with NIH software ImageJ using the NeuronJ plugin.23 Neurite outgrowth was 
expressed as mean neurite lengths and statistical analysis was performed using the 
student’s unpaired t-test. 
UEA I Lectin Enrichment and Photocrosslinking Capture. Fluorescein- 
conjugated UEA1  (100 µg, Vector Laboratories) was treated with 50µM polymer II or III 
in lectin binding buffer and was incubated with gentle end-over-end mixing at 37oC for 3 h 
in dark. The samples were irradiated with UV light using Blak-Ray B100 AP (Upland) for 
15 mins at 4oC and allowed to mix further at rt for 45 mins in dark. The samples were 
diluted with binding buffer to a final concentration of 1 mg/ml and were incubated with 
pre-treated (blocked with 0.1% fish gelatin) streptavidin agarose resin (Pierce) at 4oC for 
2h. The resin was washed twice with 10 column volumes each of low salt buffer (0.1 M 
Na2HPO4 pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% 
SDS), twice with 10 column volumes each of high salt buffer (0.1 M Na2HPO4 pH 7.5, 0.5 
M NaCl, 0.2% Triton X-100), and once with 10 column volumes of 50 mM Tris•HCl pH 
7.4. Captured protein was eluted in boiling sample buffer (50 mM Tris pH 6.8, 2.5% SDS, 
2mM DTT, 10% Glycerol and 2 mM Biotin) for 5 min. The sample was resolved on a 
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NuPAGE 4-12% Bis-Tris gel (Invitrogen), transferred to polyvinylidene difluoride 
(PVDF) membrane (Millipore) and visualized using a Typhoon Scanner (GE Healthcare).  
Fucα(1-2)Gal Lectin Enrichment and Photocrosslinking Capture. Brain lysates 
from synaptosome and membrane fractions (1.2 mg) obtained as described above, were 
pre-treated with 35µM polymer III in lectin binding buffer and were precleared with high 
capacity streptavidin agarose resin (Pierce) with gentle end-over-end mixing for 2 h in 
dark. After centrifugation, the supernatant was treated with 75µM polymer II or III in 
lectin binding buffer and was incubated with gentle end-over-end mixing at 37oC for 3 h in 
dark. The samples were irradiated with UV light using Blak-Ray B100 AP for 15 mins at 
4oC and allowed to mix further at rt for 45 mins in dark. After diluting with binding buffer 
to a final concentration of 1 mg/ml, samples were incubated with pre-treated (blocked with 
0.1% fish gelatin) high capacity streptavidin agarose resin at 4oC for 4 h. The resin was 
washed twice with 10 column volumes each of low salt buffer, twice with 10 column 
volumes each of high salt buffer, once with 20 column volumes of 4 M urea + 1% SDS and 
once with 10 column volumes of 50 mM Tris•HCl pH 7.4. Captured protein was eluted in 
boiling sample buffer for 5 min and subsequently resolved by 10% SDS-PAGE for LC-MS 
analysis. 
Silver Staining, In-Gel Digestion, and LC-MS Analysis. All silver staining 
reagents were prepared fresh before they were used. The staining and destaining, in-gel 
tryptic digests, and peptide extractions were performed as described previously.24 NanoLC-
MS of in-gel tryptic digests was performed on a Thermo Fisher LTQ XL linear ion trap 
mass spectrometer using a modified vented column setup and data-dependent scanning.25 
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Samples were loaded onto a 360 μm x 100 μm precolumn (2 cm, 5 μm Monitor C18) and 
desalted before the precolumn was placed in-line with the analytical column. Peptides were 
then eluted with a linear gradient from 0 to 40% B over 30min (A, 0.1M aqueous HOAc; 
B, 0.1MHOAc in CH3CN), with a flow rate of approximately 250 nL/min, and using a 360 
μm x 75 μm self-packed column with an integrated electrospray emitter (10 cm, 5 μm 
Monitor C18). For data-dependent experiments, the mass spectrometer was programmed to 
record a full-scan ESI mass spectrum (m/z 400-2000), followed by five data-dependent 
MS/MS scans in the ion trap (relative collision energy of 35%, 3.5 Da isolation window). 
Dynamic exclusion parameters were set as follows: repeat count=1, repeat duration=15 s, 
and exclusion duration=30 s.  
MS/MS spectra were searched against a rat subset of the European Bioinformatics 
Institute-International Protein Index (EBI-IPI) database (downloaded August 1, 2007), with 
an appended reversed database using Sequest 3.0. A fixed modification of Cys (+57), a 
variable modification of Met (+16), and trypsin cleavage were specified. Mass tolerances 
of 3.0 Da for the parent and 0.8 Da for the fragment ions were employed. Search results 
were compiled and filtered in Scaffold 2.0 (Proteome Software, Inc., Portland, OR). 
Peptide identifications were accepted if they could be established at ≥95.0% probability as 
specified by the Peptide Prophet algorithm.26 Protein identifications were accepted if they 
could be established at ≥ 99.0% probability and contained at least three unique identified 
peptides. Protein probabilities were assigned by the Protein Prophet algorithm.27 For a 
protein to be listed in Table 4.1, the protein had to be identified as described above in at 
least two of the three synaptosome and/or neural membrane fractions. 
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C h a p t e r  5  
VALIDATION OF FUCα(1-2)GAL LECTIN CANDIDATES 
5.1. Biological Impact of MS-Based Proteomics 
Glycomics is an integrated approach to study structure–function relationships of 
complex carbohydrates. Glycomic studies have been challenged by the sheer diversity and 
functional information encoded in the glycan structures. These challenges arise from two 
fundamental aspects of the glycan structure–function relationships. First, the biosynthesis 
of glycans is a non–template-driven process involving the coordinated expression of 
multiple glycosyltransferases. Second, understanding the biochemical basis of glycan–
protein interactions in the context of a biological pathway is complicated by the 
multivalency and the graded affinity towards different glycan structures.1 Therefore, the 
study of glycans requires a systems-level approach involving multiple components as well 
as integration of information at molecular, cellular, tissue and higher levels. 
Global analyses of the Fucα(1-2)Gal lectin proteome identified diverse roles for our 
candidate lectins. However, the discovery of ‘true’ lectins is confounded by the fact that 
although receptor-glycan interactions are governed by carbohydrate recognition specificity, 
other factors, such as the protein domain contribution of the glycoconjugates and 
subcellular localization of the lectin and its ligand, must also be considered. As such, only 
specific lectin-glycoprotein pair interactions are functional in situ. As Fucα(1-2)Gal 
carbohydrates have been implicated in synaptic regulation and neuronal plasticity,2,3 we 
focused our attention on lectins associated with similar functions. Candidate lectins were 
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additionally prioritized based on their reported expression and functional profiles. As a 
result, we sought to pursue the validation of four candidate lectins; double cortin-like 
kinase 1 (DCLK1), protein kinase C epsilon subunit (PKCε), synaptic vesicle glycoprotein 
2a (SV2a) and guanine nucleotide-binding protein G(o) alpha subunit (GαO). 
DCLK1 is a brain-associated, membrane-bound protein that is closely related to 
doublecortin (DCX), a protein that is critical for neuronal migration and adult 
neurogenesis.4,5 In addition to the N-terminal DCX-domain-like that binds to microtubules, 
DCLK1 also has a C-terminal serine/threonine kinase domain (CPG 16) that has been 
shown to be upregulated during LTP.6 PKCε has been shown to regulate neurotransmission 
through GABAA receptor trafficking and modulate Na+ channels in hippocampal 
neurons.7,8 Furthermore, PKCε has also been reported to mediate neurite outgrowth through 
its actin-binding activity.9 GαO is a member of the heterotrimeric G protein family that has 
been implicated as modulator of calcium channels and reported to promote neurite 
outgrowth in neuronal cells.10,11 SV2a is a synaptic vesicle transmembrane protein that 
mediates neurotransmitter release by enhancing the Ca2+ responsiveness of each synaptic 
vesicle.12 Indeed, SV2a has been implicated in the regulation of presynaptic Ca2+  through 
its interaction with synaptotagmin 1 (syt1).13 With functions that are complementary to the 
role of Fucα(1-2)Gal glycoproteins, these lectin candidates would be ideal for our initial 
target validation. 
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5.2. Validating Lectin Binding towards Fucα(1-2)Gal Carbohydrates 
We first sought to validate the binding interactions of these lectins with Fucα(1-
2)Gal glycans in vitro.  Two candidate lectins (SV2a and PKCε) were expressed and 
purified and their binding specificities for Fucα(1-2)Gal were assessed using carbohydrate 
microarrays from the Consortium of Functional Glycomics. Lectin candidates were 
incubated with printed microarray slides containing 511 different mammalian glycans, and 
the bound lectins were detected and visualized with fluorescently-labeled antibodies. Both 
SV2a and PKCε bound to the glycan arrays with weak affinity and exhibited binding 
specificities that were not limited to Fucα(1-2)Gal carbohydrates (Fig 5.1). The observed 
low affinities were consistent with monovalent interaction and were mediated presumably 
by imposing a one-to-one association between the lectin and its immobilized glycan 
substrate.  Furthermore, lectins typically suffer from limited binding specificity as they 
exhibit cross-reactivity towards multiple glycan epitopes.14,15 Therefore, we sought to 
characterize these weak interactions by measuring the affinity enhancement contributed by 
the Fucα(1-2)Gal epitopes.  
Further analysis of these binding data revealed that the top 10% of all glycan 
structures recognized by PKCε and SV2a were decorated with terminal Fucα(1-2)Gal or 
NeuAc epitopes. These fucose and/or sialic acid residues are commonly added to the non-
reducing end of an oligosaccharide chain and are often important for lectin recognition. To 
establish their roles in lectin binding, we assessed several top binders containing Fucα(1-
2)Gal-terminated saccharides and measured their relative change in binding affinities when 
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the terminal Fucα(1-2)Gal epitopes were removed. Significant affinity enhancement 
towards Fucα(1-2)Gal sugars was reported for PKCε and SV2a (up to 24- and 45-fold, 
respectively), while a similar comparison for the terminal NeuAc showed more modest 
results with up to fourfold and sixfold increase for PKCε and SV2a, respectively (Fig 5.2).  
 
 
 
 
 
 
 
 
 
 
Fig 5.1. Binding profiles of PKCε and SV2a. Lectin candidates were 
incubated with mammalian glycoarrays in replicates of 6. Top glycan 
chains recognized by the lectin candidates contain terminal fucose (red) 
or terminal sialic acid (green) epitopes. Other top binders are made up 
of charged glycan epitopes 
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Fig 5.2.  Binding affinity is measured on Fucα(1-2)Gal-terminated glycan 
and its precursor glycan chain.  Fucα(1-2)Gal carbohydrates promote 
significant affinity enhancement of up to 45-fold for SV2a (glycan a) and 
25-fold for PKCε (glycan p) in vitro.  
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Next, we sought to verify the multivalent interactions between Fucα(1-2)Gal 
carbohydrates and the four candidate lectins (DCLK1, PKCε, SV2a and GαO). The 
putative lectins were expressed and purified, and their binding affinity for Fucα(1-2)Gal 
was assessed using enzyme-linked lectin assays (ELLA). Briefly, biotinylated 
glycopolymers containing Fucα(1-2)Gal (10-3–102 µM) were incubated with the lectins 
immobilized on microtiter plates, and bound polymer was detected using streptavidin 
conjugated to horseradish peroxidase (-HRP). For comparison, we also examined the 
binding of biotinylated glycopolymers bearing Galα(1-2)Gal sugar epitopes to the 
candidate lectins.  We found that all four lectins interacted with the Fucα(1-2)Gal 
glycopolymer in a dose-dependent manner, albeit with different affinities (Fig 5.3; Kd,app  = 
~ 1–3 µM).  Furthermore, three of the four lectins (DCLK1, PKCε and SV2a) showed 
significantly greater binding to the Fucα(1-2)Gal glycopolymers compared to the Galα(1-
2)Gal glycopolymers, suggesting the importance of the terminal fucose residue for lectin 
recognition. In contrast, GαO exhibited greater binding affinity towards Galα(1-2)Gal 
glycopolymers, suggesting it may not be a true lectin with Fucα(1-2)Gal specificity (Fig 
5.3).  Together, our results show that all four candidate lectins bind to Fucα(1-2)Gal sugars 
in vitro and highlight the importance of multivalency for enhancing low-affinity glycan-
receptor interaction. 
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Fig 5.3. Binding profiles of lectin candidates using ELLA (n=3). DCLK1, 
PKCε and SV2a bind Fucα(1-2)Gal carbohydrates with moderate affinities 
(Kd,app = 1.77 µM, 1.26 µM and 2.86 µM, respectively). 
5.3. Structural Analysis of Lectin Candidate SV2a 
Consequently, we were interested in understanding the functional implications of 
such binding events. Specifically, we focused on SV2a to elucidate the physiological 
relevance of this glycan-lectin interaction in the brain. SV2 is a conserved integral 
membrane protein that is present on all vertebrate synaptic vesicles.16 All SV2 proteins 
contain 12 putative transmembrane regions (TMRs) with N- and C-terminal cytoplasmic 
sequences and a large intravesicular loop that is N-glycosylated (Fig 5.4).17 In mammals, 
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there are three SV2 isoforms, designated SV2A, SV2B, and SV2C.18 SV2a is the most 
widely distributed isoform, being nearly ubiquitous in the central nervous system, as well 
as being present in endocrine cells.16,19 Interestingly, SV2A and SV2A/B knock-out (KO) 
mice exhibit a severe seizure phenotype whereas the SV2B KOs do not.20,21 Furthermore, 
SV2a was shown to be the target of the anti-epileptic drug levetiracetam, implicating its 
role in neural transmission.22 Studies of the SV2 KOs indicate that SV2 has a crucial role in 
the regulation of vesicle function, although not in vesicle biogenesis or synaptic 
morphology.22  
Fig 5.4. Model of SV2 topology. Black circles indicate conserved 
residues in all SV2 isoforms, gray circles are residues conserved in 
two SV2 isoforms, and open circles represent non-conserved 
residues. Adapted with permission from (17). 
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Like UEAI, SV2a exhibited a Ca2+-dependent binding towards Fucα(1-2)Gal 
sugars. This characteristic is mostly observed in the C-type mammalian lectin superfamily. 
As a result, we assessed the existence of a lectin-like domain in SV2a by performing an 
extensive structural analysis against other known C-type animal lectins. Specifically, we 
sought to identify SV2a sequence homology with three well-studied C-type lectins: 
dendritic cell-specific ICAM-3 grabbing nonintegrin (DC-SIGN), asialoglycoprotein 
receptor 1 (ASGR1) and rattle snake lectin (RSL). DC-SIGN is a C-type lectin receptor that 
binds to the terminal mannose and fucose-containing oligosaccharide of a virus envelope 
glycoprotein.23-25 ASGR1 is a hepatic endocytic receptor protein that plays a critical role in 
scavenging desialylated glycoproteins with exposed terminal galactose (Gal) or N-
acetylgalactosamine (GalNAc) residues for lysosomal degradation.26 RSL is a readily-
prepared decameric C-type lectin that binds to terminal Gal and GalNAc sugars.27 Given 
their specific glycan preferences, we performed multiple sequence alignment on SV2a and 
observed regions of significant sequence homologies (50–60%) around the putative L3–L4 
intravesicular loop domain. Furthermore, sequence alignment analysis of SV2a with DC-
SIGN, ASGR1 and RSL identified many conserved residues in the C-type lectin domain 
(CTLD) (Fig 5.5). In particular, high conservation of the consensus cysteine residues and 
WIGL motif were consistent with formation of the characteristic disulfide bridges in 
CTLD, implicating the existence of a lectin-like domain in SV2a.28,29  
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Fig 5.5. Sequence alignment of SV2a with the C-type lectin superfamily. Residues that 
match the sequence motif characteristic of the canonical CTLD are highlighted in 
yellow. Other highly conserved residues in the C-type lectin proteins are highlighted in 
blue. Significance homologies are observed around the L3-L4 region. 
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5.4. Characterization of SV2a Function in FUT KO Mice 
A major challenge associated with the study of glycan-binding proteins has been 
elucidating their functional roles in vivo.  The mere presence of a carbohydrate interaction 
in vitro is not sufficient to infer biological function.  Therefore, we sought to elucidate the 
physiological relevance of this glycan-lectin interaction by focusing on the well-established 
role of SV2a in neurotransmitter release.30 Trafficking of SV2a to synaptic vesicles is 
implicated during activity-dependent neurotransmission20 because SV2a contributes to the 
priming of synaptic vesicle during Ca2+-dependent exocytosis.  To investigate the role of 
Fucα(1-2)Gal sugars in mediating SV2a trafficking, we utilized genetically altered mice 
lacking the α(1-2) fucosyltransferase enzymes (FUT1 and FUT2) responsible for Fucα(1-
2)Gal biosynthesis.  FUT1 and FUT2 -deficient mice have been shown to differentially 
regulate Fucα(1-2)Gal expression in the olfactory bulb, gastrointestinal tract and 
reproductive organ.3,31,32 As a result, we examined whether Fucα(1-2)Gal expression in the 
mouse cortex was regulated by FUT1 or FUT2 using a chemoenzymatic labeling strategy.33 
This approach utilizes the substrate tolerance of bacterial glycosyl transferase A (BgtA) to 
rapidly label the specific glycan of interest with a non-natural sugar analogue. This 
analogue can then be detected and labeled with fluorescent-conjugated reporter using click 
chemistry (Fig 5.6). 
A significant reduction in Fucα(1-2)Gal expression was observed in glycoproteins 
from the cortex of FUT2(-/-) mice compared to WT littermate controls. In contrast, FUT1(-
/-) mice showed a lower reduction in the extent of protein fucosylation with Fucα(1-2)Gal 
(Fig 5.7a). Importantly, we observed a twofold increase in membrane-associated SV2a in 
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FUT2(-/-) cortical neurons compared to WT or FUT1(-/-) cortical neurons  (Fig 5.7b). 
Furthermore, we corroborated our finding through the cell-surface biotinylation of SV2a 
and identified a 1.9-fold increase in SV2a labeling on the plasma membrane of FUT2(-/-) 
cortical neurons (Fig 5.7c). As SV2a regulates the expression and sorting of the calcium 
sensor protein synaptotagmin (syt1),34 the interaction between SV2a and Fucα(1-2)Gal 
sugars could have important functional implications for syt1 localization.  Indeed, we 
found that colocalization of SV2a and syt1 puncta at the neuronal synapse, expressed as the 
relative puncta density along the neuronal processes, increased by 1.6-fold compared to 
WT neurons (Fig 5.7d). This suggests that SV2a-mediated endocytosis of syt1 had been 
altered. We hypothesize that the increase in membrane-associated SV2a as caused by an 
attenuation of SV2a trafficking, is mediated by the loss in glycan-assisted interaction in 
FUT2(-/-) neuron, which resulted in the subsequent impairment of syt1 endocytosis. Thus, 
we provide evidence that the association of Fucα(1-2)Gal sugars with SV2a may play 
important roles in the regulation of SV2a trafficking and syt1 endocytosis. Together, these 
results provide compelling support for a functional interaction between SV2 and Fucα(1-
2)Gal sugars. 
 
 
 
Fig 5.6. Chemoenzymatic strategy for the detection of Fucα(1-2)Gal glycan 
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Fig 5.7. Functional analysis of Fucα(1-2)Gal interaction with SV2a. (A) Fucα(1-2)Gal 
expression is reduced on FUT2(-/-) cortical neurons as detected by chemoenzymatic 
labeling; (B) Relative level of SV2a in the membrane. SV2a is enriched in the membrane 
fractions of FUT2 (-/-) mice (n= 3, p < 0.02); (C) Cell-surface biotinylation of SV2a. 
Increased surface biotinylation of SV2a on FUT2 (-/-) cortical neurons (n=4, p < 0.05);  
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Fig 5.7. (D) Colocalization studies of SV2a and Syt1 in neuronal processes. Distinct 
puncta positively stained with SV2a and Syt1 are quantified per unit area of 
measurement (n=70-80, p < 0.005). Scale bar = 10 µM 
In summary, we demonstrate the design and synthesis of multivalent, photoaffinity 
capture glycopolymers as chemical tools for the identification of novel lectins. Our studies 
identify several new candidate lectins for Fucα(1-2)Gal sugars in the brain and suggest that 
the interaction of these sugars with SV2a may have important functional consequences for 
protein trafficking. This work illustrates the potential use of glycopolymer mimetics as 
general tool to identify important low-affinity interactions that are characterized by 
multivalency in vivo. Continued investigations into Fucα(1-2)Gal-lectin interactions will 
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provide further insights into the importance of these novel lectins and molecular 
mechanisms underlying neuronal communication in the brain.  More importantly, we are 
excited about identifying specific glycan-lectin interaction pairs in neuron to understand 
how Fucα(1-2)Gal- mediates learning and memory consolidation process. 
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5.5. Experimental Methods 
Protein Expression and Purification. DCLK1 (DCAMKL1) was expressed and 
purified from E. coli BL21 (DE3) harboring the recombinant plasmid vector pET28a-
DCLK1-His as previously described.35 SV2a was expressed and purified from HEK293 
cells transfected with plasmid vector SV2a-FLAG-pIRES2 as previously described.36 GαO 
protein was kindly provided by Dr Tohru Kozasa (University of Illinois, Chicago). PKCε 
protein was commercially purchased (ProspecBio).  
Binding Validation of Lectin Candidate to Fucα(1-2)Gal by Microarray. 
Binding assays were performed following a known procedure.37 Protein binding was 
carried out on mammalian glycan array by the core H of Consortium Functional 
Glycomics. Briefly, 200 µg/ml of proteins (PKCε and SV2a) in PBS (pH 7.4 with 1 mM 
CaCl2 and 4 mM MgCl2) were incubated in a sandwich procedure with their labeled 
antibody on the glycan array. The samples (50–100 μl) were applied either directly onto the 
surface of a single slide and covered with a microscope cover slip and then incubated in a 
humidified chamber for 30–60 min. Slides were subsequently washed by successive rinses 
in (i) Tris-HCl-0.05% Tween, (ii) Tris-HCl, and (iii) deionized water, then immediately 
subjected to imaging 
Binding Validation of Lectin Candidates to Fucα(1-2)Gal by ELLA. Nunc 
Maxisorp 384-well plates were coated overnight at 4oC with lectins (50 ng/well) in 
carbonate buffer (50µl, 50mM H2CO3, pH 9.0). The wells were then washed with washing 
buffer (3 x 100 µl, TBS containing 0.03% Tween 20). The washing procedure was repeated 
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after each incubation throughout the assay. After washing, the wells were filled with 
serial dilutions of biotinylated polymers (Fucα(1-2)Gal, Galα(1-2)Gal and control (-OH) 
polymer, 25µl/well, GlycoTech) in binding buffer ( PBS, 1 mM CaCl2, 4 mM MgCl2) and 
incubated at rt for 2.5 h. The wells were washed and blocked with 10% Fetal Bovine 
Serum, FBS (80 µl) at 37oC for 1 hr.  After blocking, the plates were incubated with 
horseradish peroxidase-conjugated streptavidin (1∶40000, Pierce) at rt for 1 h, developed 
with TMB substrate (3,3′,5,5′-tetramethylbenzidine, Pierce) and quenched with 2 M 
H2SO4. Absorbances were measured at 450 nm using PerkinElmer Victor plate reader and 
were fitted to a linear regression analysis using KaleidaGraph (version 4.1.2). Experiments 
were performed in triplicate, and data represent the mean ± SEM. 
Sequence Alignment. Multiple sequence alignment between SV2a and three other 
C-type lectins: RSL, ASGR1 and DC-SIGN were carried out using the alignment program 
T-coffee (V-8.93) (http://www.ebi.ac.uk/Tools/msa/tcoffee/). Protein sequences were 
collected with BLAST by using the query sequences of mouse SV2a (UniProtKB ID: 
Q9JIS5), rat ASGR1 (UniProtKB ID: P02706), mouse DC-SIGN (UniProtKB ID: 
Q91ZX1) and croat RSL (UniProtKB ID: P21963).  
Chemoenzymatic Labeling of Cell Lysates. The cortices of adult C57BL/6, 
FUT1-/- and FUT2-/- mice were dissected on ice and lysed in boiling 1% SDS (5 
volumes/weight) with sonication until the mixture was homogeneous. Protein was 
precipitated using methanol/chloroform/water. Briefly, protein was diluted to 200 μL and 
precipitated by sequential mixing with 600 μL of MeOH, 200 μL of CHCl3 and 450 μL 
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H2O, after which the mixture was centrifuged at 23,000 x g for 15 min. Precipitated 
protein was washed with 450 μL of MeOH and centrifuged at 23,000 x g for 10 min. After 
the protein pellet was allowed to dry briefly, the pellet was re-dissolved at 5 mg/mL in 20 
mM HEPES pH 7.9 containing 1% SDS, and diluted fivefold into a buffer with the 
following final concentrations: 20 mM HEPES pH 7.9, 50 mM NaCl, 2% NP-40, 5 mM 
MnCl2. UDP-GalNAz (25 μM; Invitrogen) and BgtA (0.16 mg/mL) were added, and the 
samples were incubated at 4 °C for 16-20 h. The labeled proteins were precipitated as 
above and resuspended in 50 mM Tris pH 7.4 containing 1% SDS at 4 mg/mL. The 
resuspended proteins were subsequently reacted with alkyne-TAMRA (Invitrogen) as per 
the Click-It™ TAMRA Protein Analysis Detection kit instructions (Invitrogen), except that 
EDTA-free Complete™ protease inhibitors were added during the reaction. Negative 
controls were performed under identical conditions except that BgtA was omitted from the 
labeling reaction. After the labeling reactions, protein was precipitated using 
chloroform/methanol/water as described above and re-dissolved in boiling 2% SDS. This 
precipitation and resolubilization was then repeated once more to ensure removal of non-
specific interactions. TAMRA-labeled proteins were resolved on a NuPAGE 4-12% Bis-
Tris gel and transferred to PVDF membrane. The membrane was blocked with 5% milk 
(Biorad) in TBST (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.05% Tween 20) for 1 hr at rt 
and immunoblotted with rabbit anti-TAMRA (1:1000, Invitrogen) and mouse anti-Tubulin 
(1:5000, Sigma-Aldrich). Membranes were washed with TBST, incubated with the 
appropriate Alexa Fluor 680-conjugated (Invitrogen) or IR800-conjugated (Rockland) 
secondary antibody, and visualized using a LiCOR Odyssey Imaging System.  
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Neuronal Cultures for Functional Assay. For biochemical assay, cortical 
neuronal cultures were prepared as previously described,37 except that neurons from E15-
16 timed-pregnant C57BL/6, FUT1(-/-) and FUT2(-/-) mice were plated onto poly-DL-
lysine coated 6-well plates (BD Bioscience). Neurons were maintained for up to 10 days in 
vitro (DIV) in Neurobasal medium (NBM) supplemented with 2 mM Glutamax-I and 2% 
B-27 (Invitrogen). For staining and imaging, hippocampal neurons were prepared as 
previously described,38 except that neurons from E15-16 timed-pregnant mice were plated 
on poly-DL-lysine coated glass coverslips (Carolina Biological) at a density of 75 
cells/mm2. Neurons were maintained for up to 10 DIV in NBM supplemented with 2 mM 
Glutamax-I and, and 2% B-27.  
Assaying SV2a Distribution in cortical neuron. Ten DIV cortical neuron cultures 
(C56BL/7, FUT1(-/-) and FUT2(-/-)) were washed once with ice-cold PBS, gently scraped 
with trypsin and suspended in DMEM (Dubelco Modified Eagle Medium) supplemented 
with 10% FBS (Invitrogen) before being cleared by centrifugation for 10 min at 500 x g at 
4oC. Pellets were washed with cold PBS and fractionated using the Qproteome Cell 
Compartment Kit (Qiagen). The resulting membrane extract protein concentrations were 
quantified using the BCA assay. Equal amount of proteins were resolved on a NuPAGE 4-
12% Bis-Tris gel and transferred to PVDF membrane. The membrane was blocked in 5% 
milk, immunoblotted with goat anti-SV2a (E-15, 1:200, Santa Cruz) and mouse anti-
Synaptophysin (1:800, Sigma-Aldrich) and visualized using a LiCOR Odyssey Imaging 
System. SV2a distribution in the membrane of FUT1(-/-) and FUT2(-/-) neurons were 
expressed relative to the control C57Bl/6 level (n = 3-5), and were reported as the mean ± 
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SEM. Statistical analysis was performed using the student’s unpaired t-test to compare 
the SV2a level between   FUT2(-/-) and C57BL/6 neurons.  
Surface Biotinylation. Ten DIV cortical neuron cultures (C56BL/7, FUT1(-/-) and 
FUT2(-/-)) were washed once with ice-cold PBS, pH 8.0, and biotinylated by incubating 
with 0.5 mg/ml EZ-Link Sulfo-NHS-LC-LC-Biotin (Pierce) for 25 min at 4oC with gentle 
shaking. Cultures were washed with PBS, pH 7.4, and incubated with 100 mM glycine for 
15 min at 4oC to quench the reaction.  Neurons were rinsed with ice-cold PBS, pH 7.4, and 
extracted in solubilization buffer (150 mM NaCl, 50 mM Tris-HCl, 1 mM EDTA, 1% NP-
40 and protease inhibitor) for 1 h at 4oC. Insoluble material was removed by 
ultracentrifugation (19000 x g for 20 min) and the supernatants were subjected to 
immunoprecipitation by incubating with anti-SV2a (E-15, Santa Cruz) overnight at 4oC. 
The samples were diluted with solubilization buffer to a final concentration of 1 mg/ml and 
were incubated with pre-treated (blocked with 0.1% fish gelatin) protein A/G sepharose 
beads (ThermoFisher) at 4oC for 2h. The resin was washed three times with 10 column 
volumes of solubilization buffer and captured protein was eluted with loading buffer 
without boiling.  Equal amount of proteins were resolved on a NuPAGE 4-12% Bis-Tris 
gel and transferred to PVDF membrane. The membrane was blocked in 5% milk and 
immunoblotted with rabbit anti-SV2a (1:300, Synaptic Systems) for total 
immunoprecipitated SV2a and streptavidin-HRP (1:1000, pierce) for biotinylated SV2a.  
Labeled bands were visualized and quantified using a LiCOR Odyssey Imaging System. 
The proportion of SV2a on the plasma membrane of FUT2(-/-) neurons were expressed 
relative to the control C57BL/6 level (n = 4) as the normalized intensity of biotinylated-
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SV2a signal to the total SV2a, and were reported as the mean ± SEM. Statistical analysis 
was performed using the student’s unpaired t-test to compare the SV2a level between   
FUT2(-/-) and C57BL/6 neurons. 
 Immunostaining and quantification. The hippocampal neurons on the coverslips 
were rinsed one time with PBS, fixed in 4% paraformaldehyde/sucrose at rt for 20 min, 
washed twice with PBS, permeabilized in 0.3% TritonX-100 at rt for 5 min, and washed 
twice with PBST. Non-specific binding was blocked by incubating with 5% goat serum 
(GS) in PBST at 4oC for 1 h and then rinsing twice with PBST. Cells were then incubated 
with rabbit anti-SV2a (1:300, Synaptic Systems) in 5% GS at rt for 2 h. Excess antibody 
was rinsed away with PBST and cells were further incubated overnight with mouse anti-
Synaptophysin (1:300, Millipore) in 5% GS at 4oC.  After washing with PBST, The cells 
were treated with anti-rabbit IgG AlexaFluor 488 (1:1000, Invitrogen) and anti-mouse IgG 
AlexaFluor568 (1:1000, Invitrogen) in 5% GS at rt for 2 h. The coverslips were mounted 
onto glass slides and imaged using a LSM510 Meta confocal laser scanning microscope 
with a 100X 1.40 N.A oil immersion plan apochromat objective lens (Carl Zeiss 
MicroImaging, Inc.). 
Images were analyzed with ImageJ (http://rsbweb.nih.gov/ij/) using the JACoP 
Colocalization plugin and colocalized puncta analysis was performed as previously 
described39,40 using the Colocalization Highlighter plugin. Briefly, images of synaptic 
proteins were thresholded with the same value across experimental conditions so as to 
include clusters with intensity at least twofold greater than the adjacent dendrite. Puncta 
were defined as continuous pixel clusters of 0.5–11 µm. To determine the degree of 
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colocalization between two proteins, each channel was thresholded and the distinct 
puncta in each channel is overlaid to generate colocalized region. Puncta were manually 
counted as colocalized if the average intensity within the overlaid region exceeded the 
threshold value. Counted puncta were expressed as puncta density along the neuronal 
processes and were reported relative to the control sample. Three independent experiments 
(n = 70-80 images) were conducted and statistical analysis were performed using the 
student’s unpaired t-test. 
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 SPECTRA FOR POLYMER SYNTHESIS 
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GNFGEL488_AW01-33_41_LargeGel_LTQ_RatRevDB-converted 
(Membrane) 
   
     
Identified Proteins Accession Number MW FG Ct 
Tax_Id=10116 Gene_Symbol=Ania4 84 kDa protein IPI:IPI00778626.1 84 
kDa 
9 0 
Tax_Id=10116 Gene_Symbol=Rpn2 Dolichyl-
diphosphooligosaccharide--protein 
glycosyltransferase 63 kDa subunit precursor 
IPI:IPI00188059.2 69 
kDa 
9 0 
Tax_Id=10116 Gene_Symbol=Eif3s6ip Eukaryotic 
translation initiation factor 3, subunit 6 interacting 
protein 
IPI:IPI00366436.1 67 
kDa 
9 0 
Tax_Id=10116 Gene_Symbol=Kif5b Kinesin heavy 
chain 
IPI:IPI00364904.2 110 
kDa 
8 0 
Tax_Id=10116 Gene_Symbol=Myo1b Isoform C of 
Myosin-Ib 
IPI:IPI00231045.4 
(+2) 
125 
kDa 
8 0 
Tax_Id=10116 Gene_Symbol=LOC360975 2-
oxoglutarate dehydrogenase E1 component, 
mitochondrial precursor 
IPI:IPI00215093.1 
(+2) 
116 
kDa 
8 0 
Tax_Id=10116 Gene_Symbol=Rnpep Aminopeptidase 
B 
IPI:IPI00193584.7 73 
kDa 
7 0 
Tax_Id=10116 Gene_Symbol=Hspd1 60 kDa heat 
shock protein, mitochondrial precursor 
IPI:IPI00339148.2 61 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=Aars similar to alanyl-
tRNA synthetase 
IPI:IPI00363563.3 107 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=Nars 64 kDa protein IPI:IPI00565217.3 64 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=Lrp1 similar to low 
density lipoprotein receptor-related protein 1 
IPI:IPI00369995.2 505 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=Tubb5 Isoform 1 of 
Tubulin beta-5 chain 
IPI:IPI00197579.2 50 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Sv2a Synaptic vesicle 
glycoprotein 2A 
IPI:IPI00208115.4 
(+1) 
83 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Hsph1 Heat shock 
protein 105 kDa 
IPI:IPI00471835.1 96 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Nedd4a E3 ubiquitin-
protein ligase NEDD4 
IPI:IPI00766723.1 103 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Cyln2 CAP-Gly domain-
containing linker protein 2 
IPI:IPI00195929.1 
(+1) 
115 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=LOC363309 similar to 
tubulin-specific chaperone d 
IPI:IPI00765967.1 134 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Prmt5_predicted similar 
to protein arginine N-methyltransferase 5 
IPI:IPI00359690.3 73 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Picalm Isoform 2 of IPI:IPI00194958.1 65 5 0 
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Phosphatidylinositol-binding clathrin assembly 
protein 
(+3) kDa 
Tax_Id=10116 Gene_Symbol=Ipo7_predicted similar 
to Importin-7 
IPI:IPI00206234.2 
(+2) 
120 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Sfpq Splicing factor 
proline/glutamine rich 
IPI:IPI00627068.1 
(+1) 
75 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Xpnpep1 Xaa-Pro 
aminopeptidase 1 
IPI:IPI00200054.1 
(+1) 
70 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Syn2 Isoform IIa of 
Synapsin-2 
IPI:IPI00210036.1 63 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=- 100 kDa protein IPI:IPI00192076.3 
(+2) 
100 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Gucy1b3 Guanylate 
cyclase soluble subunit beta-1 
IPI:IPI00324485.6 70 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Lphn1 Isoform 4 of 
Latrophilin-1 precursor 
IPI:IPI00208999.1 
(+3) 
162 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Ctnna2_predicted 
similar to Alpha-2 catenin 
IPI:IPI00364916.2 
(+1) 
100 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Prkce Protein kinase C 
epsilon type 
IPI:IPI00551781.4 83 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Ctnnd1_predicted 
similar to Catenin delta-1 
IPI:IPI00359491.3 
(+2) 
105 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Immt 82 kDa protein IPI:IPI00364895.4 
(+2) 
82 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Khsrp Far upstream 
element-binding protein 2 
IPI:IPI00200920.1 74 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Kars 68 kDa protein IPI:IPI00363565.3 
(+1) 
68 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=LOC682937 similar to 
WAS protein family, member 3 
IPI:IPI00766566.1 55 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Gpd2 Glycerol-3-
phosphate dehydrogenase, mitochondrial precursor 
IPI:IPI00199663.1 
(+1) 
81 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=LOC619561 
Hypothetical protein LOC619561 
IPI:IPI00203054.2 68 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Snx2_predicted similar 
to sorting nexin 2 
IPI:IPI00363187.3 
(+1) 
59 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Lrrc47_predicted similar 
to leucine rich repeat containing 47 
IPI:IPI00359172.2 
(+1) 
52 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Ubqln2_predicted 
similar to ubiquilin 2 
IPI:IPI00362791.3 67 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Vac14 VAC14 IPI:IPI00230981.1 88 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Anxa6 Annexin A6 IPI:IPI00421888.3 
(+1) 
76 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Rap1ga1 similar to Rap1 IPI:IPI00359567.3 83 4 0 
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GTPase-activating protein 1 kDa 
Tax_Id=10116 Gene_Symbol=LOC367171 
Microtubule-associated protein 4 
IPI:IPI00393975.2 
(+2) 
110 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=RGD1562629_predicted 
similar to Protein neurobeachin 
IPI:IPI00567941.2 327 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Grlf1_predicted 
Glucocorticoid receptor DNA-binding factor 1 
IPI:IPI00198211.2 
(+1) 
172 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Trim28 similar to 
Transcription intermediary factor 1-beta 
IPI:IPI00194567.4 
(+1) 
89 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Eif4g1 175 kDa protein IPI:IPI00370448.4 
(+2) 
175 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Mtap6 STOP protein IPI:IPI00210119.1 
(+3) 
100 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Daam1_predicted 
similar to Disheveled-associated activator of 
morphogenesis 1 
IPI:IPI00367408.3 
(+2) 
124 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Ripx Protein RUFY3 IPI:IPI00204065.1 
(+2) 
53 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=RGD1309461 similar to 
NIK and IKK(beta) binding protein isoform 2 
IPI:IPI00361094.4 
(+1) 
128 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Kpna1 Importin subunit 
alpha-1 
IPI:IPI00395277.1 
(+1) 
60 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Sel1h Sel-1 homolog 
precursor 
IPI:IPI00205606.3 89 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Uble1b similar to 
Ubiquitin-like 1-activating enzyme E1B 
IPI:IPI00367235.3 
(+1) 
68 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Vcp Transitional 
endoplasmic reticulum ATPase 
IPI:IPI00212014.2 
(+1) 
90 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Camk4 Isoform 1 of 
Calcium/calmodulin-dependent protein kinase type IV 
IPI:IPI00231822.4 53 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Camk2b Calmodulin-
dependent protein kinase II beta M isoform 
IPI:IPI00209824.2 
(+6) 
73 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Farslb Phenylalanine-
tRNA synthetase-like, beta subunit 
IPI:IPI00202379.1 66 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Cdc16 CDC16 cell 
division cycle 16 homolog 
IPI:IPI00190201.5 71 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=LOC304743 Coiled-coil 
domain-containing protein 93 
IPI:IPI00371846.2 73 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Gria2 Isoform Flip of 
Glutamate receptor 2 precursor 
IPI:IPI00231061.5 
(+2) 
99 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Slc8a1 Isoform 1 of 
Sodium/calcium exchanger 1 precursor 
IPI:IPI00206113.3 
(+7) 
108 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Srp68_predicted similar 
to signal recognition particle 68 
IPI:IPI00368134.2 70 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Gspt1 G1 to S phase IPI:IPI00368457.1 69 3 0 
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transition 1 kDa 
Tax_Id=10116 Gene_Symbol=Fchsd2_predicted 
similar to FCH and double SH3 domains 2 
IPI:IPI00764114.1 144 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Cpsf6_predicted similar 
to cleavage and polyadenylation specific factor 6 
IPI:IPI00366220.3 
(+1) 
59 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Igsf8 immunoglobulin 
superfamily, member 8 
IPI:IPI00372709.3 
(+1) 
64 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Stk39 STE20/SPS1-
related proline-alanine-rich protein kinase 
IPI:IPI00210537.2 60 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Tfrc similar to 
transferrin receptor 
IPI:IPI00363550.2 86 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Nova2_predicted 50 
kDa protein 
IPI:IPI00476817.3 
(+1) 
50 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Centg3_predicted 
similar to centaurin, gamma 3 
IPI:IPI00358128.3 
(+1) 
102 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Ppp3cb 
Serine/threonine-protein phosphatase 2B catalytic 
subunit beta isoform 
IPI:IPI00201407.1 
(+4) 
59 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Snx27 PDZ protein 
Mrt1a 
IPI:IPI00203641.1 61 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Aco1 Iron-responsive 
element-binding protein 1 
IPI:IPI00207003.1 
(+1) 
98 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Acadvl Very-long-chain 
specific acyl-CoA dehydrogenase, mitochondrial 
precursor 
IPI:IPI00213057.2 
(+1) 
71 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=G3bp similar to Ras-
GTPase-activating protein binding protein 1 
IPI:IPI00193648.2 59 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Cct8_predicted similar 
to T-complex protein 1 subunit theta 
IPI:IPI00370815.3 60 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=RGD1560544_predicted 
similar to Protein C11orf2 
IPI:IPI00371469.4 
(+2) 
77 
kDa 
1 0 
Tax_Id=10116 Gene_Symbol=Prkcb1 Isoform Beta-II 
of Protein kinase C beta type 
IPI:IPI00189278.4 
(+1) 
77 
kDa 
1 0 
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GNFGEL498_AW20-61_NotIncl_Gel3_LTQ_RatRevDB-converted 
(Membrane) 
     
Identified Proteins Accession Number MW FG Ct 
Tax_Id=10116 Gene_Symbol=Matr3 Matrin-3 IPI:IPI00555259.4 94 
kDa 
19 0 
Tax_Id=10116 Gene_Symbol=Col6a3_predicted 
similar to alpha 3 type VI collagen isoform 1 precursor 
IPI:IPI00565677.2 289 
kDa 
19 0 
Tax_Id=10116 Gene_Symbol=Vim Vimentin IPI:IPI00230941.5 54 
kDa 
14 0 
Tax_Id=10116 Gene_Symbol=Kif1a similar to Kinesin-
like protein KIF1A 
IPI:IPI00559725.2 
(+1) 
190 
kDa 
13 0 
Tax_Id=10116 Gene_Symbol=Flna_predicted similar 
to Filamin-A 
IPI:IPI00409539.3 281 
kDa 
13 0 
Tax_Id=10116 Gene_Symbol=- Copa protein IPI:IPI00372458.2 138 
kDa 
12 0 
Tax_Id=10116 Gene_Symbol=Myo1c myosin IC IPI:IPI00393867.4 120 
kDa 
12 0 
Tax_Id=10116 Gene_Symbol=Kif5c_predicted similar 
to kinesin family member 5C 
IPI:IPI00193402.4 109 
kDa 
10 0 
Tax_Id=10116 Gene_Symbol=Nef3 Neurofilament 
medium polypeptide 
IPI:IPI00325609.4 96 
kDa 
10 0 
Tax_Id=10116 Gene_Symbol=Bdh1 3-hydroxybutyrate 
dehydrogenase 
IPI:IPI00480620.1 38 
kDa 
10 0 
Tax_Id=10116 Gene_Symbol=RGD1305240_predicted 
similar to nodal modulator 1 
IPI:IPI00365744.1 133 
kDa 
10 0 
Tax_Id=10116 Gene_Symbol=Slc25a4 ADP/ATP 
translocase 1 
IPI:IPI00231927.11 33 
kDa 
9 0 
Tax_Id=10116 Gene_Symbol=Tcp1 T-complex protein 
1 subunit alpha 
IPI:IPI00200847.1 60 
kDa 
9 0 
Tax_Id=10116 Gene_Symbol=Prkce Protein kinase C 
epsilon type 
IPI:IPI00551781.4 83 
kDa 
9 0 
Tax_Id=10116 Gene_Symbol=Col6a1_predicted 
similar to Collagen alpha-1(VI) chain precursor 
IPI:IPI00371853.3 109 
kDa 
9 0 
Tax_Id=10116 Gene_Symbol=Copb2 Coatomer 
subunit beta' 
IPI:IPI00231953.10 103 
kDa 
9 0 
Tax_Id=10116 Gene_Symbol=Dhx9_predicted similar 
to ATP-dependent RNA helicase A 
IPI:IPI00366249.4 150 
kDa 
9 0 
Tax_Id=10116 Gene_Symbol=Plec1 Plectin 10 IPI:IPI00569024.2 518 
kDa 
8 0 
Tax_Id=10116 Gene_Symbol=Spg3a Atlastin-like 
protein 
IPI:IPI00421909.3 63 
kDa 
8 0 
Tax_Id=10116 Gene_Symbol=Atp1a2 
Sodium/potassium-transporting ATPase subunit 
alpha-2 precursor 
IPI:IPI00205693.1 112 
kDa 
7 0 
Tax_Id=10116 Gene_Symbol=Atp2b2 Isoform WB of IPI:IPI00194875.1 137 7 0 
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Plasma membrane calcium-transporting ATPase 2 (+3) kDa 
Tax_Id=10116 Gene_Symbol=Slc25a3 Slc25a3 protein IPI:IPI00209115.2 40 
kDa 
7 0 
Tax_Id=10116 Gene_Symbol=Eprs 170 kDa protein IPI:IPI00421357.2 
(+1) 
170 
kDa 
7 0 
Tax_Id=10116 Gene_Symbol=Usp9x_predicted similar 
to Probable ubiquitin carboxyl-terminal hydrolase 
FAF-X (Ubiquitin thioesterase FAF-X) (Ubiquitin-
specific-processing protease FAF-X) (Deubiquitinating 
enzyme FAF-X) (Fat facets protein-related, X-linked) 
(Ubiquitin-specific protease 9, X c 
IPI:IPI00204923.4 
(+1) 
291 
kDa 
7 0 
Tax_Id=10116 Gene_Symbol=Eftud2 similar to 116 
kDa U5 small nuclear ribonucleoprotein component 
IPI:IPI00370117.3 109 
kDa 
7 0 
Tax_Id=10116 Gene_Symbol=Abce1 similar to ATP-
binding cassette sub-family E member 1 
IPI:IPI00193816.2 67 
kDa 
7 0 
Tax_Id=10116 Gene_Symbol=Ckap5 similar to 
cytoskeleton associated protein 5 isoform 1 
IPI:IPI00764313.1 
(+3) 
223 
kDa 
7 0 
Tax_Id=10116 Gene_Symbol=Ywhae 14-3-3 protein 
epsilon 
IPI:IPI00325135.3 29 
kDa 
7 0 
Tax_Id=10116 Gene_Symbol=Ddx1 ATP-dependent 
RNA helicase DDX1 
IPI:IPI00555314.1 82 
kDa 
7 0 
Tax_Id=10116 Gene_Symbol=Lars Leucyl-tRNA 
synthetase 
IPI:IPI00363236.2 134 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=Capzb F-actin capping 
protein subunit beta 
IPI:IPI00365283.1 31 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=Atp5c1 ATP synthase 
gamma chain 
IPI:IPI00454288.1 68 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=Slc25a11 Mitochondrial 
2-oxoglutarate/malate carrier protein 
IPI:IPI00231261.7 34 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=Slc25a5 ADP/ATP 
translocase 2 
IPI:IPI00200466.3 33 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=LOC315676 similar to 
Dmx-like 2 
IPI:IPI00369671.3 344 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=Cul5 Cullin-5 IPI:IPI00325517.5 91 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=Gria2 103 kDa protein IPI:IPI00780113.1 103 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=Pde10a PDE10A2 IPI:IPI00561300.1 90 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=Idh3g Isocitrate 
dehydrogenase [NAD] subunit gamma, mitochondrial 
precursor 
IPI:IPI00194047.3 43 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=- 102 kDa protein IPI:IPI00366397.2 102 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=Strn3 Isoform 1 of 
Striatin-3 
IPI:IPI00760130.2 
(+1) 
87 
kDa 
6 0 
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Tax_Id=10116 Gene_Symbol=Ywhaz 14-3-3 protein 
zeta/delta 
IPI:IPI00324893.4 28 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Alg2 similar to Alpha-
1,3-mannosyltransferase ALG2 
IPI:IPI00367294.2 47 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Eif3s10 ZH12 protein IPI:IPI00372810.4 162 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Ctnna2_predicted 
similar to Alpha-2 catenin 
IPI:IPI00364916.2 
(+1) 
100 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Nars 64 kDa protein IPI:IPI00565217.3 64 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Cyln2 111 kDa protein IPI:IPI00476704.1 111 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Dync1li1 Cytoplasmic 
dynein 1 light intermediate chain 1 
IPI:IPI00213552.1 57 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Tardbp 45 kDa protein IPI:IPI00191216.1 45 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Dhcr7 7-
dehydrocholesterol reductase 
IPI:IPI00210431.1 54 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=LOC362012 similar to 
Protein FAM40A 
IPI:IPI00373402.3 
(+3) 
99 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Ybx1 Ybx1 protein IPI:IPI00551815.2 
(+2) 
36 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=RGD1565486_predicted 
similar to RNA binding motif protein 25 
IPI:IPI00765889.1 
(+1) 
96 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Atp2b4 Isoform XA of 
Plasma membrane calcium-transporting ATPase 4 
IPI:IPI00230910.1 
(+1) 
129 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=LOC360975 2-
oxoglutarate dehydrogenase E1 component, 
mitochondrial precursor 
IPI:IPI00215093.1 
(+2) 
116 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Ndufa9 similar to NADH 
dehydrogenase (ubiquinone) 1 alpha subcomplex, 9 
IPI:IPI00358441.1 43 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Qars Glutaminyl-tRNA 
synthetase 
IPI:IPI00362720.1 88 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Fmo1 Dimethylaniline 
monooxygenase [N-oxide-forming] 1 
IPI:IPI00201564.4 60 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Aacs Acetoacetyl-CoA 
synthetase 
IPI:IPI00204738.1 75 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Cul1_predicted similar 
to Cullin-1 
IPI:IPI00358206.2 90 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=- 100 kDa protein IPI:IPI00192076.3 
(+2) 
100 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Slc1a3 Isoform GLAST-1 
of Excitatory amino acid transporter 1 
IPI:IPI00324377.1 60 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Synj1 similar to 
Synaptojanin-1 
IPI:IPI00210153.3 
(+3) 
173 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Ddost_predicted IPI:IPI00471645.1 49 4 0 
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Dolichyl-di-phosphooligosaccharide-protein 
glycotransferase 
kDa 
Tax_Id=10116 Gene_Symbol=Ywhab Isoform Long of 
14-3-3 protein beta/alpha 
IPI:IPI00230837.5 
(+1) 
28 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=P4hb Protein disulfide-
isomerase precursor 
IPI:IPI00198887.1 57 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Ikbkap Elongator 
complex protein 1 
IPI:IPI00389755.1 149 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Col1a2 Collagen alpha-
2(I) chain precursor 
IPI:IPI00188921.1 130 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Sec23a_predicted 
similar to Protein transport protein Sec23A 
IPI:IPI00207738.2 87 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Ndufs2 NADH 
dehydrogenase (Ubiquinone) Fe-S protein 2 
IPI:IPI00471647.1 53 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=RGD1307525_predicted 
similar to Temporarily Assigned Gene name family 
member 
IPI:IPI00358840.3 
(+2) 
179 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Hmgcs2 
Hydroxymethylglutaryl-CoA synthase, mitochondrial 
precursor 
IPI:IPI00210444.5 57 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Ctnnd2 similar to 
Catenin delta-2 
IPI:IPI00553941.3 
(+1) 
134 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Emilin1_predicted 
similar to elastin microfibril interfacer 1 
IPI:IPI00199867.1 108 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Lap3 Isoform 1 of 
Cytosol aminopeptidase 
IPI:IPI00471530.2 
(+1) 
56 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Pdhb Pyruvate 
dehydrogenase E1 component subunit beta, 
mitochondrial precursor 
IPI:IPI00194324.2 39 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Etfb Electron transfer 
flavoprotein subunit beta 
IPI:IPI00364321.3 28 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Hnrpm Isoform 1 of 
Heterogeneous nuclear ribonucleoprotein M 
IPI:IPI00209148.5 
(+1) 
74 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Acaa2 3-ketoacyl-CoA 
thiolase, mitochondrial 
IPI:IPI00201413.1 42 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Sfxn1 Sideroflexin-1 IPI:IPI00213735.3 
(+1) 
36 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=LOC681996 similar to 
AHA1, activator of heat shock 90kDa protein ATPase 
homolog 1 isoform 2 
IPI:IPI00766463.1 
(+1) 
38 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Phyhipl 42 kDa protein IPI:IPI00361492.2 42 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Vdac1 Voltage-
dependent anion-selective channel protein 1 
IPI:IPI00421874.4 31 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Vac14 VAC14 IPI:IPI00230981.1 88 
kDa 
4 0 
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Tax_Id=10116 Gene_Symbol=Mthfd1l_predicted 
similar to methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent) 1-like 
IPI:IPI00365405.3 106 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=RGD1566215_predicted 
similar to Coatomer gamma-2 subunit 
IPI:IPI00767794.1 98 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Sf3b3_predicted similar 
to splicing factor 3b, subunit 3 
IPI:IPI00363568.3 114 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Rps3 40S ribosomal 
protein S3 
IPI:IPI00212776.1 27 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Centg3_predicted 
similar to centaurin, gamma 3 
IPI:IPI00358128.3 102 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Txndc1 Thioredoxin 
domain containing 1 
IPI:IPI00365626.3 31 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Galk1 Galactokinase 1 IPI:IPI00188671.1 42 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Exoc8 Exocyst complex 
component 8 
IPI:IPI00199846.1 81 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Sarm1_predicted similar 
to sterile alpha and TIR motif containing 1 
IPI:IPI00369913.2 80 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Aytl2_predicted 1-
acylglycerophosphocholine O-acyltransferase 1 
IPI:IPI00365394.2 
(+1) 
60 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Nnt 76 kDa protein IPI:IPI00390435.1 
(+1) 
76 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Bgn Biglycan precursor IPI:IPI00191090.1 42 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Serpinh1 Serpin H1 
precursor 
IPI:IPI00204703.5 47 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Fdft1 Squalene 
synthetase 
IPI:IPI00210233.1 48 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Nid2 similar to nidogen 
2 isoform 2 
IPI:IPI00372786.5 
(+1) 
153 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Ap3b2_predicted similar 
to adaptor-related protein complex 3, beta 2 subunit 
IPI:IPI00368200.2 
(+1) 
124 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Ywhah 14-3-3 protein 
eta 
IPI:IPI00231677.5 28 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Suclg2 similar to 
succinate-Coenzyme A ligase, GDP-forming, beta 
subunit isoform 4 
IPI:IPI00471539.4 
(+4) 
47 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=RGD1306534_predicted 
similar to Phosphatidylinositol 3,4,5-trisphosphate-
dependent Rac exchanger 1 protein 
IPI:IPI00365036.4 185 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Abr_predicted similar to 
active BCR-related gene isoform 3 
IPI:IPI00370314.2 98 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Gna13 Galpha13 IPI:IPI00422053.1 44 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=RGD1309586_predicted IPI:IPI00196210.3 73 3 0 
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similar to Putative ATP-dependent RNA helicase Pl10 (+1) kDa 
Tax_Id=10116 Gene_Symbol=Crat Carnitine O-
acetyltransferase 
IPI:IPI00360158.4 72 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Gnai1 Guanine 
nucleotide-binding protein G(i), alpha-1 subunit 
IPI:IPI00231733.7 40 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=LOC296318 Similar to 
Ndr3 protein 
IPI:IPI00464777.1 
(+2) 
42 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Cadps Calcium-
dependent secretion activator 1 
IPI:IPI00199577.5 
(+2) 
146 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Snx6_predicted similar 
to sorting nexin 6 
IPI:IPI00365613.2 47 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Arhgap1_predicted 
similar to Rho GTPase activating protein 1 
IPI:IPI00363427.3 55 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Atp1b3 
Sodium/potassium-transporting ATPase subunit beta-
3 
IPI:IPI00208061.3 32 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Gsk3a Glycogen 
synthase kinase-3 alpha 
IPI:IPI00189904.1 51 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Pdcd6ip similar to 
Programmed cell death 6-interacting protein 
IPI:IPI00767837.1 97 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Map2k1 Dual specificity 
mitogen-activated protein kinase kinase 1 
IPI:IPI00231247.9 43 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Gls Glutaminase kidney 
isoform, mitochondrial precursor 
IPI:IPI00199465.1 74 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Slc25a20 Mitochondrial 
carnitine/acylcarnitine carrier protein 
IPI:IPI00205413.1 
(+1) 
33 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Lancl2_predicted LanC 
(Bacterial lantibiotic synthetase component C)-like 2 
IPI:IPI00192484.2 51 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Scfd1 Sec1 family 
domain-containing protein 1 
IPI:IPI00210389.1 
(+1) 
72 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Dncli2 Cytoplasmic 
dynein 1 light intermediate chain 2 
IPI:IPI00207202.1 
(+1) 
55 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Psat1 Phosphoserine 
aminotransferase 
IPI:IPI00331919.5 41 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Clptm1_predicted 
similar to cleft lip and palate associated 
transmembrane protein 1 
IPI:IPI00193869.1 
(+1) 
75 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Acsl3 Isoform Long of 
Long-chain-fatty-acid--CoA ligase 3 
IPI:IPI00205908.1 
(+1) 
80 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Gnb1 Guanine 
nucleotide-binding protein G(I)/G(S)/G(T) subunit 
beta 1 
IPI:IPI00212655.4 37 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Cndp2 Cytosolic non-
specific dipeptidase 
IPI:IPI00421899.1 
(+1) 
53 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Syn2 Isoform IIa of 
Synapsin-2 
IPI:IPI00210036.1 
(+1) 
63 
kDa 
3 0 
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Tax_Id=10116 Gene_Symbol=Eef1b2_predicted 
similar to eukaryotic translation elongation factor 1 
beta 2 
IPI:IPI00476899.1 25 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Vat1 Vesicle amine 
transport protein 1 homolog 
IPI:IPI00201969.1 43 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Col1a1 Collagen alpha-
1(I) chain precursor 
IPI:IPI00188909.2 
(+2) 
138 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Prkcsh_predicted similar 
to Glucosidase II beta subunit precursor 
IPI:IPI00388209.2 
(+1) 
59 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Slc8a1 Isoform 1 of 
Sodium/calcium exchanger 1 precursor 
IPI:IPI00206113.3 
(+7) 
108 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Ap3d1 similar to 
adaptor-related protein complex 3, delta 1 subunit 
IPI:IPI00198486.3 136 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Cope_predicted similar 
to epsilon subunit of coatomer protein complex 
IPI:IPI00201137.1 35 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=MGC93997 Similar to 
PRUNEM1 
IPI:IPI00368646.1 50 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Psmd3 Proteasome 
(Prosome, macropain) 26S subunit, non-ATPase, 3 
IPI:IPI00370009.1 61 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Pde2a cGMP-dependent 
3',5'-cyclic phosphodiesterase 
IPI:IPI00199076.2 
(+3) 
105 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Pck2_predicted similar 
to mitochondrial phosphoenolpyruvate carboxykinase 
2 
IPI:IPI00388232.4 83 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=RGD1305915 similar to 
SVH protein 
IPI:IPI00372341.3 
(+2) 
33 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Hsd17b12 Estradiol 17-
beta-dehydrogenase 12 
IPI:IPI00208645.6 
(+1) 
35 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Scamp3 similar to 
Secretory carrier-associated membrane protein 3 
IPI:IPI00206037.6 
(+2) 
39 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Nlgn2 Isoform 1 of 
Neuroligin-2 precursor 
IPI:IPI00209308.1 
(+1) 
91 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Eif3s6 Eukaryotic 
translation initiation factor 3 subunit 6 
IPI:IPI00366398.2 52 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Stch Stress 70 protein 
chaperone microsome-associated 60 kDa protein 
precursor 
IPI:IPI00206300.2 52 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Kif3b_predicted similar 
to Kinesin-like protein KIF3B (Microtubule plus end-
directed kinesin motor 3B) isoform 2 
IPI:IPI00765754.1 
(+1) 
85 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Prpf40a_predicted 
similar to Pre-mRNA-processing factor 40 homolog A 
IPI:IPI00372759.3 109 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Gna11 Guanine 
nucleotide-binding protein alpha-11 subunit 
IPI:IPI00200437.1 42 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Vps16 Vacuolar protein 
sorting 16 
IPI:IPI00471668.2 95 
kDa 
3 0 
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Tax_Id=10116 Gene_Symbol=Trim2 similar to 
tripartite motif protein TRIM2 
IPI:IPI00373220.4 
(+2) 
87 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Ranbp1_predicted 
similar to Ran-specific GTPase-activating protein 
IPI:IPI00363569.3 24 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Eif3s4 Eukaryotic 
translation initiation factor 3, subunit 4 
IPI:IPI00365487.2 36 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Ptpn23 162 kDa protein IPI:IPI00214150.2 
(+1) 
162 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Madd MAP kinase-
activating death domain protein 
IPI:IPI00196614.1 
(+4) 
178 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Arbp 60S acidic 
ribosomal protein P0 
IPI:IPI00200147.1 34 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Dscr3_predicted similar 
to Down syndrome critical region protein 3 homolog 
(Down syndrome critical region protein A homolog) 
isoform 1 
IPI:IPI00763791.1 33 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Kb2 Keratin, type II 
cytoskeletal 2 epidermal 
IPI:IPI00551558.2 
(+1) 
69 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=RGD1309571 Similar to 
RNA-binding protein isoform G3BP-2a 
IPI:IPI00464529.1 
(+1) 
51 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Marcksl1 MARCKS-
related protein 
IPI:IPI00189061.3 20 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Hsph1 Heat shock 
protein 105 kDa 
IPI:IPI00471835.1 
(+3) 
96 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Kb4 Keratin, type II 
cytoskeletal 4 
IPI:IPI00421778.1 58 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Robo2 Robo2 
(Fragment) 
IPI:IPI00215029.1 
(+1) 
117 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Adsl_predicted similar 
to adenylosuccinate lyase 
IPI:IPI00361216.2 55 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Prg-2 Plasticity-related 
protein PRG-2 
IPI:IPI00382123.1 77 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Aldh6a1 
Methylmalonate-semialdehyde dehydrogenase 
[acylating], mitochondrial precursor 
IPI:IPI00205018.2 58 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Ppp3ca Isoform 1 of 
Serine/threonine-protein phosphatase 2B catalytic 
subunit alpha isoform 
IPI:IPI00201410.1 
(+1) 
59 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Tuba6 Tubulin alpha-1C 
chain 
IPI:IPI00364046.2 50 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Kab 174 kDa protein IPI:IPI00776774.1 174 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Farp1_predicted similar 
to FERMRhoGEF (Arhgef) and pleckstrin domain 
protein 1 
IPI:IPI00373724.3 
(+1) 
164 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Bat3 Large proline-rich IPI:IPI00203181.2 115 2 0 
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protein BAT3 (+1) kDa 
Tax_Id=10116 Gene_Symbol=Txnl2 Isoform 1 of 
Thioredoxin-like protein 2 
IPI:IPI00553899.1 38 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Gucy1a3 Guanylate 
cyclase soluble subunit alpha-3 
IPI:IPI00851136.1 78 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Cdk5 Cell division 
protein kinase 5 
IPI:IPI00231092.3 33 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Sucla2_predicted similar 
to succinate-Coenzyme A ligase, ADP-forming, beta 
subunit 
IPI:IPI00364431.2 50 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Sqstm1 Isoform 1 of 
Sequestosome-1 
IPI:IPI00194561.1 
(+2) 
48 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Vdp General vesicular 
transport factor p115 
IPI:IPI00324618.3 107 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Sccpdh Probable 
saccharopine dehydrogenase 
IPI:IPI00372804.2 
(+1) 
47 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Bcat1 Branched-chain-
amino-acid aminotransferase, cytosolic 
IPI:IPI00215523.1 
(+1) 
46 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Ywhag 14-3-3 protein 
gamma 
IPI:IPI00230835.5 28 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Hsdl1 Hydroxysteroid 
dehydrogenase like 1 
IPI:IPI00365202.1 37 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=RGD1307235_predicted 
hypothetical protein 
IPI:IPI00360079.4 135 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Snx2_predicted similar 
to sorting nexin 2 
IPI:IPI00769194.1 74 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Col6a2 similar to 
procollagen, type VI, alpha 2 
IPI:IPI00372839.3 110 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Dnpep Aspartyl 
aminopeptidase 
IPI:IPI00358059.2 53 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Epm2aip1_predicted 
similar to EPM2A (laforin) interacting protein 1 
IPI:IPI00371118.3 
(+1) 
70 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Actn1 Alpha-actinin-1 IPI:IPI00209082.1 
(+3) 
103 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Bzw1 Basic leucine 
zipper and W2 domain-containing protein 1 
IPI:IPI00366953.1 48 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Ruvbl2 RuvB-like 2 IPI:IPI00364340.2 51 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Eif2s2 Eukaryotic 
translation initiation factor 2, subunit 2 
IPI:IPI00373164.1 38 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=RGD1559864_predicted 
45 kDa protein 
IPI:IPI00560515.2 45 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Capza2 F-actin capping 
protein subunit alpha-2 
IPI:IPI00370681.1 33 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Rpl5 60S ribosomal 
protein L5 
IPI:IPI00230914.5 
(+1) 
34 
kDa 
2 0 
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Tax_Id=10116 Gene_Symbol=Ptprd Leukocyte 
common antigen-related phosphatase precursor 
IPI:IPI00214375.1 
(+1) 
207 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Cars_predicted similar 
to Cysteinyl-tRNA synthetase 
IPI:IPI00371408.2 95 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Dnm2 Isoform IIBA of 
Dynamin-2 
IPI:IPI00210319.2 
(+2) 
98 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Sgpl1 Sphingosine-1-
phosphate lyase 1 
IPI:IPI00193172.1 64 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Srp68_predicted similar 
to signal recognition particle 68 
IPI:IPI00368134.2 70 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Fus Fusion, derived 
from t(12;16) malignant liposarcoma 
IPI:IPI00362587.3 53 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Itsn1 similar to 
Intersectin-1 
IPI:IPI00554196.3 194 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Hnrpl Hnrpl protein IPI:IPI00364061.4 
(+1) 
64 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Irgq_predicted similar 
to FKSG27 
IPI:IPI00367047.3 59 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=- Ab2-076 IPI:IPI00382233.1 
(+1) 
103 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Tnpo2_predicted similar 
to transportin 2 
IPI:IPI00205920.4 101 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Unr Cold shock domain-
containing protein E1 
IPI:IPI00190971.1 
(+1) 
89 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Rph3a Rabphilin-3A IPI:IPI00189927.1 
(+1) 
76 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Wdr7 Isoform 1 of WD 
repeat protein 7 
IPI:IPI00190963.1 
(+1) 
163 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Pabpc1 Polyadenylate-
binding protein 1 
IPI:IPI00189074.3 71 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=RGD1303066 35 kDa 
protein 
IPI:IPI00214510.2 
(+3) 
35 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Strn4_predicted similar 
to Striatin-4 
IPI:IPI00213355.1 81 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Nes Isoform 1 of Nestin IPI:IPI00194103.2 
(+1) 
209 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Ppfia3 similar to Liprin-
alpha-3 
IPI:IPI00365736.3 
(+1) 
150 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Becn1 beclin 1 IPI:IPI00325272.3 52 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Cse1l_predicted similar 
to chromosome segregation 1-like 
IPI:IPI00193247.1 110 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Arpc1a Actin-related 
protein 2/3 complex subunit 1A 
IPI:IPI00200845.1 42 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Syngr1 21 kDa protein IPI:IPI00188732.2 
(+1) 
21 
kDa 
2 0 
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Tax_Id=10116 Gene_Symbol=Safb Scaffold 
attachment factor B 
IPI:IPI00209618.2 105 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Rdh11 LRRGT00111 IPI:IPI00421314.1 
(+1) 
45 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Ptges2_predicted 
similar to prostaglandin E synthase 2 
IPI:IPI00197369.1 43 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Grin1 Isoform A of 
Glutamate [NMDA] receptor subunit zeta-1 precursor 
IPI:IPI00198625.5 
(+2) 
106 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Slc25a1 Tricarboxylate 
transport protein, mitochondrial precursor 
IPI:IPI00327694.3 34 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Pmpcb Mitochondrial-
processing peptidase subunit beta, mitochondrial 
precursor 
IPI:IPI00209980.6 54 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Mtap6 STOP protein IPI:IPI00210119.1 
(+1) 
100 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Slc27a4 similar to solute 
carrier family 27 (fatty acid transporter), member 4 
IPI:IPI00372070.2 72 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=LOC362015 similar to 
adenosine monophosphate deaminase 2 
IPI:IPI00554244.3 95 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Ppp1cc Isoform 
Gamma-1 of Serine/threonine-protein phosphatase 
PP1-gamma catalytic subunit 
IPI:IPI00203358.1 
(+2) 
37 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=LOC362855 UPF0027 
protein C22orf28 homolog 
IPI:IPI00209916.1 55 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Cnp1 2',3'-cyclic-
nucleotide 3'-phosphodiesterase 
IPI:IPI00199394.2 47 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Lasp1 LIM and SH3 
domain protein 1 
IPI:IPI00198567.1 30 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Timm44 Import inner 
membrane translocase subunit TIM44, mitochondrial 
precursor 
IPI:IPI00205394.1 51 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Preb Prolactin 
regulatory element-binding protein 
IPI:IPI00553950.3 45 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=RGD1306694_predicted 
similar to Hook-related protein 1 
IPI:IPI00763697.1 212 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=RGD1307966_predicted 
hypothetical protein 
IPI:IPI00370116.3 67 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Vapa Vesicle-associated 
membrane protein-associated protein A 
IPI:IPI00209290.3 28 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Acsl6 Acyl-CoA 
synthetase isoform 6 variant2 
IPI:IPI00421952.2 81 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Clic1 Chloride 
intracellular channel 1 
IPI:IPI00421995.1 27 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Ddah2 NG,NG-
dimethylarginine dimethylaminohydrolase 2 
IPI:IPI00215294.1 30 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Pdk1 [Pyruvate IPI:IPI00204957.1 49 2 0 
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dehydrogenase [lipoamide]] kinase isozyme 1, 
mitochondrial precursor 
(+1) kDa 
Tax_Id=10116 Gene_Symbol=Dnm3 Dynamin-3 IPI:IPI00213318.4 
(+2) 
96 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Inpp1 Inositol 
polyphosphate-1-phosphatase 
IPI:IPI00362407.2 43 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Lamc1 similar to 
Laminin gamma-1 chain precursor 
IPI:IPI00363849.2 177 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Cul2_predicted similar 
to Cullin-2 
IPI:IPI00364910.1 87 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Syncrip 70 kDa protein IPI:IPI00557424.3 
(+4) 
70 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=RGD1563580_predicted 
similar to AP2 associated kinase 1 
IPI:IPI00556943.2 
(+2) 
104 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Acbd3 Golgi resident 
protein GCP60 
IPI:IPI00339079.6 60 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Tollip_predicted Toll 
interacting protein 
IPI:IPI00366104.2 
(+1) 
30 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Dsp similar to 
desmoplakin isoform I isoform 2 
IPI:IPI00366081.3 332 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Dnaja1 DnaJ homolog 
subfamily A member 1 
IPI:IPI00210884.1 45 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Ube4a Ab2-232 IPI:IPI00369411.1 
(+1) 
124 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Dfna5h similar to 
Nonsyndromic hearing impairment protein 5 homolog 
IPI:IPI00382346.3 
(+1) 
57 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Osbpl11_predicted 
similar to oxysterol binding protein-like 11 
IPI:IPI00362151.5 
(+2) 
84 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Lamb1_predicted 
similar to Laminin beta-1 chain precursor 
IPI:IPI00365542.3 
(+1) 
203 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Fkbp4 similar to FK506-
binding protein 4 
IPI:IPI00358443.3 
(+1) 
62 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Uble1b similar to 
Ubiquitin-like 1-activating enzyme E1B 
IPI:IPI00768246.1 71 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=RGD1565416_predicted 
similar to talin 2 
IPI:IPI00370137.2 
(+3) 
273 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=LOC682967 similar to 
Protein disulfide-isomerase TXNDC10 precursor 
IPI:IPI00769287.1 66 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Gpiap1 GPI-anchored 
membrane protein 1 
IPI:IPI00560977.2 78 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Sel1h Sel-1 homolog 
precursor 
IPI:IPI00205606.3 
(+1) 
89 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Rcn1_predicted similar 
to Reticulocalbin-1 precursor 
IPI:IPI00192912.1 38 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=- 72 kDa protein IPI:IPI00476922.3 
(+1) 
72 
kDa 
2 0 
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Tax_Id=10116 Gene_Symbol=Gria1 Isoform Flip of 
Glutamate receptor 1 precursor 
IPI:IPI00231012.2 102 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Camk2d Isoform Delta 1 
of Calcium/calmodulin-dependent protein kinase type 
II delta chain 
IPI:IPI00212226.1 
(+3) 
60 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Nsdhl NAD(P) 
dependent steroid dehydrogenase-like 
IPI:IPI00360954.1 40 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Tuba4 Tubulin alpha-4A 
chain 
IPI:IPI00362927.1 50 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Pitpnm1 Membrane-
associated phosphatidylinositol transfer protein 1 
IPI:IPI00366129.3 135 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Ppp2r5d similar to delta 
isoform of regulatory subunit B56, protein 
phosphatase 2A isoform 1 
IPI:IPI00366908.3 77 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Sf3b1 similar to splicing 
factor 3b, subunit 1 isoform 1 
IPI:IPI00366952.3 147 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Snip 135 kDa protein IPI:IPI00190619.3 
(+2) 
135 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=RGD1311196 
RGD1311196 protein 
IPI:IPI00370637.3 62 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Ehd3 EH-domain 
containing protein 2 
IPI:IPI00200258.2 61 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Hrmt1l2 Protein 
arginine N-methyltransferase 1 
IPI:IPI00205168.2 42 
kDa 
2 0 
 
 
GNFGEL498_AW54-91_NotIncl_Gel4_LTQ_RatRevDB-converted 
(Membrane) 
   
     
Identified Proteins Accession Number MW FG Ct 
Tax_Id=10116 Gene_Symbol=Acta1 Actin, alpha 
skeletal muscle 
IPI:IPI00189813.1 
(+1) 
42 
kDa 
7 0 
Tax_Id=10116 Gene_Symbol=Slc25a4 ADP/ATP 
translocase 1 
IPI:IPI00231927.11 33 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=Sv2a Synaptic vesicle 
glycoprotein 2A 
IPI:IPI00208115.4 
(+1) 
83 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=Slc1a3 Isoform GLAST-
1A of Excitatory amino acid transporter 1 
IPI:IPI00230956.1 
(+1) 
54 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Eif4a1 Eukaryotic 
translation initiation factor 4A1 
IPI:IPI00369618.1 46 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Ehd1 EH-domain 
containing 1 
IPI:IPI00360340.3 
(+1) 
61 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=RGD1560871_predicted IPI:IPI00358371.3 212 5 0 
 134 
similar to plexin A1 kDa 
Tax_Id=10116 Gene_Symbol=Kb36 Type II keratin 
Kb36 
IPI:IPI00421780.1 60 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=RGD1306694_predicted 
similar to Hook-related protein 1 
IPI:IPI00763697.1 212 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Sbf1_predicted similar 
to SET binding factor 1 isoform a 
IPI:IPI00764860.1 
(+1) 
210 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Hmgcs2 
Hydroxymethylglutaryl-CoA synthase, mitochondrial 
precursor 
IPI:IPI00210444.5 57 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Idh3a Isocitrate 
dehydrogenase [NAD] subunit alpha, mitochondrial 
precursor 
IPI:IPI00198720.1 40 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Kif3a similar to Kinesin-
like protein KIF3A (Microtubule plus end-directed 
kinesin motor 3A) isoform 6 
IPI:IPI00326085.4 
(+6) 
80 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=LOC367171 
Microtubule-associated protein 4 
IPI:IPI00393975.2 
(+2) 
110 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Cct5 T-complex protein 
1 subunit epsilon 
IPI:IPI00470301.1 60 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=RGD1308307_predicted 
similar to pyruvate dehydrogenase phosphatase 
regulatory subunit isoform 1 
IPI:IPI00359656.3 99 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=LOC315676 similar to 
Dmx-like 2 
IPI:IPI00369671.3 344 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Prkacb cAMP-
dependent protein kinase, beta-catalytic subunit 
IPI:IPI00560492.1 46 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Epm2aip1_predicted 
similar to EPM2A (laforin) interacting protein 1 
IPI:IPI00766207.1 70 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Gnas Isoform Gnas-1 of 
Guanine nucleotide-binding protein G(s) subunit 
alpha isoforms short 
IPI:IPI00199872.2 
(+1) 
46 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Gnaq guanine 
nucleotide binding protein, alpha q polypeptide 
IPI:IPI00230868.4 42 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Adsl_predicted similar 
to adenylosuccinate lyase 
IPI:IPI00361216.2 55 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Phgdh D-3-
phosphoglycerate dehydrogenase 
IPI:IPI00475835.3 56 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=RGD1560544_predicted 
similar to Protein C11orf2 (Another new gene 2 
protein) isoform 1 
IPI:IPI00762984.1 
(+1) 
86 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Vac14 VAC14 IPI:IPI00230981.1 88 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Centg3_predicted 
similar to centaurin, gamma 3 
IPI:IPI00358128.3 102 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Cand2 Isoform 1 of IPI:IPI00326431.1 140 3 0 
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Cullin-associated NEDD8-dissociated protein 2 (+2) kDa 
Tax_Id=10116 Gene_Symbol=Sqstm1 Isoform 1 of 
Sequestosome-1 
IPI:IPI00194561.1 
(+2) 
48 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=LOC686545 similar to 
slit homolog 1 
IPI:IPI00768734.1 81 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Ptprd Leukocyte 
common antigen-related phosphatase precursor 
IPI:IPI00214375.1 
(+1) 
207 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Ddx1 ATP-dependent 
RNA helicase DDX1 
IPI:IPI00555314.1 82 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Ctnnd1_predicted 
similar to Catenin delta-1 
IPI:IPI00359491.3 
(+2) 
105 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Vps18_predicted similar 
to Vacuolar protein sorting 18 
IPI:IPI00197453.1 110 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Ywhaq 14-3-3 protein 
theta 
IPI:IPI00196661.1 28 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=RGD1307235_predicted 
hypothetical protein 
IPI:IPI00360079.4 135 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Vars2 Valyl-tRNA 
synthetase 
IPI:IPI00372557.2 141 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Synj1 similar to 
Synaptojanin-1 
IPI:IPI00210153.3 
(+3) 
173 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Acbd3 Golgi resident 
protein GCP60 
IPI:IPI00339079.6 60 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Pde10a PDE10A11 IPI:IPI00213904.5 
(+3) 
96 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=P4hb Protein disulfide-
isomerase precursor 
IPI:IPI00198887.1 57 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Ankfy1_predicted 
similar to Ankyrin repeat and FYVE domain protein 1 
IPI:IPI00364871.3 129 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Kif5a Kinesin heavy 
chain isoform 5A 
IPI:IPI00417753.1 117 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Ipo9_predicted similar 
to Importin-9 
IPI:IPI00195818.3 117 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Wdr7 Isoform 1 of WD 
repeat protein 7 
IPI:IPI00190963.1 
(+1) 
163 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Ap2a2 Adaptor protein 
complex AP-2, alpha 2 subunit 
IPI:IPI00471901.3 104 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Cct6a Chaperonin 
subunit 6a 
IPI:IPI00188111.1 58 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Rasa1 Ras GTPase-
activating protein 1 
IPI:IPI00203320.1 115 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Fdft1 Squalene 
synthetase 
IPI:IPI00210233.1 48 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Atp2b4 Isoform XA of 
Plasma membrane calcium-transporting ATPase 4 
IPI:IPI00230910.1 
(+1) 
129 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Bin1 Isoform AMPH2-1 IPI:IPI00196509.2 65 2 0 
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of Myc box-dependent-interacting protein 1 (+2) kDa 
Tax_Id=10116 Gene_Symbol=Itsn1 Isoform 2 of 
Intersectin-1 
IPI:IPI00231962.1 
(+2) 
129 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Dctn1 Dynactin subunit 
1 
IPI:IPI00196703.1 142 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Cask Peripheral plasma 
membrane protein CASK 
IPI:IPI00388752.3 
(+1) 
103 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Clptm1_predicted 
similar to cleft lip and palate associated 
transmembrane protein 1 
IPI:IPI00193869.1 
(+1) 
75 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=LOC362012 similar to 
Protein FAM40A 
IPI:IPI00373402.3 
(+3) 
99 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Cct4 T-complex protein 
1 subunit delta 
IPI:IPI00337168.5 58 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Gpd2 Glycerol-3-
phosphate dehydrogenase, mitochondrial precursor 
IPI:IPI00199663.1 81 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Nsdhl NAD(P) 
dependent steroid dehydrogenase-like 
IPI:IPI00360954.1 40 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Slc25a3 Slc25a3 protein IPI:IPI00209115.2 
(+1) 
40 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Hdac6 similar to Histone 
deacetylase 6 
IPI:IPI00200498.5 126 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Add2 Isoform 1 of Beta-
adducin 
IPI:IPI00192626.3 
(+1) 
81 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Hnrpl Hnrpl protein IPI:IPI00364061.4 
(+1) 
64 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Nlgn1 Isoform 1 of 
Neuroligin-1 precursor 
IPI:IPI00208218.1 
(+6) 
94 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Sars1 61 kDa protein IPI:IPI00373410.3 
(+1) 
61 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Kit Tyrosine-protein 
kinase receptor 
IPI:IPI00205775.1 109 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Exoc2 Exocyst complex 
component 2 
IPI:IPI00324275.3 
(+1) 
104 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Kif21b_predicted similar 
to Kinesin family member 21B 
IPI:IPI00363445.4 
(+1) 
181 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=RGD1306534_predicted 
similar to Phosphatidylinositol 3,4,5-trisphosphate-
dependent Rac exchanger 1 protein 
IPI:IPI00365036.4 185 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Robo2 similar to 
Roundabout homolog 2 precursor 
IPI:IPI00558943.2 161 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Pgm3_predicted similar 
to Phosphoacetylglucosamine mutase 
IPI:IPI00205603.3 
(+1) 
60 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Csk Tyrosine-protein 
kinase CSK 
IPI:IPI00188950.1 51 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Ikbkap Elongator IPI:IPI00389755.1 149 2 0 
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complex protein 1 kDa 
Tax_Id=10116 Gene_Symbol=Fthfd 10-
formyltetrahydrofolate dehydrogenase 
IPI:IPI00196725.5 99 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Cnp1 2',3'-cyclic-
nucleotide 3'-phosphodiesterase 
IPI:IPI00199394.2 47 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Ntrk2 Isoform GP145-
TrkB of BDNF/NT-3 growth factors receptor precursor 
IPI:IPI00210944.1 
(+2) 
92 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Pcbp2 Poly(RC) binding 
protein 2 
IPI:IPI00464805.2 
(+1) 
39 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=- 94 kDa protein IPI:IPI00368857.4 94 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Ube2o_predicted 
similar to ubiquitin-conjugating enzyme E2O 
IPI:IPI00361541.3 
(+1) 
143 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Rasgrp2_predicted RAS 
guanyl releasing protein 2 
IPI:IPI00372470.2 
(+1) 
70 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=RGD1560587_predicted 
similar to Eph receptor A4 
IPI:IPI00361893.2 
(+1) 
110 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=RGD1560511_predicted 
similar to vacuolar protein sorting 41 
IPI:IPI00768079.1 99 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Aytl2_predicted 1-
acylglycerophosphocholine O-acyltransferase 1 
IPI:IPI00365394.2 
(+1) 
60 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Spnb2 Non-erythrocyte 
beta-spectrin 
IPI:IPI00373419.2 
(+1) 
251 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Txnl2 Isoform 1 of 
Thioredoxin-like protein 2 
IPI:IPI00553899.1 38 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Sh3glb1 43 kDa protein IPI:IPI00363770.2 
(+1) 
43 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Ap3b2_predicted similar 
to adaptor-related protein complex 3, beta 2 subunit 
IPI:IPI00368200.2 
(+1) 
124 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Xpo7 similar to exportin 
7 isoform 1 
IPI:IPI00768094.1 
(+1) 
125 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Gnai2 Guanine 
nucleotide-binding protein G(i), alpha-2 subunit 
IPI:IPI00231925.8 41 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Plaa Phospholipase A-2-
activating protein 
IPI:IPI00562304.2 
(+1) 
87 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=RGD1559939_predicted 
similar to peroxisome biogenesis factor 1 
IPI:IPI00388336.3 
(+1) 
148 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Vps53_predicted similar 
to vacuolar protein sorting 53 
IPI:IPI00369705.3 
(+2) 
94 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=RGD1560248_predicted 
similar to formin-like 2 isoform B 
IPI:IPI00389912.2 
(+3) 
65 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Ivd Isovaleryl-CoA 
dehydrogenase, mitochondrial precursor 
IPI:IPI00193716.1 46 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Birc6_predicted similar 
to baculoviral IAP repeat-containing 6 
IPI:IPI00360081.4 
(+2) 
551 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Pde2a cGMP-dependent IPI:IPI00199076.2 105 2 0 
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3',5'-cyclic phosphodiesterase (+3) kDa 
Tax_Id=10116 Gene_Symbol=Ptk2b Isoform 1 of 
Protein tyrosine kinase 2 beta 
IPI:IPI00190485.1 
(+1) 
116 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Rrm1 Ribonucleoside-
diphosphate reductase 
IPI:IPI00361151.2 90 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=RGD1306143_predicted 
similar to CG9339-PE, isoform E 
IPI:IPI00368722.3 
(+1) 
63 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Igsf3_predicted similar 
to immunoglobulin superfamily, member 3 
IPI:IPI00368876.3 140 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Pgap1 GPI inositol-
deacylase 
IPI:IPI00409514.1 104 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Trim2 similar to 
tripartite motif protein TRIM2 
IPI:IPI00373220.4 
(+2) 
87 
kDa 
2 0 
 
#GNFGEL507_AW01-43_GelA_RatRevDB 
(Synaptosome) 
    
     
Identified Proteins Accession Number MW FG Ct 
Tax_Id=10116 Gene_Symbol=Atp1a3 
Sodium/potassium-transporting ATPase subunit 
alpha-3 
IPI:IPI00231451.4 112 
kDa 
19 0 
Tax_Id=10116 Gene_Symbol=Dync1h1 Dynein heavy 
chain, cytosolic 
IPI:IPI00327630.1 532 
kDa 
21 0 
Tax_Id=10116 Gene_Symbol=Fasn Fatty acid synthase IPI:IPI00200661.1 273 
kDa 
14 0 
Tax_Id=10116 Gene_Symbol=Atp5a1 ATP synthase 
subunit alpha, mitochondrial precursor 
IPI:IPI00396910.1 60 
kDa 
7 0 
Tax_Id=10116 Gene_Symbol=Lrpprc Leucine rich 
protein 157 
IPI:IPI00360075.2 157 
kDa 
8 0 
Tax_Id=10116 Gene_Symbol=Dcx Neuronal migration 
protein doublecortin 
IPI:IPI00324409.3 41 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Acly Isoform 1 of ATP-
citrate synthase 
IPI:IPI00214665.2 
(+1) 
121 
kDa 
8 0 
Tax_Id=10116 Gene_Symbol=Ania4 84 kDa protein IPI:IPI00778626.1 84 
kDa 
10 0 
Tax_Id=10116 Gene_Symbol=Map1b similar to 
Microtubule-associated protein 1B 
IPI:IPI00372009.3 270 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Kif5c_predicted similar 
to kinesin family member 5C 
IPI:IPI00193402.4 109 
kDa 
8 0 
Tax_Id=10116 Gene_Symbol=Kif21b_predicted similar 
to Kinesin family member 21B 
IPI:IPI00363445.4 
(+1) 
181 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=Tubb3 Tubulin beta-3 
chain 
IPI:IPI00362160.1 50 
kDa 
7 0 
Tax_Id=10116 Gene_Symbol=Hspd1 60 kDa heat IPI:IPI00339148.2 61 8 0 
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shock protein, mitochondrial precursor kDa 
Tax_Id=10116 Gene_Symbol=Cltc Clathrin heavy chain IPI:IPI00193983.3 
(+1) 
192 
kDa 
8 0 
Tax_Id=10116 Gene_Symbol=Cand1 Cullin-associated 
NEDD8-dissociated protein 1 
IPI:IPI00205466.1 136 
kDa 
8 0 
Tax_Id=10116 Gene_Symbol=Crmp1 
Dihydropyrimidinase-related protein 1 
IPI:IPI00561065.2 74 
kDa 
8 0 
Tax_Id=10116 Gene_Symbol=Hk1 Hexokinase-1 IPI:IPI00202543.1 102 
kDa 
10 0 
Tax_Id=10116 Gene_Symbol=Jup Junction plakoglobin IPI:IPI00421429.3 82 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Epb4.1l1 Isoform S of 
Band 4.1-like protein 1 
IPI:IPI00203237.2 
(+2) 
98 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Dctn1 Dynactin subunit 
1 
IPI:IPI00196703.1 142 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=Dnm1 Dynamin-1 IPI:IPI00782657.1 96 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=Hspcb Heat shock 
protein HSP 90-beta 
IPI:IPI00471584.7 83 
kDa 
8 0 
Tax_Id=10116 Gene_Symbol=Opa1 Isoform 3 of 
Dynamin-like 120 kDa protein, mitochondrial 
precursor 
IPI:IPI00192639.5 
(+1) 
116 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=Atp1a1 
Sodium/potassium-transporting ATPase subunit 
alpha-1 precursor 
IPI:IPI00326305.3 113 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Gnao Guanine 
nucleotide-binding protein G(o) subunit alpha 1 
IPI:IPI00231505.5 40 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=LOC314432 Similar to 
ubiquitin-protein ligase (EC 6.3.2.19) E1-mouse 
IPI:IPI00368347.2 118 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=Gap43 Neuromodulin IPI:IPI00212320.1 24 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Usp9x_predicted similar 
to Probable ubiquitin carboxyl-terminal hydrolase 
FAF-X (Ubiquitin thioesterase FAF-X) (Ubiquitin-
specific-processing protease FAF-X) (Deubiquitinating 
enzyme FAF-X) (Fat facets protein-related, X-linked) 
(Ubiquitin-specific protease 9, X c 
IPI:IPI00204923.4 
(+1) 
291 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=LOC360975 2-
oxoglutarate dehydrogenase E1 component, 
mitochondrial precursor 
IPI:IPI00215093.1 
(+2) 
116 
kDa 
7 0 
Tax_Id=10116 Gene_Symbol=Aco2 Aconitate 
hydratase, mitochondrial precursor 
IPI:IPI00421539.3 85 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Eef2 Elongation factor 2 IPI:IPI00203214.6 95 
kDa 
7 0 
Tax_Id=10116 Gene_Symbol=Tufm_predicted similar 
to Tu translation elongation factor, mitochondrial 
IPI:IPI00371236.3 50 
kDa 
4 0 
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Tax_Id=10116 Gene_Symbol=Uqcrc2 Ubiquinol-
cytochrome-c reductase complex core protein 2, 
mitochondrial precursor 
IPI:IPI00188924.4 48 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Spnb3 Spectrin beta 
chain, brain 2 
IPI:IPI00327662.3 271 
kDa 
7 0 
Tax_Id=10116 Gene_Symbol=Ripx Protein RUFY3 IPI:IPI00204065.1 
(+2) 
53 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Mtap2 Isoform MAP2x 
of Microtubule-associated protein 2 
IPI:IPI00206171.1 
(+2) 
202 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Cyln2 CAP-Gly domain-
containing linker protein 2 
IPI:IPI00195929.1 
(+1) 
115 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=RGD1566016_predicted 
similar to SLIT-ROBO Rho GTPase-activating protein 2 
IPI:IPI00363832.3 121 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Aldh1l2_predicted 
similar to aldehyde dehydrogenase 1 family, member 
L2 
IPI:IPI00361193.5 102 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Atp2a2 Isoform 
SERCA2B of Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2 
IPI:IPI00190020.3 
(+1) 
115 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Phgdh D-3-
phosphoglycerate dehydrogenase 
IPI:IPI00475835.3 56 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Hsph1 Heat shock 
protein 105 kDa 
IPI:IPI00471835.1 96 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Ndufs1 NADH-
ubiquinone oxidoreductase 75 kDa subunit, 
mitochondrial precursor 
IPI:IPI00358033.1 79 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=Cct3 T-complex protein 
1 subunit gamma 
IPI:IPI00372388.1 61 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=Prss15 Lon protease 
homolog, mitochondrial precursor 
IPI:IPI00205076.1 106 
kDa 
7 0 
Tax_Id=10116 Gene_Symbol=Hmgcs1 
Hydroxymethylglutaryl-CoA synthase, cytoplasmic 
IPI:IPI00188158.1 57 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Gprin1_predicted 
similar to G protein-regulated inducer of neurite 
outgrowth 1 
IPI:IPI00360030.4 
(+1) 
94 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Aars similar to alanyl-
tRNA synthetase 
IPI:IPI00363563.3 107 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=LOC367171 
Microtubule-associated protein 4 
IPI:IPI00393975.2 
(+2) 
110 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Centg3_predicted 
similar to centaurin, gamma 3 
IPI:IPI00358128.3 102 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Trio similar to triple 
functional domain 
IPI:IPI00360644.3 
(+1) 
348 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Ckap5 similar to 
cytoskeleton associated protein 5 isoform 1 
IPI:IPI00764313.1 
(+3) 
223 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Dpysl3 Isoform 2 of IPI:IPI00203250.1 74 4 0 
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Dihydropyrimidinase-related protein 3 (+1) kDa 
Tax_Id=10116 Gene_Symbol=Acaca Isoform 1 of 
Acetyl-CoA carboxylase 1 
IPI:IPI00194102.2 
(+1) 
265 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=LOC363309 similar to 
tubulin-specific chaperone d 
IPI:IPI00765967.1 134 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Exoc4 Exocyst complex 
component 4 
IPI:IPI00209144.1 
(+2) 
111 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Kab 174 kDa protein IPI:IPI00776774.1 174 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Eno1 Alpha-enolase IPI:IPI00464815.11 
(+2) 
47 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Kif5b Kinesin heavy 
chain 
IPI:IPI00364904.2 110 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Cct8_predicted similar 
to T-complex protein 1 subunit theta 
IPI:IPI00370815.3 60 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Ap2b1 Isoform 2 of AP-2 
complex subunit beta-1 
IPI:IPI00231502.3 
(+2) 
106 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Lancl2_predicted LanC 
(Bacterial lantibiotic synthetase component C)-like 2 
IPI:IPI00192484.2 51 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Vps18_predicted similar 
to Vacuolar protein sorting 18 
IPI:IPI00197453.1 110 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Hip1 similar to 
huntingtin interacting protein 1 isoform 2 
IPI:IPI00370335.3 
(+1) 
116 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Cyfip1_predicted similar 
to cytoplasmic FMR1 interacting protein 1 
IPI:IPI00367829.4 145 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Afap Actin filament 
associated protein 
IPI:IPI00206325.1 81 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Tpp2 Tripeptidyl-
peptidase 2 
IPI:IPI00213579.3 
(+1) 
138 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Npepps similar to 
aminopeptidase puromycin sensitive 
IPI:IPI00372700.1 
(+3) 
103 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Cad_mapped similar to 
carbamoyl-phosphate synthetase 2, aspartate 
transcarbamylase, and dihydroorotase isoform 4 
IPI:IPI00365582.3 
(+2) 
243 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Vps35_mapped similar 
to vacuolar protein sorting 35 
IPI:IPI00363493.2 92 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Plaa Phospholipase A-2-
activating protein 
IPI:IPI00562304.2 87 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Tra1_predicted 93 kDa 
protein 
IPI:IPI00365985.4 
(+1) 
93 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Wdr47 similar to WD 
repeat domain 47 
IPI:IPI00768998.1 102 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Spna2 Spectrin alpha 
chain, brain 
IPI:IPI00209258.4 285 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Ap2a2 Adaptor protein 
complex AP-2, alpha 2 subunit 
IPI:IPI00471901.3 104 
kDa 
3 0 
 142 
Tax_Id=10116 Gene_Symbol=Cct6a Chaperonin 
subunit 6a 
IPI:IPI00188111.1 58 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Pygb similar to Glycogen 
phosphorylase, brain form 
IPI:IPI00357945.1 97 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=RGD1562629_predicted 
similar to Protein neurobeachin 
IPI:IPI00567941.2 327 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Immt 82 kDa protein IPI:IPI00364895.4 
(+1) 
82 
kDa 
3 0 
 
#GNFGEL517_AW01-59_GelF_RatRevDB 
(Synaptosome) 
    
     
Identified Proteins Accession Number MW FG Ct 
Tax_Id=10116 Gene_Symbol=Dync1h1 Dynein heavy 
chain, cytosolic 
IPI:IPI00327630.1 532 
kDa 
43 0 
Tax_Id=10116 Gene_Symbol=Fasn Fatty acid synthase IPI:IPI00200661.1 273 
kDa 
9 0 
Tax_Id=10116 Gene_Symbol=Kif5c_predicted similar 
to kinesin family member 5C 
IPI:IPI00193402.4 109 
kDa 
9 0 
Tax_Id=10116 Gene_Symbol=Crmp1 
Dihydropyrimidinase-related protein 1 
IPI:IPI00561065.2 74 
kDa 
8 0 
Tax_Id=10116 Gene_Symbol=Stxbp1 Isoform 1 of 
Syntaxin-binding protein 1 
IPI:IPI00205372.3 
(+1) 
68 
kDa 
7 0 
Tax_Id=10116 Gene_Symbol=Hspcb Heat shock 
protein HSP 90-beta 
IPI:IPI00471584.7 83 
kDa 
7 0 
Tax_Id=10116 Gene_Symbol=Ania4 84 kDa protein IPI:IPI00778626.1 84 
kDa 
7 0 
Tax_Id=10116 Gene_Symbol=Atp5a1 ATP synthase 
subunit alpha, mitochondrial precursor 
IPI:IPI00396910.1 60 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=Tubb3 Tubulin beta-3 
chain 
IPI:IPI00362160.1 50 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=Lrpprc Leucine rich 
protein 157 
IPI:IPI00360075.2 157 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=Aco2 Aconitate 
hydratase, mitochondrial precursor 
IPI:IPI00421539.3 85 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=Tubb2b Tubulin beta-2B 
chain 
IPI:IPI00655259.1 50 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=LOC681252 similar to 
Myristoylated alanine-rich C-kinase substrate 
IPI:IPI00371946.3 
(+1) 
30 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Mtap2 Isoform MAP2x 
of Microtubule-associated protein 2 
IPI:IPI00206171.1 
(+2) 
202 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=LOC362587 831 kDa 
protein 
IPI:IPI00359003.4 
(+1) 
831 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Dctn1 Dynactin subunit IPI:IPI00196703.1 142 5 0 
 143 
1 kDa 
Tax_Id=10116 Gene_Symbol=Gnao Guanine 
nucleotide-binding protein G(o) subunit alpha 2 
IPI:IPI00204843.2 
(+1) 
40 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Cand1 Cullin-associated 
NEDD8-dissociated protein 1 
IPI:IPI00205466.1 136 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Dpysl3 Isoform 2 of 
Dihydropyrimidinase-related protein 3 
IPI:IPI00203250.1 
(+1) 
74 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=RGD1565889_predicted 
similar to Calcium-binding mitochondrial carrier 
protein Aralar2 
IPI:IPI00358163.3 74 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Dpysl2 similar to 
Dihydropyrimidinase-related protein 2 
IPI:IPI00192034.2 73 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Hspd1 60 kDa heat 
shock protein, mitochondrial precursor 
IPI:IPI00339148.2 61 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Hk1 Hexokinase-1 IPI:IPI00202543.1 102 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Hspa8 Heat shock 
cognate 71 kDa protein 
IPI:IPI00208205.1 
(+1) 
71 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Hadha Trifunctional 
enzyme subunit alpha, mitochondrial precursor 
IPI:IPI00212622.1 83 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Dcd Dermcidin IPI:IPI00421832.1 11 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Dbn1 Isoform A of 
Drebrin 
IPI:IPI00231407.4 
(+1) 
77 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Map1b similar to 
Microtubule-associated protein 1B 
IPI:IPI00372009.3 270 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Camkv CaM kinase-like 
vesicle-associated protein 
IPI:IPI00205056.1 54 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Dync1li1 Cytoplasmic 
dynein 1 light intermediate chain 1 
IPI:IPI00213552.1 57 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Atp2b1 Isoform D of 
Plasma membrane calcium-transporting ATPase 1 
IPI:IPI00194873.1 
(+5) 
139 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Uqcrc2 Ubiquinol-
cytochrome-c reductase complex core protein 2, 
mitochondrial precursor 
IPI:IPI00188924.4 48 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Prss15 Lon protease 
homolog, mitochondrial precursor 
IPI:IPI00205076.1 106 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Cad_mapped similar to 
carbamoyl-phosphate synthetase 2, aspartate 
transcarbamylase, and dihydroorotase isoform 4 
IPI:IPI00365582.3 
(+3) 
243 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Add1 Isoform 2 of 
Alpha-adducin 
IPI:IPI00231810.1 
(+2) 
70 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Gprin1_predicted 
similar to G protein-regulated inducer of neurite 
outgrowth 1 
IPI:IPI00360030.4 94 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Slc25a4 ADP/ATP IPI:IPI00231927.11 33 2 0 
 144 
translocase 1 kDa 
Tax_Id=10116 Gene_Symbol=Syn1 Isoform IA of 
Synapsin-1 
IPI:IPI00191335.1 
(+2) 
74 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Pkm2 Isoform M1 of 
Pyruvate kinase isozymes M1/M2 
IPI:IPI00231929.6 
(+3) 
58 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=RGD1562629_predicted 
similar to Protein neurobeachin 
IPI:IPI00567941.2 327 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Hspa12a_predicted 
similar to heat shock protein 12A 
IPI:IPI00358537.2 75 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Exoc4 Exocyst complex 
component 4 
IPI:IPI00209144.1 111 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Gna13 Galpha13 IPI:IPI00422053.1 
(+1) 
44 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Ndufs1 NADH-
ubiquinone oxidoreductase 75 kDa subunit, 
mitochondrial precursor 
IPI:IPI00358033.1 79 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Eef2 Elongation factor 2 IPI:IPI00203214.6 95 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Tubb4 similar to tubulin, 
beta 4 
IPI:IPI00765366.1 50 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Hspa9a_predicted 
Stress-70 protein, mitochondrial precursor 
IPI:IPI00363265.3 74 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Mark3 81 kDa protein IPI:IPI00206262.3 
(+2) 
81 
kDa 
2 0 
 
#GNFGEL524_AW01-47_GelH_RatRevDB 
(Synaptosome) 
    
     
Identified Proteins Accession Number MW FG Ct 
Tax_Id=10116 Gene_Symbol=Mtap2 Microtubule-
associated protein 
IPI:IPI00328017.4 199 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=Ania4 84 kDa protein IPI:IPI00778626.1 84 
kDa 
6 0 
Tax_Id=10116 Gene_Symbol=Dpysl5 
Dihydropyrimidinase-related protein 5 
IPI:IPI00331981.7 62 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Camkv CaM kinase-like 
vesicle-associated protein 
IPI:IPI00205056.1 54 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=Hspa12a_predicted 
similar to heat shock protein 12A 
IPI:IPI00358537.2 75 
kDa 
5 0 
Tax_Id=10116 Gene_Symbol=RGD1311640_predicted 
similar to centrosome protein cep290 
IPI:IPI00560237.2 290 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=LOC362587 831 kDa 
protein 
IPI:IPI00359003.4 
(+1) 
831 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Hmgcs1 IPI:IPI00188158.1 57 4 0 
 145 
Hydroxymethylglutaryl-CoA synthase, cytoplasmic kDa 
Tax_Id=10116 Gene_Symbol=Syn1 Isoform IA of 
Synapsin-1 
IPI:IPI00191335.1 
(+2) 
74 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Tufm_predicted similar 
to Tu translation elongation factor, mitochondrial 
IPI:IPI00371236.3 50 
kDa 
4 0 
Tax_Id=10116 Gene_Symbol=Kns2 kinesin light chain 
1 isoform B 
IPI:IPI00231498.2 63 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Ndufv1 NADH 
dehydrogenase (Ubiquinone) flavoprotein 1 
IPI:IPI00191913.1 51 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Vdac1 Voltage-
dependent anion-selective channel protein 1 
IPI:IPI00421874.4 31 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Acad9 similar to very-
long-chain acyl-CoA dehydrogenase VLCAD homolog 
isoform 1 
IPI:IPI00337099.2 
(+1) 
69 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Phgdh D-3-
phosphoglycerate dehydrogenase 
IPI:IPI00475835.3 56 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Acot7 Isoform 1 of 
Cytosolic acyl coenzyme A thioester hydrolase 
IPI:IPI00213571.1 
(+2) 
38 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Gnaq guanine 
nucleotide binding protein, alpha q polypeptide 
IPI:IPI00230868.4 42 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Camk2b Calmodulin-
dependent protein kinase II beta M isoform 
IPI:IPI00209824.2 
(+3) 
73 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Pfkm 6-
phosphofructokinase, muscle type 
IPI:IPI00231293.7 86 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Vps35_mapped similar 
to vacuolar protein sorting 35 
IPI:IPI00363493.2 92 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Idh1 Isocitrate 
dehydrogenase [NADP] cytoplasmic 
IPI:IPI00194045.1 
(+1) 
47 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Myh10 234 kDa protein IPI:IPI00391300.3 234 
kDa 
3 0 
Tax_Id=10116 Gene_Symbol=Spnb2 Non-erythrocyte 
beta-spectrin 
IPI:IPI00373419.2 251 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Ncdn NORBIN IPI:IPI00205396.1 79 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Dync1li1 Cytoplasmic 
dynein 1 light intermediate chain 1 
IPI:IPI00213552.1 57 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Npepps similar to 
aminopeptidase puromycin sensitive 
IPI:IPI00372700.1 
(+1) 
103 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Ppp2ca 
Serine/threonine-protein phosphatase 2A catalytic 
subunit alpha isoform 
IPI:IPI00200391.1 
(+1) 
36 
kDa 
2 0 
Tax_Id=10116 Gene_Symbol=Eno1 Alpha-enolase IPI:IPI00464815.11 
(+2) 
47 
kDa 
2 0 
 
